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Abstract 
 
At least 50% of people will develop cancer at some point during their 
lifetime and half these will end in fatality. Improving patients’ prognosis relies on 
early and accurate diagnosis and treatment. Current diagnostic methods are 
based on histopathological analysis and are time-consuming, expensive and 
require biopsy. Raman spectroscopy can measure subtle biochemical changes 
and provides a rapid, non-destructive and objective technique that can be used 
in vivo for identifying pathological changes in tissue samples. 
 
This study investigates both a standard Raman spectrometer system and 
also a Raman needle probe for their use as diagnostic techniques and clinical 
tools. Oesophageal, femoral and head and neck lymph nodes were analysed in 
this study. Metastatic lymph nodes from the three areas could be identified from 
the non-cancer lymph nodes with a sensitivity of 71% and specificity of 89%. 
Lymphoma was identified from non-cancer lymph nodes with a sensitivity of 64% 
and specificity of 86%. It was observed that oesophageal nodes often contained 
carbon particles, clinically diagnosed as anthracosis. These nodes were much 
harder to study than the femoral or head and neck, due to strong Raman signal 
detected from the carbon particles. Lymph nodes are embedded in adipose tissue 
and as a consequence, very strong lipid peaks were frequently observed in 
spectra. Spectral differences were exhibited in the measurements of the lymph 
nodes from the three different anatomical regions.  
 
A comparison of the point measurements and mapped data showed no 
difference in classification. Therefore, indicating that just a few measurements 
can be sufficient enough sampling to represent a specimen, and demonstrates 
the practicability of Raman use in vivo for rapid analysis. The Raman needle 
probe feasibility study showed its potential for in vivo use for real-time diagnosis 
and as a surgical tool to support biopsy. A sensitivity and specificity of 80% and 
79% for the identification of non-cancer head and neck lymph nodes from non-
cancer provides similar accuracies to the standard Raman approach, therefore 
supports its viability for use as a diagnostic tool.      
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Introduction 
 
In the UK, people who are born after 1960 have a 50% chance of 
developing cancer at some point in their lifetime.1 Approximately half will die as a 
result of the disease within 5 years of diagnosis. Cancer is responsible for 29% 
of deaths in the UK and it is estimated that at least one person dies from the 
disease every four minutes.2 
 
Early and rapid diagnosis of disease is essential for increasing survival 
rates and improving prognosis. It also provides economic benefits through the 
relief of hospital resources and the reduction in healthcare costs.3 Currently the 
method of choice for cancer diagnosis is histopathological analysis of stained 
tissue sections. This method requires tissue samples to be acquired from 
patients, typically through invasive biopsy. The unnecessary removal of tissue 
can result from sampling errors. This is a costly procedure and the time taken for 
diagnoses to be made can also be lengthy,4 thus delaying treatment. Diagnosis 
is made based on observations of the tissue morphology and staining; thus, this 
method can be subjective and may result in incorrect diagnosis and treatment.5 
Diagnosis of a disease often only occurs as a result of the presenting of 
symptoms. However, by the time symptoms present, tumours tend to be of a 
significant size and curing the cancer completely is more difficult.6   
 
There is a need for a diagnostic technique that can rapidly, non-invasively 
and non-subjectively identify the pathology of tissues, whilst being accurate and 
cost-effective.  
 
Vibrational spectroscopic techniques are rapid, non-destructive and cost-
effective methods of diagnosis. They are also minimally invasive when used in 
vivo and are non-subjective.7 When a cell becomes diseased biochemical 
changes occur, which are reflected by alterations to its spectral fingerprint when 
compared to normal tissue spectra.8 Vibrational techniques comprise Raman and 
infrared spectroscopy and function based on the interaction of optical light and 
matter to generate molecule specific spectra. Raman spectra are not significantly 
affected by water bands; therefore the technique offers the advantage of in vivo 
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use through the employment of optical fibres,9 enabling immediate diagnosis and 
treatment with minimal invasion.    
 
Although previous studies have been carried out on lymph node cancers, 
limited research has been conducted on primary lymphomas. There is a need for 
a larger study to analyse many of the different cancers that can occur in lymph 
nodes, including both primary and secondary. A study involving a larger range of 
pathologies will allow spectral comparisons to take place over many different 
cancers, enabling the evaluation of Raman spectroscopy as a diagnostic tool for 
the classification of lymph node cancers. The ability of Raman spectroscopy to 
correctly stage lymphomas will also be investigated, as the stage of a cancer 
often determines patient prognosis. The in vivo use of Raman spectroscopy is 
the ultimate aim of this technique’s use diagnostically. Thus, a needle probe will 
be used to collect spectra ex vivo and analysed to evaluate its diagnostic potential 
for in vivo lymph node cancer classification.     
 
In order to achieve the aims of the study, tissue will be obtained and 
analysed using vibrational spectroscopy. The spectra produced will then be 
assessed in order to evaluate the differences between the classification and 
stage assigned to the tissue section by standard histopathological assessment. 
Therefore, the ability of Raman spectroscopy to form pathological classifications 
will be assessed. The tissue that will be used in this study will be lymph node and 
the pathologies will consist of non-cancerous, lymphoma and metastatic tissue.  
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Chapter 1: Background and Literature Review 
 
1.1 Cancer 
 
1.1.1 Cancer Epidemiology   
 
Currently in the UK, approximately 33%, of people will be diagnosed with 
cancer at some point during their lifetimes and around half of these will die as a 
result of the disease within 5 years of diagnosis. This occurrence is expected to 
rise to 50% of people. Cancer is the cause of death in one in every four fatalities 
in the UK and in 2010 it was estimated that cancer took a person’s life every four 
minutes.10 More than 60% of cancers are typically diagnosed in people who are 
over 65 years old. In 2006, 250,000 overall cancer diagnoses and 120,000 
cancer-caused fatalities were estimated in the UK.11  
 
Cancer represents a group of over 100 diseases which are characterised 
by their uncontrolled growth, invasion and cell dissemination; and classified 
according to their tissue of origin. Carcinomas are cancers that occur in epithelial 
cells and account for roughly 85% of overall cancers. Adenocarcinoma is the 
collective name for cancers that occur in glandular epithelial tissue, such as that 
found in the breast. Mesoderm cells give rise to bone and muscle tissue; cancers 
that occur in mesenchymal tissue are referred to as sarcomas.12 Cancers that 
occur in blood forming cells and those from the immune system are either 
leukaemia or lymphomas and account for 7% of all cancers.13 Cancers that occur 
in glial cells of the brain are collectively called gliomas.14    
 
It is estimated that up to 90% of cancers are caused by environmental or 
lifestyle factors and are often the initial trigger for tumour development; genetics 
also is known to contribute to the growth of neoplasms.11  
 
1.1.2 Cancer Pathogenesis 
 
A constant equilibrium between cell proliferation, growth arrest and 
differentiation, and apoptosis is successfully controlled through homeostasis in 
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normal tissue. Alterations to the homeostatic mechanisms that control this 
equilibrium can result in an increase in tissue mass and thus tumour formation.15 
Cell proliferation is a mechanism needed for the normal growth and development 
of organisms, where cells are exponentially produced through DNA synthesis 
followed by mitosis. A typical, healthy human cell can divide once or twice a day, 
replication is controlled to prevent over-proliferation. Differentiation is tightly 
regulated in normal tissue; directly related to a cells ability to proliferate, it refers 
to the specialisation of cells. Apoptosis is a form of cell death and essential for 
homeostatic maintenance in healthy tissue. In neoplastic tissue the following 
cellular functions are typically regulated incorrectly: cell proliferation is not 
controlled effectively, cell differentiation is distorted, chromosomal and genetic 
organisation is weak and apoptosis is inefficiently monitored.16 Telomeres are 
repeated sections of DNA that protect chromosomes. Alteration or shortening of 
telomeres can result in a loss of this protection and can result in cell apoptosis 
and chromosome fusion. Telomerase can be expressed by cells to reverse 
telomere shortening through the addition of nucleotides. It has been shown that 
over expression of telomerase results in greater cell mobilisation and a greater 
life span, leading to a higher ability of tumour initiation.17 
 
Hanahan and Weinberg18 propose six hallmarks of cancer cells: sustained 
proliferative signalling, evasion to growth suppressors, activation of invasion and 
metastasis, enabled replicative immortality, induced angiogenesis, and 
resistance to cell death. They state, that as a normal cell progresses into a 
neoplastic state these hallmark capabilities are acquired successively to enable 
them to become tumorigenic and eventually malignant. They explain that normal 
cells control cell numbers through maintenance of the generation and release of 
growth-promoting signals; cancer cells sustain their proliferation by deregulating 
these signals. Tumour-suppressor genes negatively regulate cell proliferation; 
cancer cells have the ability to evade their suppression. Contact inhibition aids 
proliferation in normal cells, this mechanism is not present in many cancer cells 
allowing invasion of tissue. Angiogenesis is the formation of new vessels from 
existing ones, needed in cancerous tissue to provide oxygen and nutrients and 
remove waste to sustain neoplastic growth. Apoptosis is a method of cell death 
whereby the dying cells contract and are engulfed by neighbouring cells; cancer 
cells are able to evade this mechanism.  
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1.1.3  DNA Mutation    
 
Deoxyribonucleic acid (DNA), a double stranded helix structure, is formed 
from a sugar-phosphate backbone attached to nitrogenous bases responsible for 
the specific genetic code. The backbone is composed of sugar units of 
deoxyribose connected together by a phosphate group. A 3’-hydroxyl group is 
free at one end of the chain and a terminal 5’-hydroxyl group is found at the other 
end with opposing polarity; this results in the two DNA strands of the double helix 
running in opposite directions. Nitrogenous bases include the purines: guanine 
(G) and adenine (A), and the pyrimidines: thymine (T) and cytosine (C), which 
complement each other G:C and A:T. Amino acids are coded for by a codon 
which consists of three bases. RNA polymerase, the enzyme that copies DNA 
into messenger mRNA after the strands of the double helix are separated, reads 
in a 5’-3’ direction. Base mutations occur from misreading of the strands during 
synthesis and occur in three ways: single base alteration, insertion of a base, or 
deletion of a base. DNA mutations can result in repair and return to the normal 
sequence, cell death, or the continued misreading of the mutated DNA strand in 
subsequent DNA syntheses. Cancer occurs when the damaged DNA sequence 
codes for a gene, the coding sequence of a protein, and thus alters cellular 
function and imbalances homeostatic maintenance which leads to tumour 
formation.19  
 
1.1.4  Carcinogenesis 
 
Carcinogenesis is a multistage process whereby normal cells progress 
into cancerous cells, and is typically divided into three stages: initiation, promotion 
and progression (Figure 1.1).20  
 
In the initiation step, exposure to a chemical carcinogen, radiation or a 
virus results in a mutagenic effect that causes damage to the DNA of a cell. This 
is an irreversible process, occurs with no change in outward appearance and 
dramatically increases a cells suceptibility to develop cancer. Chemicals capable 
of causing initiation of a cell are highly reactive electrophiles, where the electron-
deficient atom can react with the electron-rich nucleophilic sites within cells, a 
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primary target being DNA or RNA. Promotion is a reversible process where a 
promoting-agent does not directly affect DNA, but causes proliferation of the cell 
and angiogenesis. Promoters are non-mutagenic and do not typically cause 
tumours themselves, but stimulates the initiated cell to undergo cell division and 
produce more DNA-mutated cells. Thus, promotion aids tumour progression 
through proliferation, and results in the formation of a benign tumour. A long 
interval may occur between initiation and promotion due to the requirement of a 
prolonged promoting-agent exposure. The progression stage involves irriversible 
processes such as de-differentiation and an increase in autonomous growth and 
mitotic activity. The tumour becomes malignant, can invade local tissue and has 
the ability to metastatisise to secondary locations around the body.11,15,19,21    
 
 
Figure 1.1- The basic process of carcinogenesis. Adapted from 22.  
 
       
A metastasis occurs when tumour cells detach themselves from the 
malignant site and travel to other secondary locations where they form deposits 
and proliferate.23 All cancers have the ability to metastasise and can do so by 
various routes after cell detachment; invading local tissue, seeding into surfaces 
and body cavities, haemotogenous spread or lymphatic spread.24 Figure 1.2 
shows how a primary tumour may result in metastatic deposits in the lungs. The 
cell of origin of a tumour affects metastatic proclivity; the cells of connective tissue 
cancer typically migrate independently whereas carcinomas typically migrate 
collectively. Cancer patients tend to die as a result of the metastases rather than 
the primary cancer. It is estimated that every day, for every gram of tumour tissue, 
four million cancer cells are released into the circulatory system.25 Within twenty-
four hours of the cancer cells entering the blood stream only 0.1% remains viable, 
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and of those, approximately only 0.01% will eventually produce metastases. 
Subsequently, only a small proportion of primary malignancies result in the 
formation of metastases at secondary locations.26 Tumour cells are genetically 
less stable than normal cells 27 and are highly heterogeneous. Comparative 
genomic hybridisation has found that there is a high level of similarity between 
brain metastases and their primary site.28 However, it has also been reported that 
cells which possess a higher metastatic potential, measured using in vitro assays 
to calculate the proliferation, also have a higher mutation capability than those 
without such a high metastatic potential. Thus cells at secondary locations may 
genetically differ from their primary site cells.26  
 
 
 
Figure 1.2- Schematic showing the process of metastasis. Replicated from reference.26 
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1.1.5 Cancer Cell Morphology  
 
Increased cell growth and proliferation that occurs in cancerous cells can 
be recognised by localised and progressive tissue expansion. This is caused by 
an increase in the number of cells as a result of proliferation. Cancerous epithelial 
cells exhibit pleomorphism that can be recognised under a light microscope. 
Morphological differences of cancerous cells compared to non-cancer cells 
include: altered nuclear size and shape, the distribution of chromatin and staining 
affinity. Invasion and metastasis of cells are also indications of cancer. Invasion 
is the random and uncontrolled penetration of the cancerous cells into 
surrounding tissue. Metastasis is demonstrated by the dissemination of 
cancerous cells from the site of origin to secondary sites in the body.29 
Morphological differences also reported include: variable cell shape and size, no 
basement membrane, lack of tissue organisation, altered epithelium/stroma ratio, 
invasion of blood vessels and lymphatic vessels, increased and abnormal mitotic 
activity and a loss of differentiation.19   
 
The conformations and quantities of: nucleic acids, proteins, lipids and 
carbohydrates are also altered when a normal cell becomes neoplastic. These 
morphological and biochemical changes vary between the type and location of 
the cancer.30 
 
Benign and malignant tumours need to be correctly identified to ensure the 
correct treatment. Benign tumours, though not typically fatal, can cause health 
problems depending on their anatomical location. Malignant tumours progress 
and usually result in mortalities if the tumour is unnoticed and is not treated or if 
the treatment is unsuccessful. Microscopic observation of invasion into 
surrounding tissue and tumour metastasis to secondary locations primarily 
identifies malignant cancers from benign tumours.31 
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1.2 Lymph Node Cancers 
 
1.2.1  Lymphatic Anatomy and Functionality 
 
The lymphatic system consists of a network of vessels throughout the body 
which flow with a fluid called lymph (Figure 1.3). Lymph fluid is derived from the 
interstitial fluid that surrounds tissues and originates in the interstitial spaces 
between tissues.32 There is both primary and secondary lymphoid tissue. Primary 
lymphoid tissue consists of the bone marrow, where B cells and T cells arise and 
B cells differentiate into mature B-cells, and the thymus where T cells differentiate 
into mature T-cells. These mature B and T cells express antigen receptors and 
migrate into the secondary lymphoid tissues. The secondary lymphoid tissues 
include the lymph nodes, the spleen, mucosa associated lymphoid tissue and the 
blood.33   
 
 
Figure 1.3- The lymphatic system and associated organs in the Human body. Reproduced from 
reference.34 
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The lymphatic system is involved in the body’s immunity against foreign 
microbes. The tissues of the lymphatic system, such as the spleen and lymph 
nodes, contain macrophages, a phagocytic cell that engulfs foreign bodies, to 
enable pathogen destruction. Microbes from the blood are trapped in the spleen 
and those present in interstitial fluid are taken into the lymphatic vessels and 
travel to lymph nodes for destruction by macrophages. Fluid from the circulatory 
system escapes the vessels as a result of blood pressure. Through osmotic 
pressure, approximately 85% of fluid re-enters the circulatory system. However, 
4 L of fluid is lost every day from the capillaries into the interstitial fluid and does 
not re-enter the circulatory system. Through diffusion this fluid enters the vessels 
of the lymphatic system and is transported by rhythmic movement of the vessel 
walls and contractions of the skeletal muscles. Similarly to veins, valves are 
present on the walls of the lymphatic vessels to prevent backflow.35           
 
As well as extravasated fluid, the lymphatic vessels also collect 
macrophages and other cellular material related to the immune system. The 
lymphatic network begins as capillaries that drain into collecting vessels which 
return lymph fluid to the systemic blood circulatory system through the thoracic 
duct at the base of the neck. The lymphatic system is lined with endothelial cells 
and is designed for cell entry and transportation through a variety of 
characteristics: Lymphatic vessels contain no basement membrane and few 
intracellular junctions, aiding cell entry; cells are easily washed into the lymphatic 
vessels with interstitial fluid and proteins; the flow velocity in the lymphatic 
network is slow and the chemistry of lymph is similar to that of interstitial fluid, 
thus generates an environment that facilitates cell survival. Therefore, the 
lymphatic system aids the body’s immunity by taking lymphocytes and antigen-
presenting cells to the lymph nodes. However, it can also act as a transportation 
system for the dissemination of tumour cells and thus aids metastasis. The 
presence and over-expression of specific lymphangiogenic growth factors may 
contribute to the migration of tumour cells by providing a suitable environment. 
The over-expression of the family of vascular endothelial growth factor proteins 
facilitates lymphatic and vascular proliferation.36 
 
Lymph nodes are located at positions along the vessels and filter lymph 
fluid; they can be felt in the neck, armpit and groin region. Lymph nodes consist 
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of a ‘honeycomb’ of connective tissue containing white blood cells to aid the 
body’s immunity. When the body is fighting infection white blood cells divide 
rapidly and thus the nodes can be swollen. They can be assessed in cancer 
patients to enable the monitoring of metastasis.35     
 
 
 
Figure 1.4- A diagram of the structure of a lymph node. It can be divided into three primary areas: 
cortex, paracortex and the medulla. Reproduced from reference 37.   
      
 
Lymph nodes are secondary organs in the lymphatic system. Their 
structure consists of a cortex with lymph follicles (where B-cells are located), a 
paracortex (where T-cells are located), and a medulla (Figure 1.4). Each 
compartment contains specific subsets of T lymphocytes and B lymphocytes, 
macrophages, dendritic cells and stroma cells.38 Lymphocytes are a type of white 
blood cell produced in the bone marrow. T lymphocytes are responsible for cell-
mediated cytotoxic reactions and for mediating inflammatory reactions. T cells 
also produce the cytokines that regulate the immune response and provide helper 
activity for B cells. B lymphocytes are the precursors of immunoglobulin-secreting 
plasma cells and they concentrate and present antigens to T cells. Resting 
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lymphocytes are typically small round cells with a dense nucleus and little 
cytoplasm in appearance.39 Lymph nodes are typically 8-12 mm in diameter but 
can vary greatly depending on the individual and anatomical location.40  
 
 
Lymph nodes are found where vessels converge; they are discrete 
masses of fibrovascular tissue enclosed by the lymphatic vessel. Approximately 
450 lymph nodes are found in the human body. Lymph nodes are formed during 
development when a mesenchymal bud invaginates into a lymphatic sac and 
compresses the lumen of the sac against the opposite wall. The sac becomes 
covered by the endothelium lining as it expands. The sac wall becomes the 
capsule and the point at which invagination occurs becomes the hilum. A number 
of lobules are found within lymph nodes. The mesenchymal tissue differentiates 
into these lobules and the sac lumen develops into the system of sinuses that 
surround the lobules; the capsule encloses these structures. The lobules collect 
inflammatory mediators and dendritic cells (antigen-presenting cells) from lymph 
which flows through the system of sinuses, exposing its content to lymphocytes.32 
After monocytes are released from the bone marrow into circulation they migrate 
into various tissues where they differentiate into dendritic cells or macrophages. 
Macrophages are found in almost all tissue of the body and respond to external 
stimuli as a result of infection to aid the body’s immunity.41 Receptors on their 
surface detect the signals that are not usually present in normal cells. 
Macrophages in lymph nodes remove viruses from lymph and initiate antiviral 
humoral immune responses. Therefore, macrophages both fight infection and 
remove dead cells and toxic materials. They also restore tissue homeostasis 
through reducing the inflammation following infections.42 The lymphoid lobule is 
the basic functional unit of the lymph node and their number varies between 
nodes. Its anatomical structure provides indications regarding the functionality 
and pathology of the lymph node. The primary immune response occurs in the 
lymph nodes. In the reticular meshwork of the stromal structure, antigens are 
displayed by antigen-presenting cells to lymphocytes, which then undergo clonal 
expansion to produce new lymphocytes and plasma cells to secrete and release 
antibodies into the lymph. When foreign antibodies invade the body, a local 
immune response is activated at the site of infection. The lymphatic vessels 
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collect the antigenic material, dendrite cells and inflammatory mediators present 
at the site of infection and transport them in the lymph fluid.32 
 
 
1.2.2  Cancers of the Lymph Nodes 
 
Cancers of the lymph node can be either primary neoplasms, which have 
originated from the cells of the lymph node, or secondary neoplasms, where cells 
from tumours in other organs metastasise to the lymph nodes and form deposits. 
Primary cancers of the lymph node are primarily classified as either Hodgkin’s or 
non-Hodgkin’s lymphoma, and constitute the most common type of blood 
cancer.43  
 
In 1832 Thomas Hodgkin first recognised human lymphomas, leading to 
the classification of Hodgkin lymphoma and their distinction from other types of 
lymphomas. Classification is based on both morphology and molecular 
constituency of the tissue.44 Lymphomas are types of blood cancer and are 
primary lymph node cancers, which originate from lymphocyte cells found in the 
nodes. Lymphomas are divided into Hodgkin’s lymphoma (HL) and non-
Hodgkin’s lymphoma (NHL). According to the Cancer Research incident and 
mortality UK reports for 2010,10 NHL was the 5th most common cancer in men 
and the 7th most common cancer in women. Of those diagnosed, 37% of males 
and 36% females died as a result of the disease. In males, NHL accounted for 
approximately 8% of the total cancers diagnosed in 25-49 year olds, 4% in 50-74 
year olds and 4% in 75 year olds and over. A 12% increase of NHL diagnoses 
has been observed from 1999-2010; however, the death rate has decreased by 
15% in males and 21% in females. Hodgkin’s lymphoma is much more infrequent 
with only 17% of those diagnosed resulting in fatalities. In males, an 11% increase 
in HL diagnosis has been observed from 1999–2010. 
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Figure 1.5- A bar graph to show the number of diagnoses and fatalities of non-Hodgkin’s and 
Hodgkin’s lymphoma in the UK (top) and worldwide (bottom).45  
 
 
Hodgkin’s lymphoma will almost always present as a nodal disease with a 
propensity for occurrence in head and mediastinal nodes. However, in up to 40% 
of non-Hodgkin’s lymphomas, the disease will evidence itself in an extranodal 
location.46 Extranodal lymphomas are those that arise from tissue other than the 
lymph nodes. The most frequent site for extranodal non-Hodgkin’s lymphoma is 
the gastrointestinal tract, being the location for 30-40% of this type of 
lymphoma.47 Extranodal lymphomas associated with the skin or central nervous 
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system (CNS) are also common. They often originate from mucosa-associated 
lymphoid tissue and are identified if there is little or no involvement of the lymph 
nodes and there is a clinically dominant extranodal component. The incidence of 
extranodal lymphomas has increased in years, especially those of the CNS, 
thought to be attributed to the increase in viral infections, such as acquired 
immunodeficiency syndrome (AIDS), and the use of immunosuppressant 
treatments. Patients with these lymphomas are less likely to present with B 
symptoms (Table 1.1) than patients with lymphomas arising in lymphatic nodal 
regions.48                
 
 
Table 1.1- Revised European American Lymphoma (REAL)/World Health Organisation (WHO) 
classification of lymphoid neoplasms.49   
Non-Hodgkin’s lymphoma 
 
B-Cell neoplasms 
Precursor B-cell neoplasm 
- Precursor B-lymphoblastic leukaemia/lymphoma (precursor B-cell acute lymphoblastic 
leukaemia) 
Mature (peripheral) B-cell neoplasms 
- B-cell chronic lymphocytic leukaemia/small lymphocytic lymphoma 
- B-cell prolymphocytic leukaemia 
- Lymphoplasmacytic lymphoma 
- Splenic marginal zone B-cell lymphoma (1/2 villous lymphocytes) 
- Hairy cell leukaemia 
- Plasma cell myeloma/plasmacytoma 
- Extranodal marginal zone B-cell lymphoma of MALT type 
- Nodal marginal zone B-cell lymphoma (1/2 monocytoid B cells) 
- Follicular lymphoma 
- Mantle-cell lymphoma 
- Diffuse large B-cell lymphoma 
- Mediastinal large B-cell lymphoma 
- Primary effusion lymphoma 
- Burkitt’s lymphoma/Burkitt cell leukaemia 
 
 
T-cell and NK-cell neoplasms 
- Precursor T-cell neoplasm 
- Precursor T-lymphoblastic lymphoma/leukaemia (precursor T-cell acute lymphoblastic 
leukaemia) 
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- Mature (peripheral) T-cell neoplasms 
- T-cell prolymphocytic leukaemia 
- T-cell granular lymphocytic leukaemia 
- Aggressive NK-cell leukaemia 
- Adult T-cell lymphoma/leukaemia (HTLV11) 
- Extranodal NK/T-cell lymphoma, nasal type 
- Enteropathy-type T-cell lymphoma 
- Hepatosplenic gamma-delta T-cell lymphoma 
- Subcutaneous panniculitis-like T-cell lymphoma 
- Mycosis fungoides/Sezary syndrome 
- Anaplastic large-cell lymphoma, T/null cell, primary cutaneous type 
- Peripheral T-cell lymphoma, not otherwise characterized 
- Angioimmunoblastic T-cell lymphoma 
- Anaplastic large-cell lymphoma, T/null cell, primary systemic type 
 
 
Hodgkin’s lymphoma (Hodgkin’s disease) 
Nodular lymphocyte-predominant Hodgkin’s lymphoma 
Classical Hodgkin’s lymphoma 
- Nodular sclerosis Hodgkin’s lymphoma (grades 1 and 2) 
- Lymphocyte-rich classical Hodgkin’s lymphoma 
- Mixed cellularity Hodgkin’s lymphoma 
- Lymphocyte depletion Hodgkin’s lymphoma 
 
 
 
Cancer classification is based on the assumption that cancers from the 
same anatomical location and of the same histology will have similar patterns of 
development and thus will have similar prognostic outcomes.50 Currently 
lymphomas are classified in accordance with the Revised European American 
Lymphoma (REAL)/World Health Organisation (WHO) classification system. The 
development of the REAL and WHO classification systems involved the 
consensus of 19 and 50 pathologists respectively.51 Two lymphoid differentiation 
pathways occur in the immune system, either involving T (thymus-derived) cells 
or B (bursa-derived) cells. Therefore, non-Hodgkin’s lymphomas are separated 
into either T-cell tumours or B-cell tumours.52 Approximately 90% of aggressive 
lymphoma cases are derived from B-cells.53 Diffuse large B-cell lymphoma is the 
most common subtype of non-Hodgkin’s lymphoma. It is clinically heterogeneous 
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and approximately only 40% of patients respond to treatment sufficiently enough 
to prolong life.44    
 
There are two classifications of Hodgkin’s lymphoma, nodular lymphocyte 
predominance HL and classical HL. Neoplastic cells can be characterised by 
lineage specific markers, activation markers and transcription factors. Reed-
Sternberg cells are often present in the lymph nodes of individuals with Hodgkin’s 
lymphomas and thus the identification of these cells is essential for diagnosis of 
the disease. However, affected lymph nodes consist of less than 1% of these 
neoplastic cells.54  
 
 
Table 1.2- The stages of lymphoma disease55 based on the Ann Arbor method of lymphoma 
staging.56   
Stage Features 
I Single lymph node region affected/one extralymphatic site affected 
II Two or more lymph nodes affected on the same side of the 
diaphragm/one extralymphatic site and at least one lymph node 
region affected on the same side of the diaphragm. 
III Lymph node regions on both sides of the diaphragm affected and 
can include extralymphatic site involvement also. 
IV Diffuse involvement of at least one extralymphatic site. 
Suffix  
A No symptoms  
B The patient experiences any of the following symptoms: weight loss 
(>10% baseline during 6 months before staging), recurrent 
unexplained fever (>38oC), or night sweats. 
X Bulky tumour tissue (>10cm in largest diameter or mediastinal 
tumour which is >1/3 of maximum transverse transthoracic, diameter 
measured on posterior-anterior chest radiograph) 
 
 
Lymphatic vessels aid cancer metastasis by undergoing changes to assist 
the entry of cells into lymphatic vessels. These changes involve 
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lymphangiogenesis and lymphatic enlargement in the lymphatics around the 
primary tumour. Growth factors, produced from tumour cells and cells from the 
immediate environment encourage lymphangiogenesis, where new lymphatic 
vessels are formed from the pre-existing lymphatic network, and the enlargement 
of the lymphatic vessels in and around the tumour site. Enlargement of the 
vessels can also lead to remodelling of the lymphatics by the surrounding smooth 
muscles. The prognosis of a patient is decreased rapidly upon the dissemination 
of cancer from a primary site to the lymph nodes.57 Metastatic cancers in the 
lymph nodes are those that have spread there from other organs. They can be 
squamous cell carcinomas (SCC), from malignant primary cancers of the upper 
aero-digestive tract, or adenocarcinomas, from malignant primary cancers in the 
head, neck, breast and oesophagus.58 When a cancerous cell spreads from one 
organ and settles in another it continues to divide and although the cells are 
mutated, it typically recreates its original tissue where it metastasised from. Thus, 
the secondary tumour structure takes the form of the tissue architecture of the 
primary cancer.  
 
 
 
Figure 1.6- Lymph node anatomy, reproduced from reference 59. 
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Afferent lymphatic vessels draining connective tissue and peripheral 
lymph nodes empty into the subcapsular sinus. The lymph fluid then enters the 
medullary sinuses, via intermediate sinuses, and eventually is collected by 
efferent lymphatic vessels. Around the hilus the subcapsular sinus filters the 
lymph fluid directly into the medullary sinises. The direction of lymph flow is 
controlled by valves in the vessels.60 Thus, infiltrating tumour cells first collect in 
the subcapsular sinus as individual cells or clusters and then infiltrates the 
medullary sinuses, medulla and eventually the cortex. Partial or whole lymph 
node replacement finally occurs. Due to the invading metastasis the lymph node 
undergoes changes throughout its structures, for example hyperpasia to the 
follicles and paracortex and sinus histiocytosis are a few. Cytologically the 
metastatic cells should largely be similar to the cells of the primary tumour, 
although not in all cases.61 
 
 
Figure 1.7- The metastatic process of tumour cells using the lymphatic system as a pathway for 
dissemination to lymph nodes and other secondary sites. Reproduced from reference.57 
 
 
 
As primary malignancies increase in size, the frequency of regional lymph 
node involvement and distant metastases also increase.62  Although the pattern 
of lymphatic drainage varies between anatomical locations of lymph nodes, the 
prognostic outlook of a patient is influenced by the site of the lymph node 
metastases. Prognosis of a patient with head and neck lymph node metastases 
is often worse if metastases occur in lymph nodes beyond the first level of 
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lymphatic drainage and if the lymph nodes that are involved are in lower regions 
of the neck, such as the supraclavicular region.50 The presence of lymph node 
metastases is a useful indicator of a patient’s prognosis and is often used to stage 
the cancer. Studies have shown that as the number of lymph node metastases 
increase, patients’ chance of survival decrease.63 
 
 
 
Figure 1.8- Image of oesophageal lymph nodes, reproduced from reference.64 
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Table 1.3- Head and neck lymph nodes are distinguished based on 7 anatomically distinguished 
sites.50 
Lymph node level Anatomical location  
Level I Submental 
Submandibular  
Level II Upper jugular 
Level III Mid jugular 
Level IV Lower jugular 
Level V Posterior triangle 
Level VI Prelaryngeal  
Pretracheal 
Paratracheal  
Level VII Upper mediastinal 
Other groups Sub occipital  
Retropharyngeal  
Parapharyngeal 
Buccinator  
Preauricular 
Periparotid and intraparotid 
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Figure 1.9- Schematic of the anatomical location associated with the classification level of head 
and neck lymph nodes. Replicated from reference50. 
 
 
1.2.3 Symptoms 
 
The most frequent symptom of a lymphoma is lymphadenopathy which is 
the enlargement of the lymph nodes in the neck, armpit or groin. They are usually 
painless but can ache. Other associated symptoms, which are often rare, include: 
prolonged infections and a susceptibility to develop them, fatigue, night sweats, 
weight loss, vomiting, high body temperature, breathlessness and persistent itchy 
skin. These symptoms are not specific to lymphomas and infections and other 
conditions can produce the same symptoms.65  
 
1.2.4 Pre-operative Diagnosis 
 
Blood tests can be carried out initially to assess the level of each type of 
blood cell: white blood cells, red blood cells and platelets, and to examine the 
efficacy of the liver and kidneys. Diagnosis can also be aided by imaging 
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techniques such as computed tomography (CT), magnetic resonance imaging 
(MRI) and positron emission tomography (PET). CT is used to produce a series 
of two-dimensional images in order to construct a three-dimensional image. The 
images are produced by scanning the patient with a narrow beam of x-rays which 
are detected by a device directly opposite the x-ray source.66 The variation 
between magnetic susceptibility of tissues is the basis for MRI. The magnetic 
susceptibility is a measure of a materials’ ability to interact with and distort a 
magnetic field 67. PET is an imaging technique that labels the small biological 
molecules of interest with positron-emitting radionuclides. When these positron-
emitting labels undergo radioactive decay they can be detected by the PET 
scanner. Temporal distribution imaging can allow the formation of physiological 
maps. Unlike MRI and CT, PET has the potential to differentiate between benign 
and malignant tumour masses.68 Imaging techniques enable non-invasive, in vivo 
monitoring allowing analysis of the tumour mass, its margins and its location.69 
The assessment of nodal size is limited as lymph node enlargement is not 
confined to cancer alone and can occur as a result of other factors, such as 
infection. When an upper limit in nodal size of 1 cm is used a sensitivity of ~64% 
and a specificity of ~62% occurs.70 Kerr et al. reported that 58% of malignant and 
43% of benign lymph nodes were over 15 mm in size.71 The similar features of 
benign and malignant cancers also limit the diagnostic use of MRI.70 
Ultrasonography can also be used to assess tumours; however, these non-
invasive pre-operative techniques cannot differentiate between benign and 
malignant tumours alone.72  
 
These examinations are only used to preliminary assess a suspected 
tumour due to the risk of misdiagnosis when relied upon alone. For brain cancer, 
it has been reported that false positive diagnoses occur in approximately 11% of 
patients with brain lesions when based only on the MRI scan. More definitive, 
examinations must be carried out to allow more accurate diagnosis.73 Moreover, 
early and accurate diagnosis is required; these methods cannot identify solid 
tumour masses smaller than 1 cm3 in diameter (approximately 109 cancer cells). 
74  
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1.2.5 Post-operative Diagnosis 
 
Currently the gold standard for cancer diagnosis is histopathological 
analysis of excised specimens, where the architecture of the tissue is 
microscopically assessed. In order for this method of analysis to be performed 
the tissue must be sectioned and stained, therefore requiring tissue removal. The 
enlarged lymph node is removed in cases of suspected primary lymphatic 
cancers. For cases of suspected metastasis, a sentinel lymph node biopsy is 
conducted. It is carried out on the basis that cancer cells that have invaded the 
lymphatic system from external locations, will have initially passed through 
sentinel nodes, as these nodes are closest to the tumour. Sampling the sentinel 
nodes is therefore a less invasive method of identifying metastatic spread, than 
sampling all regional nodes. However, in approximately 25–30% of cases the 
result from sentinel lymph node analysis will be positive for metastases and a 
subsequent operation will be required to remove affected lymph nodes. This 
delays treatment, uses up hospital resources and can cause psychological upset 
to the patient.75 Unnecessary removal of the lymph nodes can cause unneeded 
health problems for the patient such as lymphoedema. Lymphoedema is caused 
when the lymph nodes that would otherwise filter lymph fluid have been removed, 
causing the fluid to build up without a way of removal. This condition results in 
disfigurement, physical discomfort and the loss of functionality in affected areas.76 
After biopsy of the tissue, it is usually placed in formalin and subsequently 
embedded with paraffin. It can then be sectioned and stained for evaluation by a 
pathologist.    
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Figure 1.10- H&E stained lymph node section. Replicated from reference.77 
 
 
Staining is done in order to clearly visualise cellular components in the 
section. Haematoxylin and Eosin (H&E) are often the stains of choice for 
histology. Haematoxylin dyes the cell’s nuclear components blue and eosin dyes 
the cytoplasm of cells and connective tissue pink.78 The cut surface of a normal 
lymph node is grey/pink in colour, has a soft texture and is homogenous. 
Whereas, the cut surface of a lymph node with neoplasia has a white colouration, 
a firm texture and is nodular.79 Neoplasms are typically identified by increased 
cellular crowding and disorder to the tissue structure.30 Analysis consists of 
assessment of the tissue’s morphology, architecture and staining to form a 
diagnosis. Neoplastic cells exhibit cytological differences: increased nuclear 
material, inflammation, increased nuclear-to-cytoplasmic ratio, increased nuclear 
staining, abnormal nuclear shape and size, abnormal chromatin distribution, 
decreased differentiation and increased mitotic activity.80 Figure 1.10 shows a 
microscopic image of an H&E stained lymph node section. The presence of 
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Hodgkin and Reed/Sternberg (HRS) cells (Figure 1.11) aid the differentiation of 
Hodgkin’s lymphoma from non-Hodgkin’s lymphoma; however, only 1% of these 
cells are present in tumour tissue.81 Tindle states that the presence of a Reed-
Sternberg cell alone does not identify Hodgkin’s lymphoma but a diagnosis will 
not be made without them.82  
Tissue can also be frozen rather than formalin-fixed but whilst metastatic 
disease is relatively simple for the pathologist to distinguish due to invasion of a 
different cell type, lymphoma is much harder to identify on frozen tissue sections. 
 
 
 
Figure 1.11- Classic binucleate Reed-Sternberg cell replicated from reference.54 
 
 
This histopathological method of diagnosis requires a trained 
histopathologist, is invasive, due to the need of biopsy, have lengthy processing 
times, delays the start of treatment, and its findings may result in the need of 
subsequent surgical procedures. Histopathological examination can also be a 
highly subjective method of diagnosis83 and it has been reported that diagnostic 
pathological discrepancies can occur in 1–43% of all specimens.84 If the biopsy 
procedure fails to locate and remove tumorous tissue, normal tissue may be 
46 
 
analysed and result in false negatives. Treatments, which could potentially be life 
threatening, are chosen based on the outcome of histopathological diagnosis.85 
Tumours are heterogeneous and there are a wide range of cancer morphologies; 
thus, many tumours do not exhibit typical identifying features.86 Tumours are 
poorly differentiated in adenocarcinomas and the microscopic appearance of the 
primary and metastatic cancers of different locations are similar to each other. 
Consequently histopathological examination is problematic and hence diagnosis 
is difficult.87 It has been reported that there were major diagnostic disagreements 
between pathologists in 16.6% of Hodgkin’s lymphoma cases and 27.3% of non-
Hodgkin’s lymphoma cases.88 The analysis of sections by another pathologist to 
provide a second opinion is claimed to be too costly. However, Hahm et al.5 argue 
that a second review would actually reduce the costs that misdiagnoses can 
cause. They go on to support this by stating that the cost of unnecessary surgery 
caused by misdiagnosis of a benign tumour as malignant, or the delayed 
treatment of a malignant tumour misclassified as benign, would be eliminated.      
 
 A WHO (World Health Organisation) classification could be assigned to 
91% of non-Hodgkin lymphoma cases, however only 57.5% could be done so 
with high confidence.89 WHO grading is typically more clinically reproducible than 
other classification methods.89 The classification enables collaboration between 
the oncologists and pathologists and enables better understanding of lymphoid 
neoplasms and their treatment. Although pathologists primarily determine the 
classification of specimens, clinicians know the practical efficacy and outcome of 
classifications. WHO classification of lymphomas is based on cell lineage and 
morphology as either Hodgkin’s lymphomas or non-Hodgkin’s lymphomas: either 
B-cell neoplasms or T-cell neoplasms. T-cell and B-cell neoplasms can be further 
grouped into precursor neoplasms, representing the early stage of differentiation, 
and mature neoplasms, representing the tumours which are highly 
differentiated.90            
 
 Histopathological diagnosis involves the examination of only a portion of a 
lymph node. As a result, sampling errors can occur and lead to misdiagnosis. 
Figure 1.12 diagrammatically explains how sampling errors can occur. 
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Figure 1.12- Diagram showing the results of sampling error as a result of tissue sectioning. 
Section 1 would result in a true positive diagnosis for a macrometastasis (>2 mm). Section 2 
would result in a true positive for both a macrometastasis and a micrometastasis (<2 mm). Section 
3 would result in a false negative diagnosis. Section 4 would result in a true positive diagnosis for 
isolated tumour cells (ITC) as well as a false negative diagnosis, where a macrometastasis 
appears to be a micrometastasis. Replicated from reference.91    
 
 
1.2.6  Cytology 
 
Cytological diagnosis is made as a result of the skilled interpretation of the 
microscopic appearance of cells. It is less reliable than histopathology for 
definitive diagnosis but is highly useful for detecting cellular differences in large 
population screening.92 Fine needle aspiration cytology (FNAC) is an established 
method for the diagnosis of lymph node cancers. Although it cannot distinguish 
all types of neoplasms, it is a much safer procedure than open biopsy.93 FNAC 
can be used in the diagnosis of common lymphomas such as large B cell 
lymphoma, small lymphocytic lymphoma and follicular lymphoma, which 
constitute approximately 70% of all lymphomas.94 It is also a rapid and 
economical technique and is safer than core biopsies for superficial lesion 
analysis. It is also less invasive, due to a fine needle size, and hence reduces the 
trauma a patient can experience. The fine needle aspirates can be further 
examined using immunocytochemistry techniques. However, low sensitivities 
and specificities has led to questions concerning the further use of this technique 
diagnostically.95 A wide range of FNAC sensitivities and specificities have been 
reported from 68–98% and 56–100% respectively.96 Leenders et al. 97 calculated 
a sensitivity of just 24.7% for the identification of axillary metastases in breast 
48 
 
cancer using ultrasound guided FNAC, and concluded that the technique should 
not be relied upon alone for diagnosis.  
 
1.2.7 Molecular Diagnosis 
 
Molecular diagnosis offers the advantage of complete objectivity, precision 
and reproducibility. However, the current lack of accepted pathologically 
identifying biomarkers prevents the universal application of these techniques.86 
Cross et al. 98 stress the importance of identifying and detecting biomarkers for 
more accurate cancer diagnosis as the disease is highly complex. Usually 
molecular techniques employ a polymerase chain reaction (PCR) step using 
homogenised lymph node tissue or fine needle aspiration (FNA) samples. 
However, this is a destructive method and risk of contamination presents an issue 
for the reliability of results produced from this technique.91 
  
Molecular diagnosis functions based on the fact that only specific genes 
are transcribed into messenger RNA (mRNA) in each cell. The mRNA in a cell 
dictates the proteins expressed and the amount present is dependent on the cell’s 
lineage and differentiation stage, activity of intracellular regulatory pathways and 
the influence of extracellular stimuli. Firstly, mRNA must be extracted from the 
cell and copied, using enzymes, to produce fluorescent complimentary DNA 
probes which represent the expressed genes in the cell. The probes are 
incubated on the surface of a DNA microarray, which contain DNA spots for 
thousands of specific genes, to enable the probes to hybridise to the 
complimentary microarray spot. The extent of hybridisation can be quantified 
using a scanning fluorescent microscope. The expression of thousands of genes 
can be measured at one time with this technique. The diagnosis of cancers rely 
on the assessment of morphology, however differential patient response to 
treatment suggest that subcategories could exist within current clinical 
classifications. These subcategories could be recognised by the identification of 
varying gene expression in different cells.99 Although gene profiling is an 
expensive technique it has been argued that it is cheaper than current methods 
in the long term; as accurate diagnosis leads to early and targeted treatment, 
resulting in better prognosis and increased survival rates which is more cost-
effective.100 However, DNA micro-array studies are limited to a few types of 
49 
 
cancers and have been investigated using a wide variety of methodologies, which 
can lead to the inability to compare the results of the studies to one another.86   
 
Immunohistochemical staining involves the staining of tissue or cells with 
coloured/fluorescent dye tagged antibodies, which can identify cancer cells 
based on the alteration of protein expression when compared to normal cells 19. 
However, technical failure or sample heterogeneity can result in lack of staining 
and thus misdiagnosis, as observed by Nielsen et al.101 where the use of a single 
basal marker missed approximately half of basal-like tumours.  
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1.3 Optical Spectroscopy 
 
Spectroscopy is the study of the interaction of electromagnetic radiation 
(Figure 1.13) with matter. Information about a sample’s molecular structure can 
be gained, such as the symmetry, bond distances and angles. The chemical 
properties of a sample, such as electronic distribution and the bond strength, can 
also be acquired.102 Techniques utilise the emission, absorption or scattering of 
this radiation, to gain the information regarding the molecules’ identity. Emission 
is where a molecule drops from a state of high energy to a state of low energy, 
and thus emits the excess energy as a photon, such as fluorescence. Absorption 
of radiation by molecules can be monitored by measuring the intensities of 
transmitted light over a range of wavelengths in order to ascertain which 
wavelengths have been absorbed by the sample. Molecules also have the ability 
to scatter the light it interacts with.103 This scattering can occur both elastically 
with no energy change, or inelastically, where energy is transferred between the 
light and molecule. It is these inelastic collisions that are detected in Raman 
spectroscopy.    
 
 
 
Figure 1.13- Electromagnetic spectrum. 
 
 
1.3.1 Vibrational Spectroscopy 
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Spectroscopy utilises the interaction of light and matter to produce 
characteristic spectra unique to specific molecules. A molecule consists of atoms 
and the bonds that bind them together. These molecules consist of sets of 
coupled harmonic oscillators that vibrate when disturbed from a state of 
equilibrium.104 A molecule exposed to a static electric field, associated with 
radiation, becomes distorted as the positively charged nuclei are attracted toward 
the negative pole and the negatively charged electrons are attracted toward the 
positive pole. The charge centre separates and an induced dipole moment occurs 
as a result, the molecule is polarised.105 This dipole moment (µ) is proportional to 
the magnitude of the applied electric field (E) and the ease of molecular 
distortion105 and can be represented by the following equation, where α is the 
polarisability:  
 
 =𝜇
→ 𝛼𝐸
→ Eq. 2.3.7105 
 
 
Vibrational motions of a molecule involve a set of nuclei 
that are connected by forces that act between the nuclei. 
Strong forces occur between the nuclei of bonded atoms and provide resistance 
during the stretching mode of molecules. Weak forces occur between the nuclei 
of non-bonded atoms and provide resistance during bending modes that cause 
an increase or decrease to the angle. Displacement of the nuclei leads to complex 
motions of the molecule.106 Molecular vibrations can occur by both stretching and 
bending of bonds (Figure 1.14). Stretching involves the variation of a bond length 
between two atoms, through lengthening and compression. Stretching can be 
symmetric, where it occurs in phase, or asymmetric, where it occurs out of phase. 
Bending is where an atom moves out of its regular plane, leading to a change in 
the angle of the bond.107 The different modes of vibration can be seen in Figure 
1.14. 
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Figure 1.14- Vibrational modes. 
 
 
Vibrating molecules can interact with radiation either by absorption, which 
is measured in infrared spectroscopy, or scattering, which is measured in Raman 
spectroscopy.104 The frequencies of the Raman shifts measured in Raman 
spectroscopy correspond to the absorption frequencies measured in infrared 
spectroscopy. This is because each normal mode of vibration oscillates at a 
characteristic frequency and in turn either scatters or absorbs light at a frequency 
of either the difference or the sum of the incident radiation and the molecule’s 
vibrational frequency, thus the energy exchange in both the absorption and 
scattering of light is specific to molecules (Figure 1.15).  
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Figure 1.15- Energy transitions for different types of vibrational spectroscopy. The virtual state 
represents the temporary distortion of the electron distribution 108,109. 
 
 
 
For the vibrational modes to be active, both techniques have different 
selection rules. Therefore, some vibrational modes are mutually exclusive, being 
only active in either Raman or infrared spectroscopy, and the band is expressed 
in only one of the technique’s spectrum. The vibrational modes of molecules with 
a centre of symmetry are typically active in either Raman or infrared but not 
both.110 
 
For a diatomic molecule there are three degrees of translational freedom 
and two degrees of rotational freedom. Only the symmetrical stretching 
vibrational mode is present in diatomic molecules. Polyatomic molecules 
containing (N) number of atoms will have 3N degrees of freedom (Table 1.4).107  
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Table 1.4- The degrees of freedom for linear and non-linear molecules. Reproduced from 
reference 107 
Degrees of freedom Linear Non-linear 
Translational 3 3 
Rotational 2 3 
Vibrational 3N-5 3N-6 
 
 
The degrees of freedom of a molecule depend on whether the molecule is 
of a linear or non-linear composition. The frequency of these vibrational modes 
is dependent on the masses of the atoms involved and the stiffness of the 
bond.107 Hooke’s law can be applied to the vibrational properties of atoms. 
Hooke’s law states that the force (F) needed to move a solid from its equilibrium 
state by a specific distance (𝑥), is related to the force constant (𝑓), a measure of 
bond strength. In equation 2.3.1 the restoring force is shown by – 𝑓 (the force in 
the opposite direction to the elongation): 
 
 𝐹 = −𝑓 ⋅ 𝑥 
 
Eq. 2.3.1 
 
Newton’s law states that force is also directly proportional to the mass (𝑚) 
and its acceleration (the second derivative of the elongation with respect to time 
(t)): 
 
 𝐹 = 𝑚 ⋅ (ⅆ2𝑥 ⅆ𝑡2 ⁄ ) 
 
Eq. 2.3.2 
 
Combining these equations (2.3.1 and 2.3.2) results in: 
 
 𝑚 ⋅ (ⅆ2𝑥 ⅆ𝑡2)⁄ = −𝑓 ⋅ 𝑥 
 
Eq. 2.3.3 
 
55 
 
Solving this equation for 𝑥 describes the motion of the atom as a harmonic 
oscillation where 𝑣 is the vibrational frequency and 𝜑 the phase angle:  
 
 𝑥 = 𝑥0 ⋅ cos(2𝜋𝑣𝑡 + 𝜑) 
 
Eq. 2.3.4 
 
The second derivative of distance (𝑥) by time (t) is found to be: 
 
 ⅆ2𝑥 ⅆ𝑡2⁄ = 4𝜋2𝑣2𝑥0 cos(2𝜋𝑣𝑡 + 𝜑) = −4𝜋
2𝑣2𝑥 
 
Eq. 2.3.5 
 
Insertion into equation 2.3.3: 
 
 𝑣 = (1 ∕ 2𝜋)√(𝑓 ∕ 𝑚) 
 
Eq. 2.3.6 
 
The reduced mass (µ) is a combination of the atomic masses (m1, m2) that 
are involved in the vibrational mode, and is calculated by:  
 
 𝜇 = 𝑚1𝑚2 ∕ 𝑚1 + 𝑚2 
 
Eq. 2.3.7 
The wavenumber of the vibrational mode can then be calculated, using the 
speed of light constant (c) as: 
 
 ?̅? = (1 ∕ 2𝜋𝑐)√(𝑓 ∕ 𝜇) 
 
Eq. 2.3.8 
 
Therefore the wavenumber of the vibrational mode is indicative of the bond 
stiffness reduced mass in order to understand the molecular structure. 
  
Both Raman and Infrared spectroscopy have many advantages as 
analytical techniques. They are both rapid, non-destructive, objective, 
economical and their instrumentation is relatively small.104  
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1.3.2 Raman Spectroscopy 
 
 Raman spectroscopy is named after the Indian physicist Chandrasekhar 
Venkata Raman, who first observed and described the phenomenon of inelastic 
light scattering in 1928 and received the Nobel Prize for it in 1930.111  
 
 
Figure 1.16- Schematic of a Raman Spectrometer coupled with an objective (silver). 
 
 
Raman spectroscopy utilises a monochromatic and coherent light source 
(laser) for sample illumination, the interaction between the sample and the light 
results in photon scattering which is detected and measured. The instrumental 
schematic is shown in Figure 1.16. Scattering can occur either with or without an 
exchange in energy between the light and the molecule. When light illuminates 
molecules in a state of equilibrium, radiation of the same frequency as the 
incident light is scattered from the molecules. This form of elastic scatter is 
frequent and is referred to as Rayleigh scattering.105 Raman scattering on the 
other hand, is inelastic and generally comprises less than 0.001% of the total 
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scattered light.112 An energy exchange occurs between the molecules within a 
sample and the incident light in accordance with its vibrational frequency. The 
light is scattered with a different frequency, and thus wavelength, to that of the 
incident light. The wavelength change is directly related to specific normal modes 
of vibration. The energy change must be equal to the difference in energy 
between two of the allowed energy states of the molecule. When a molecule 
gains energy, photons will be scattered with hѵ-ΔE and the light will have a 
frequency of ѵ-ΔE/h. Conversely if a molecule loses energy, photons will be 
scattered with hѵ+ΔE and the light will be scattered with a frequency of ѵ+ΔE/h. 
Where hѵ is the photon energy, ѵ is the radiation frequency and h is Planck’s 
constant (6.62x10-34 J.s).105 Scattered light with a lower frequency to that of the 
incident light is called Stokes scattering. At room temperature the majority of 
molecules are found at ground state and thus, this form of Raman scattering is 
more common. Energy is transferred from the incident light to the molecule; the 
excited molecule does not return to its ground state from the virtual state, but to 
its vibrational state, and a lower energy photon is emitted (Figure 1.15). Scattered 
light of a higher frequency to that of the incident light is called anti-Stokes 
scattering. This is where the molecule is already at its vibrational state, due to 
prior excitement or thermal disturbance, and the molecule is excited to a virtual 
state. Energy is transferred to the incident light from the molecule, returning it to 
its ground state, and a photon of higher energy is emitted. Raman shift (cm-1) is 
calculated based on the energy difference between the scattered light and the 
wavelength of the incident radiation.113,114 
 
  The ability of a molecule to scatter light is based on its polarisability. 
Polarisability represents the ability of an electric field to induce a dipole moment 
in a molecule. The electron clouds of molecules and atoms that are further away 
from the nucleus are easier to distort, thus have a stronger polarisability, than 
those that are closer to the nucleus. However, rotation and vibrations of a 
molecule can alter its polarisability, α, and can be explained by the following 
equation. Where, 𝛼0 is the polarisability of a molecule at its equilibrium nuclear 
geometry, Δr is the distance from a molecule’s equilibrium geometry, and (
𝜕𝛼
𝜕𝑟
) is 
the change in polarisability in relation to the change in the position during vibration 
or rotation.     
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𝛼 = 𝛼0 + (
𝜕𝛼
𝜕𝑟
) 𝛥𝑟 
Eq. 2.3.10 
 
The sinusoidal behaviour of a rotating or vibrating molecule causes Δr to 
be written as: 
 
 𝛥𝑟 = 𝑟𝑚𝑎𝑥 cos(2𝜋𝑣𝑡) 
 
Eq. 2.3.11 
 
 Where 𝑣 is the frequency of the vibration, t is the time, and rmax is the 
maximum vibrational amplitude. The electric field, E, associated with light has 
sinusoidal behaviour and therefore is represented by the following equation. 
Where, 𝑣in is the frequency of light and Emax is the maximum electric field 
frequency. 
 
 𝐸 = 𝐸𝑚𝑎𝑥𝑐𝑜𝑠(2𝜋𝑣𝑖𝑛𝑡) Eq. 2.3.12 
 
These equations can then be combined with equation 2.3.10 to produce: 
 
 𝜇𝑖𝑛 = 𝛼0 𝐸max𝑐𝑜𝑠(2𝜋𝑣𝑖𝑛𝑡)
+ 𝐸𝑚𝑎𝑥𝑟𝑚𝑎𝑥 (
𝜕𝛼
𝜕𝑟
) 𝑐𝑜𝑠(2𝜋𝑣𝑡) cos(2𝜋𝑣𝑖𝑛𝑡) 
 
Eq. 2.3.13 
The following equation describes the relationship for the product of two 
cosines: 
 
cos 𝑎 × cos 𝑏 =
1
2
(cos(𝑎 + 𝑏) + cos(𝑎 − 𝑏)) 
 
Eq. 2.3.14 
 
From the previous equation (2.3.13) it can be seen that 2𝜋𝑣𝑖𝑛𝑡 is 
represented by ‘a’ and that 2𝜋𝑣𝑡 is represented by ‘b’ in equation 2.3.14, which 
results in the following equation:  
 
𝜇𝑖𝑛 = 𝛼0𝐸𝑚𝑎𝑥 cos(2𝜋𝑣𝑖𝑛𝑡)
+
𝐸𝑚𝑎𝑥𝑟𝑚𝑎𝑥
2
(
𝜕𝛼
𝜕𝑟
) (cos(2𝜋𝑡(𝑣𝑖𝑛 + 𝑣)) + cos(2𝜋𝑡(𝑣𝑖𝑛 − 𝑣))) 
Eq. 2.3.15 
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The first term in the equation describes Rayleigh scattering, as both the 
incident and scattered light frequencies are the same as one another. The second 
term describes Raman anti-Stokes scattering as the scattered light has a higher 
frequency and lower wavelength than that of the incident light. Thus, the third 
term describes Raman Stokes scattering as the scattered light has a lower 
frequency and higher wavelength than that of the incident light. If the change in 
polarisability (
𝜕𝛼
𝜕𝑟
), is zero, the second and third term will equal zero and there will 
be no Raman scattering. Thus, the selection rule for vibrational modes to be 
Raman active, is that there must be a change in polarizability.115 A change in a 
molecule’s polarisability is reflected in either the magnitude or direction of the 3-
dimensional polarisability ellipsoid.105 
 
The scattered light is then detected and in Raman spectroscopy this is 
done using charge coupled device (CCD) detectors, primarily composed of pure 
silicon. The detector’s quantum efficiency (QE) is dependent on silicon’s 
absorption ability. At wavelengths outside 3500-8000 Å photons will pass through 
the silicon, be reflected off the surface or absorb into only the surface layers of 
the silicon.116 The quantum efficiency is calculated by: QE = Number of photons 
emitted/Number of photons absorbed.117 
 
Silicon atoms covalently bond to one another and their electrons are not 
detectable when they are bound to the structure. If the structure receives energy 
that is greater than the band gap (photons that have wavelengths shorter than 10 
m) an electron hole pair is created. The electron can then be promoted to a 
conduction band and detected. Thermal energy can also produce free electrons 
which result in signal, not due to photons, called noise. These free electrons are 
collected and stored on a silicon chip defined by electric field regions, called 
‘pixels’, aligned in rows and columns. The electrons are read-out off the chip in 
order to produce a digital signal. A shift register runs horizontally below the pixel 
matrix to enable the signal to be read off the chip through shifting the entire 
charge pattern one row at a time to the shift register using electrodes. Vertical 
electrodes are then used to transfer the charge pattern across the shift register 
one element at a time into the on-chip output amplifier. The signal then is 
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transferred to the analogue-to-digital (A/D) converter which produces a 16 bit 
binary code of each charge packet. Binning can be used to allow faster readout 
and the production of reduced noise spectra due to the combining of two or more 
pixels on the CCD chip.118 The use of a CCD detector allows multiple pixels to be 
detected simultaneously as opposed to a single detector which would require a 
rotatin grating and the acquisition of each data point separately. Therefore CCD 
detectors speed up spectral collection by the channels in the CCD on the 
wavelength axis 
 
 
1.3.3 Raman Spectra 
 
Raman spectra are plotted as Raman shift against the intensity of the 
scatter. The Raman shift is typically presented as the difference in wavenumber 
between the incident and scattered light, and is independent of the incident 
wavelength. Therefore, it is characteristic to specific molecular vibrations and 
peak positions will remain the same for the same specimens regardless of the 
wavelength of the incident laser chosen to take measurements. The intensity of 
the scatter is directly proportional to the concentration of the responsible 
molecules within a specimen.119 Therefore, Raman spectroscopy is both a 
qualitative and quantitative technique that produces a characteristic spectral 
fingerprint of samples.  
 
The Raman spectra can be considerably affected by artefacts and non-
sample contributions. Gaussian noise can occur as a result of fluorescence of the 
sample or thermal fluctuations on the charge coupled device (CCD), and can 
result in an unwanted intense spectral background. The most significant source 
of random noise is shot/Poisson noise. It occurs as a result of the random 
probability of detecting photons at specific wavelengths. Shot noise is 
proportional to the square root of the total counts measured. Therefore, for a 
spectrum of n number of counts, the associated shot noise will be n1/2. Due to this 
square-root relationship, although the variation in counts will increase as the total 
number of counts increases, the relative error will decrease. The signal-to-noise 
(S/N) ratio is a measurement for the relative error and represents the total number 
of counts divided by the noise associated counts.120 Increasing either the 
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acquisition time or the number of accumulations will reduce the overall noise 
contribution in the resulting spectrum.  Thermal/dark noise is detector associated 
and arises due to the generation of spontaneous electron-hole pairs, even in the 
absence of photons. This noise occurs as a result of CCD temperature and can 
therefore be reduced by cooling the detector. Readout noise occurs as a result 
of the conversion of the analogue signal to digital. It originates from the electric 
components, such as amplifiers, and the analogue-to-digital convertor, and it is 
not proportional to the measurement time.121 Hardware binning can be carried 
out prior to signal readout by the preamplifier, it combines the pixel charges on 
the CCD and thus improves the S/N ratio. Binning improves S/N ratio of readout 
noise limited data linearly with the number of pixels co-added, and improves S/N 
ratio of shot noise limited data by the square-root of the number of combined 
pixels.122 Noise contributions should be reduced as much as possible 
experimentally.  
 
Cosmic spikes can also arise in spectra, caused by high energy particles 
(cosmic rays) hitting the CCD. These artefacts can be eliminated, most simply, 
during spectral measurements by taking multiple accumulations and also 
applying a median filter.123 
 
More intense backgrounds can be caused by the substrate chosen to 
support the sample. Fullwood et al.124 showed that calcium fluoride (CaF2) 
windows (Crystran, UK) result in lower spectral backgrounds when compared 
with low-emissivity Mirr IR (Kevley technologies) and spectrosil quartz slides. 
Lower spectral contributions from substrates reduces the rquirement of 
background correction techniques. Near-IR radiation can have a penetration 
depth of 1 mm.125 Therefore with samples which are less than this, the substrate 
will be probed and scatter light, thus it is important to have a substrate which only 
minimally contributes to the resulting spectrum. 
 
1.3.4 Raman Spectroscopy for Biological Materials 
 
Raman Spectroscopy is a non-destructive, minimally-invasive, rapid and 
relatively low cost technique that can provide objective and reproducible 
diagnostic information about biological samples based on their biochemical 
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constituents. As a tissue develops from a normal to neoplastic state, biochemical 
changes occur. DNA concentrations increase and the concentrations of other 
components in the cell change.126 These biochemical changes should be 
reflected in its Raman spectra and thus enable molecular information to be 
obtained and a pathological diagnosis made of tissue samples. Biological tissue 
is highly heterogeneous and consists of a number of components, including 
blood, lymph, fibrous tissue and parenchymal tissue, some of which contribute 
towards noise and fluorescence in Raman spectra when excited.127 Higher 
frequency lasers increase the intensity of the Raman scatter, 𝐼 ∝ 𝜆−4, however 
they also result in fluorescence and phosphorescence caused by the induction of 
electronic transitions which result in light re-emission.128 Biological chromophores 
include haeme, carotenoids, bilin and chloroplasts.129 Intense spectral 
backgrounds are often attributed to fluorescence as a result of biomolecules 
within the sample absorbing at the excitation wavelength. Although, short-
wavelength lasers are more likely to be responsible for the production of molecule 
fluorescence within biological specimens and for photolytic degradation of a 
sample.130 Lasers with longer wavelengths, such as in the near-infrared region, 
produce less of these phenomena and can often be used at much higher output 
powers. Intense spectral backgrounds can still occasionally be measured at 
longer wavelengths, however these are not the result of sample fluorescence. 
The excitation wavelengths of biological chromophores are generally below 500 
nm, and although haemoglobin fluoresces at longer wavelengths, little occurs 
above 600 nm.131,132 Lasers with wavelengths below 270 nm can also be used to 
reduce fluorescent contributions in spectra due to the wavelength shift of the 
fluorescence at these wavelengths; however, the penetration depth is limited to 
only a few micrometres.133 UV and blue light is readily absorbed by molecules 
within biological samples, such as haemolglobin, leading to fluorescence and 
thus has a much shorter penetration depth of <100 μm. Near infrared light is 
absorbed less by haem molecules and therefore has a deeper penetration depth 
of around 1000 μm.134 Puppels et al.135 studied the presence of carotenoids in 
lymphocytes in order to investigate previously reported inverse relationships 
between cancer and the concentration of carotenoids in blood plasma.135,136 
Using Raman spectroscopy they observed that carotenoids generally accumulate 
in the gall body of lymphocytes and suggested their use in identifying individuals 
at risk of developing cancer.                       
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Figure 1.17- Spectra of DNA and its nitrogenous bases. Replicated from reference 137. 
 
 
Huang et al.138 studied Raman spectroscopy of various organs in murine (rodent) 
models using a catheter for probing the surface of the tissue with a 785 nm laser. 
The catheter consisted of low hydroxide fibres to deliver the incident radiation, 
one fibre of 200 μm diameter, and collect the scattered light, 27 fibres of 100 μm 
diameter. They concluded that Raman spectroscopy is a useful technique for 
disease diagnosis and observed that the spectra taken from tissue types that are 
alike are also similar to each other. For example, the spectra measured from bone 
and teeth tissue are similar, attributed to their high calcium content. Spectral 
measurements taken from the stomach, small intestine, colon and bladder were 
also found to be similar due to their structural similarities and high muscle 
compositions. They found that the Raman spectra of biological samples primarily 
comprised lipid and protein peaks, however, the intensities and ratios of these 
peaks altered depending on organ. They also noted that unique peaks are also 
present in spectra, observed only in specific tissue types, such as the brain, lungs 
and bone.   
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Figure 1.18- Raman spectra of human cells and constituents. Reproduced from reference.139 
 
 
Raman spectroscopy utilises radiation of the electromagnetic spectrum 
that is non-ionising (when using visible or IR excitation). The -OH vibrational 
modes of water molecules have low polarisability and generate weak Raman 
signals, and thus do not substantially contribute to resultant spectra. As a result, 
Raman spectroscopy can analyse fresh tissue, with no prior sample preparation, 
both ex vivo and in vivo without destroying biological samples. The use of fibre 
optic probes can aid in vivo Raman analysis of biological tissues and enable real-
time diagnosis, when inserted into a needle or endoscope.140 Optic probes have 
fibres that deliver the incident radiation to the sample and fibres that collect the 
scattered light, carrying light through total internal reflection, and take it back to 
the spectrograph, enabling remote detection.141  
 
Motz et al.142 states that the fibre optic probe can guide surgery through 
identifying malignant tumours from surrounding non-cancerous tissue to 
delineate tumour margins and thus aid complete resection. Fibre optic probes are 
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limited by anatomical location and in the case of a needle probe, consideration 
must be taken regarding the gauge of the needle. A compromise must be made 
between an acceptable needle size in order to reach the target organ and a 
patient’s discomfort whilst being efficient at delivering and collecting radiation in 
order to produce spectra with good signal-to-noise. They observed a 4x increase 
in background using a 785 nm laser compared to an 830 nm laser. They note that 
most in vivo applications are carried out using commercially available probes and 
are restricted to accessible organs such as the skin. Their study shows the ability 
to gather appropriate measurements in vitro on artery and breast tissue with their 
fibre optic probe design with an acquisition time of only one second which 
supports clinical application.  
 
Another consideration is the safe exposure limit of this radiation. Although 
non-ionising, thermal heating and burning can occur as a result of irradiation. The 
laser wavelength, power and spot size all influence this. The international 
commission on non-ionising radiation protection143 state that for thermal damage 
to occur the temperature of the skin must be raised to 45 oC. However for shorter 
exposure times a temperature of 55 oC must be achieved for just 10 seconds and 
69 oC for just 1 millisecond. They suggest the limit HEL for skin exposure at 
wavelengths less than 3000 nm and under 10 seconds, can be represented by 
the following equation: 
 
 𝐻𝐸𝐿 = 2 ∗ 𝑡0.25 ∗ 104𝐽𝑚−2  
 
Eq. 2.3.16 
 
Shim and Wilson144,145 measured the spectra of different probe fibres, 
silica and sapphire. They established that whilst the spectra of low-OH silica and 
sapphire are identical, sapphire fibres have a strong background and thus it was 
determined that low-OH silica-silica fibres are the best choice for fibre optic 
probes in the near-IR region of radiation.  
    
Day and Stone146 describe their development of the incorporation of a 
fibre-optic Raman probe with a hypodermic needle (Figure 1.19). Their design is 
a low-cost and simple needle probe for subcutaneous use and is able to deliver 
and collect enough signal to identify and differentiate cancerous tissue from non-
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cancerous with acquisition times of just 10-30 seconds. The probe incorporates 
just two fibres, one that delivers the light and one that collects the scattered light. 
They suggested that improvement of the design can be made through the use of 
multiple collection fibres to increase the signal detected. Iping-Petterson et al.147 
have developed this needle probe further to incorporate one delivery fibre 
surrounded by six collection fibres and show the improved signal collection than 
the two fibre probe, and improves the signal-to-noise ratio of collected spectra by 
2.5 times. Immediate diagnosis can lead to early treatment, and Raman 
spectroscopy could aid biopsy, targeting the identification of suspicious areas or 
interrogation of tumour margins during surgery. This will reduce the risk of tumour 
recurrence and subsequent operations.148 This method of diagnosis has 
economic benefits as it reduces the need for hospital resources and personnel.3  
 
 
 
Figure 1.19- Day and Stone’s design of a fibre optic Rama probe incorporated into a hypodermic 
needle, consisting of delivery and collection fibres. Reproduced from.146 
 
 
Standard Raman spectroscopy is limited by a penetration depth of a few-
hundred microns, thus restricting laser probing to the surface or near-surface 
area of samples.149 The development of spatially offset Raman spectroscopy 
(SORS) enables spectral measurements to be taken from areas deep into the 
sample. The technique is based on the principle of photon migration. Scattered 
photons are collected from surface areas on samples that are laterally offset at 
varying distances from the incidence point of the excitation laser. A range of 
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spectra are generated with different contributions in peak intensities, which are 
relative to the surface and subsurface layers. As collection becomes further away 
from the point of laser excitation, the spectral contributions that relate to the top 
layer of the sample decrease faster than those that relate to the deeper layers. 
This is due to the probability of greater lateral migration of photons which are 
generated deeper in the sample before emission from the sample surface. 
Through processing of the dataset using multivariate analysis, pure spectra 
representing the individual layers of the sample can be produced.150 Deep Raman 
enables measurements to be taken from areas several millimetres deep into 
tissue samples, thus aiding in vivo application.151  
 
The detection of individual molecules has been demonstrated through the 
identification of DNA bases using surface enhanced Raman spectroscopy 
(SERS). This would enable the use of this technique as a label-free biomolecule 
method of detection.152    
 
 
 
Figure 1.20- Spectra taken from the cytoplasm and the nucleus of a cell. Reproduced from 
reference.153 
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 Figure 1.20 shows the ability of Raman spectroscopy to produce spectra 
at the sub-cellular level and shows the biochemical differences between the 
cytoplasm and nucleus of the cell that are reflected in their spectra. Matthaus et 
al.154 observed that, with the use of multivariate analysis, Raman 
microspectroscopy could distinguish between components of the cell such as the 
nucleolus, nucleus, cytoplasm and mitochondria based on their biochemical 
composition. The average size of a human cell is 10-20 µm, as a result of the 
laser spot sizes for Raman spectroscopy, the nucleus of a cell is often not probed 
alone and spectra will contain signal from other cellular components. However, 
lymphocytes have a large nuclear to cell ratio and through histochemical staining 
it has been observed that the nucleus accounts for approximately 80% of 
lymphocyte cells. Therefore, it is likely that the nucleus is predominantly probed 
when investigating these cells.155   
  
 
1.3.5 Infrared Spectroscopy 
 
Infrared (IR) Spectroscopy is the study of the absorption of radiation, in the 
infrared region of the electromagnetic spectrum, by molecules within a sample. 
For absorption to occur, the frequency of the incident light must be the same as 
that of one of the normal modes of vibration. The absorbed wavelengths are 
determined in order to create a spectrum, which peaks correspond to the specific 
normal mode of vibration.104 An infrared spectrum is a plot of the quantity of the 
light absorbed, represented by absorbance units, on the y-axis against the 
wavenumbers in cm-1 on the x-axis. The Beer-Lambert law, A=ɛbc, states that 
absorbance A is directly proportional to molar absorptivity ɛ (in L mol-1 cm-1), the 
path length of the sample b (in cm), and the concentration of the sample c (in mol 
L-1). The absorbed light is calculated through measurement of light transmission 
using the equation: 
 
 𝐴 = log(𝐼0 ∕ 𝐼) Eq. 2.3.17 
 
Where I0 is the incident radiation and I is the transmitted radiation. 
Interpretation of IR spectra enables information about the sample under analysis 
to be gained. Molecules within a sample can be identified due to the peak 
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positions that correspond to specific wavenumbers absorbed. The amount of light 
absorbed is directly related to the concentration of the specific responsible 
molecules.156 
 
 
Figure 1.21- Schematic of an FTIR spectrometer. 
 
 
Infrared light can be either absorbed or transmitted through a sample. IR 
spectroscopy can be used to measure the transmitted light, to determine what 
wavelengths were absorbed by the sample. This results in a spectral fingerprint 
of a sample that can indicate its molecular composition. Molecules can become 
excited and absorb light if there is a change in its dipole moment. The frequency 
of light absorbed is dependent on the energy gap between the ground state and 
excited state of its vibrational levels. The number of absorption peaks seen in the 
resulting spectra is based on the number of degrees of freedom for the molecule. 
Hence the molecular constituency and structure can be determined for a 
sample.107 Fourier-transform IR (FTIR) spectrometers are currently the most 
widely used IR spectrometer, replacing the dispersive instrumentation that first 
became available in the 1940s.107 The main reason for the development of FTIR 
was the need for faster spectral acquisitions. Dispersive instrumentation employ 
prisms or gratings to split the IR radiation into individual wavelengths, the detector 
then measures the amount of transmittance at each frequency. FTIR 
instrumentation utilise interferometers where individual spectral scans take only 
a second through simultaneous detection of high resolution spectral data.157 An 
interferometer involves a beam splitter that transmits 50% of the incoming IR 
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radiation, emitted from a blackbody source, and reflects the other 50%. This 
therefore splits the radiation into two beams where one is reflected off a static 
mirror and the other is reflected off a mirror that vibrates a few millimetres to/from 
the beam splitter.158 The two beams then recombine back at the beam splitter 
and exit as an encoded signal. The signal is an interferogram whereby every data 
point has information pertaining to every individual IR frequency of the IR source. 
The beam then reaches the sample where specific frequencies of energy can be 
absorbed. A detector collects the interferogram signal where it is digitised and 
sent to a computer for production and display of a frequency spectrum. This is 
done through the application of a mathematical technique called Fourier 
transformation. A background spectrum must be collected for removal of the part 
of the spectrum which was not contributed by the sample being analysed 
(typically consisting of water and CO2.157  
 
Fourier-transform Michelson type interferometers used in Infrared 
spectrometer instrumentation exploit the Fellgett, Jacquinot and Connes 
advantage. The Fellgett advantage is improved signal to noise ratio as a result of 
simultaneous detector measurement. Jacquinot advantage also offers increased 
signal to noise ratio but as a result of high optical throughput.159 Connes 
advantage is an improvement in frequency accuracy in the FTIR 
instrumentation.160        
 
As well as decreased acquisition time, there are other advantages to using 
FTIR instrumentation. Almost any sample in any state, such as gas, liquids and 
solids, can be analysed to generate a molecular spectral fingerprint, and the 
instrumentation is relatively cheap and simple to operate. FTIR spectrometers 
are also highly sensitive, detection of down to picograms of molecular 
constituents, and a good signal-to-noise ratio, which is a measure of peak size to 
assess spectral quality. However, there are disadvantages to this technique. 
Complex mixtures can result in spectra that are complicated and difficult to 
interpret. Molecules that do not possess IR active molecular vibrations cannot be 
detected by this technique, such as, homonuclear diatomic molecules. IR 
spectroscopy is highly affected by water in a sample and results in broad and 
intense OH bands in resultant spectra that can mask other sample peaks.156   
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Infrared focal plane array (FPA) detectors consist of an array of pixels, 
which are photon-sensitive in the infrared region, on the focal plane of a lens. The 
detector surface is a photovoltaic panel that detects photons and produces a 
voltage. The output voltage can then be digitised for computer read-out to 
construct an image of the sample. Each pixel of the detector represents an entire 
separate spectrum and therefore the number of spectra is determined by pixel 
resolution. FPA detectors allow rapid simultaneous detection of thousands of 
spectra, thus speeding up acquisition time.161  
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1.4 Data Analysis 
 
1.4.1 Spectral Pre-processing 
 
Pre-processing methods are often applied to spectra prior to multivariate 
analysis to remove unwanted non-sample contributions.162 
 
Spectra can be green glass corrected to reduce the instrumental 
contributions in spectra. This involves taking a measurement of green glass on 
the instrument and subtracting the spectra away from subsequent sample signal 
in order to remove spectral contributions which result from instrumental 
fluorescence.  
  
Baseline subtraction techniques are often applied to the data to remove 
remaining unwanted spectral baseline. A polynomial fit is a method of baseline 
correction where non-constant, low frequency baselines are adjusted for. 
Polynomials are calculated to fit a line to the data, preferably under the spectral 
baseline, which can then be subtracted from the data in order to decrease the 
intensity of the background. Afseth et al.163 reported that baseline correction 
methods should be carried out on the data prior to normalisation. They state that 
derivatisation methods can be used as baseline correction techniques; however, 
they can lower signal-to-noise ratio. Although polynomial fits are not strongly 
reproducible in their baseline subtraction, they retain the same signal-to-noise 
ratio as the original data.  
 
Spectra are often noisy and are thus frequently subjected to a degree of 
smoothing. Noise is usually high frequency and fluctuates randomly from one 
pixel to the next. Whereas, sample signal is usually of much lower frequency and 
gradually varies from one pixel to the next. This assumption is what smoothing 
techniques function on.120 Smoothing can often be based on methods of local 
averaging that is applied to the data to de-noise each spectrum.164 However, the 
ultimate objective of smoothing is to remove the noise without altering the 
relevant spectral features present. Savitzky-Gloay smoothing incorporates fitting 
an approximate polynomial across a selected window and taking the centre point, 
it then moves along one and repeats. Savitzky-Golay smoothing is less efficient 
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at reducing noise than compared to moving-window averaging methods, but is 
better at retaining the original signal shape. 
 
Cosmic ray removal is also commonly carried out on spectra to eliminate 
peaks caused by cosmic rays. Cosmic rays are caused by photons in space 
rather than from the sample scattering laser light. Cosmic spikes are detected at 
random and are not related in time or space. Therefore, they can be eliminated 
from spectra through multiple accumulations or through pre-processing whereby 
the peak caused by cosmic rays are recognised and removed, either through 
removal of the whole spectra or by replacing the spectra between the affected 
wavenumbers.165 On a Raman map median filtering can be applied for removing 
these peaks, through calculating the median spectra of a specified number of 
pixels and replacing the centre pixel with the median.  
 
Biological samples are heterogeneous and the environmental and 
instrumental settings, such as the laser power, are changeable. Thus, 
normalisation is typically carried out on all the spectral set to mathematically 
account for this inconsistency, to adjust and reduce the non-sample attributed 
intensities. This is achieved through calculating the sum of squared averages of 
the data and then dividing the dataset by the square root of that sum.   
 
Mean centring is often carried out on spectral data in order to allow 
interpretation of the intercept and calculate predicted values. The mean of the 
dataset is subtracted so it equals 0 in order to focus on the variation between the 
dataset rather than the variation between 0 and the mean.   
 
 
1.4.2 Multivariate Analysis 
 
Multivariate analysis is needed in order to overcome the limitations of 
univariate analysis, where each feature is taken as independent and the 
relationships between the groups are not considered.    
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Multivariate analysis is carried out to statistically assess variation within 
datasets166 and to evaluate the level of discrimination between different groups 
within the dataset.  
 
 Clustering techniques such as K-means can be useful to assess 
similarities within the dataset. It is an unsupervised learning method where data 
are iteratively assigned to a specified number of groups (K) based on the 
Euclidean distance from centroids. These centroids are initially randomly 
assigned, the data are subsequently assigned based on the centroid it shares 
most similarity to, and then the centroids are eventually reassigned based on the 
average of the dataset within its group.167 The number of clusters can be chosen 
based on the number of grouped may be expected within a dataset.  
 
Principal component analysis (PCA) is often used for the identification of 
data points that are responsible for spectral differences and for analysing the level 
of discrimination between the spectral groups. Principal component analysis 
(PCA) is an unsupervised method of identifying patterns in data, in order to 
highlight the similarities and differences between the dataset.168 The primary 
objective of employing PCA is to reduce the dimensions of a dataset, with a large 
number of interrelated variables, whilst preserving as much variation between the 
dataset as possible. This process is achieved through transformation of the 
principal components onto a new set of uncorrelated variables which are ordered 
to contain the majority of variation of the dataset in the first few components.169 
Dimensionality reduction offers advantages to the analysis; such as, a reduction 
in the required computational power, a decrease in the level of white noise, and 
the evasion of over fitting. Over fitting occurs when the algorithms include noise 
or spectral information that does not describe the difference in classification, 
which increases the accuracy of classification of the training dataset, however 
reduces the classification accuracy of an unknown test set.165 Analysis of 
variance (ANOVA) can be used to determine the most significant components for 
delineating between the different groups of a dataset. ANOVA analyses the group 
means using F-distribution to assess if they are equal, and results in a significant 
result if they are not. Although, ANOVA cannot identify which groups are different.  
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Partial least squares discriminant analysis (PLSDA) is a supervised 
technique that identifies the variation between the groups of a dataset. PLSDA 
has an advantage over other methods, such as Mahalanobis distance 
approaches, as it can include a number of variables that exceeds the number of 
samples, therefore allowing better quantification and thus interpretation.170 The 
objective of PLSDA is to model the response variables by a set of predictor 
variables,171 for example, relating Raman spectra to their biochemical properties. 
PLS reduces the dimensions of a dataset by extracting latent variables, known 
as PLS components, from a dataset that contribute the most to variance between 
the response variables of different groups. Therefore, statistical tests to analyse 
the variance, such as analysis of variance (ANOVA), do not need to be employed 
to select components. PLS finds the direction in the spectral space that 
contributes to the most variance in classification. The data is transformed onto a 
new set of variables to allow emphasis of the similarities and the differences 
between groups in the data. PLSDA is a multivariate technique that analyses 
multiple variables simultaneously giving it an advantage over univariate 
techniques. Least squares regression is carried out on the component-reduced 
data to calculate the coefficients for prediction through applying a regression line 
that results in the least total sum of squares error. Discriminant analysis is 
supervised through assigning labels for the different groups in the model. The 
number of components used in the model is selected to avoid overfitting resulting 
from too many components, and avoid loss of discriminatory information that is 
caused from too few components. The optimum number of PLS components is 
chosen by testing the model, adding another component each time until the 
performance of the model starts to decrease, thus stopping at the point where 
the root mean squared error (RMSE) of prediction is at a minimum. Cross 
validation uses a blind dataset, unseen by the model, and compares it to the 
training dataset. It is performed to calculate the classification accuracy of the PLS 
model using a leave-one-sample-out approach in order to compare it to 
histopathological diagnosis. The process of PLSDA validation is shown in Figure 
1.22 as a flow diagram.  
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Figure 1.22- Flow diagram for validating PLSDA.  
 
 
Variable importance in projection (VIP) highlights specific wavenumbers 
that are the most significant for discrimination and quantitatively defines their level 
of importance. Therefore, applying this technique can enable selection of specific 
wavenumbers in the spectrum, hence speed up data analysis and data collection, 
whilst also reducing file size for data storage. VIP applies a quantitative threshold 
in order to identify the most selected discriminatory variables. This enables 
impartial interpretation of the components to determine the molecular bonds in 
biochemicals that contribute the most to variance. Lloyd et al.172 demonstrate the 
ability to generate similar classification sensitivities and specificities, using only 
the regions of the spectrum identified through VIP as being >95% important for 
discrimination, to using the whole spectral range.  
 
The classification sensitivities and specificities were calculated from the 
multivariate models. Sensitivity represents the number of positive samples 
correctly classified out of the total number of samples for that pathology. Although 
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there is a continuum of disease progression for the stages of cancer, the type of 
cancer is categorical. The pathologist diagnoses the samples and this result is 
used throughout to categorise the data. Therefore, sensitivities and specificities 
are based on this gold standard, which is already known to be a subjective 
measure for determination. Only the follow up of outcomes compared to the 
histopathology would improve the reliability, and this is usually not possible. Also, 
the ease to classify disease is very dependent on the disease and anatomical 
location. For example, it is far easier for a pathologist to recognise metastatic 
disease than most primary cancers as a result of the presence of different cell 
types in a tissue specimen. Specificity represents the ability of the multivariate 
model, as a percentage, to correctly identify negative samples as non-
cancerous.173 174 
 
 
Sensitivity = [TP/(TP+FN)] x 100  
Specificity = [TN/(TN+FP)] x100 
 
Where: 
TP= true positive (spectral number correctly classified as cancer) 
FN= false negative (spectral number incorrectly classified as non-cancer) 
TN= true negative (spectral number correctly classified as non-cancer) 
FP= false positive (spectral number incorrectly classified as cancer)  
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1.5 Optical Diagnostic Studies  
 
The diagnostic potential of optical spectroscopy has been investigated in 
many studies that employ tissue specimens of a variety of pathologies. A large 
number of studies have focused their investigations on the diagnosis of 
cancerous tissue. Numerous investigations into the diagnostic potential of Raman 
spectroscopy has been carried out on cancers of the: brain87,175–178, 
gastrointestinal tract,179–181 skin,182–188 larynx,189,190 breast,9,191–194 cervix,137,195 
bladder,196 prostate,196,197 oesophagus,85,126 Nasopharynx198 lung199 and colon.85 
However, reported studies on lymph nodes are limited. Lymph nodes are small 
in size and a high level of variability between nodes can result in their 
investigation being challenging.200        
 
Smith et al.201 conducted the first reported study on the assessment of the 
malignant spread of breast cancer to axillary lymph nodes. They observed that 
through Raman spectral mapping, the presence of molecules can be assessed 
across areas of lymph node sections. They identified the presence of carotenoids, 
proteins, nucleic acids and lipids, and suggest that these constituents can be 
compared across tissue features to further understand the biochemistry of breast 
carcinoma. However, they state the need for the acquisition of maps from a larger 
sample set, for more accurate comparisons to take place. Following this study, 
Smith et al.202 investigated Raman spectroscopy for axillary lymph node 
classification. The study analysed 59 lymph nodes from 58 patients and reported 
91% and 93% correctly classified positive and negative lymph nodes 
respectively. Spectral votes for each node generated a classification sensitivity 
and specificity of 93% and 100% respectively. They reported an absence of the 
784 cm-1 peak, assigned to cytosine, thymine, uracil and O-P-O, in the spectra 
taken from negative nodes. Peaks at 1086 cm-1 and 1578 cm-1 were observed to 
be of a higher intensity and the 1329 cm-1 shoulder is more prominent in the 
spectra of positive lymph node spectra. They state that these spectral changes 
indicate a lower contribution from DNA in negative lymph nodes. A peak at 1184 
cm-1, assigned to tyrosine and possibly calcium fluoride and phenylalanine, is 
much more intense in the spectra of positive tissue. Peaks from collagen 
contributions are reported to be less intense in the spectra of positive nodes.   
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Horsnell et al.75 investigated the ex vivo diagnostic ability of Raman 
spectroscopy for lymph node metastases in breast cancer with the use of radial 
based function-support vector machines (RBF-SVM). The study generated a 
classification sensitivity of 81% and a specificity of 97%, through the analysis of 
10 spectra per node, from 16 positive and 31 negative lymph node specimens 
from different patients. This followed an earlier study by Horsnell et al.203 which 
examined 38 axillary lymph nodes from 20 patients, of which 25 nodes were 
negative and 13 exhibited metastases. Through principal component-linear 
discriminant analysis (PC-LDA) Sensitivities and specificities were calculated as 
85–92% and 88–100% respectively, analysing 5 spectra per sample and using a 
‘majority wins’ approach to form a diagnosis. They note that the false positives 
produced in the study could be due to misdiagnosis that may occur as the result 
of unidentified micro-metastases, which are typically less than 12 mm in diameter, 
during histopathological diagnosis. They report that intra-operative assessment 
of lymph nodes would have an economic benefit of roughly £1368 per patient. 
However, spectral peaks with Raman shifts below 800 cm-1 were not included in 
the analysis. Similarly, Sattlecker et al.204 also examined the diagnostic ability of 
Raman spectroscopy for the identification of breast metastases in lymph nodes. 
Through the analysis of 3385 spectra from 13 positive axillary nodes and 7092 
spectra from 30 negative axillary nodes, a classification accuracy of 100% was 
produced using a radial based function-support vector machine (RBF-SVM) 
analysis. However, the lymph nodes being examined in this study were only from 
patients with breast cancer and other lymph node cancers were not investigated. 
They state that sufficient discrimination between cancerous and non-cancerous 
tissues could be achieved through the analysis of spectra with just 300 
wavenumbers to the same testing performance as spectra with 1500 
wavenumbers, reducing computing time. They observed that no specific spectral 
region has a higher impact on the model’s performance than another spectral 
region.  
 
Orr et al.205 investigated the classification accuracy of Raman 
spectroscopy for a variety of head and neck lymph node diseases. Using a two-
group cross-validation model they measured sensitivities and specificities, on a 
spectral level, of 90% and 88% for reactive lymph node spectra (n=1389) and 
88% and 90% for cancerous lymph node spectra (n=1584) respectively. When 
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the spectra were averaged per node, sensitivities and specificities were 
calculated as 92% and 86% for reactive lymph node (n=53) classification and 
86% and 92% for cancerous node (n=50) classification respectively. The 
classification accuracy of 4 group cross-validation model was assessed on a 
spectral level. Sensitivities and specificities were measured as 81% and 88% for 
reactive node spectra (n=1389), 93% and 99% for squamous cell carcinoma 
spectra (n=242), 76% and 95% for adenocarcinoma spectra (n=786), and 80% 
and 90% for lymphoma spectra (n=554) classification respectively. When spectra 
were averaged per node the sensitivities and specificities generally increased 
slightly. These were calculated as 85% and 86% for reactive nodes (n=53), 100% 
and 99% for squamous cell carcinoma nodes (n=8), 75% and 97% for 
adenocarcinoma nodes (n=24), and 83% and 92% for lymphoma node (n=18) 
classification. The data analysis they carried out consisted of normalisation and 
mean centring of spectra followed by multivariate analysis, employing principle 
component-linear discriminant function analysis. Although the lymphoma tissue 
was distinguished into either Hodgkin’s or non-Hodgkin’s pathologies, the ability 
of Raman spectroscopy to discriminate the two pathologies was not assessed in 
this study. Through a study of the diagnosis of benign, primary and secondary 
cancers in head and neck lymph nodes, Lloyd et al.58 demonstrated the potential 
clinical efficacy of Raman spectroscopy. Through the ex vivo analysis of 123 
lymph nodes from 23 patients, 2973 spectra were generated and analysed using 
partial least squares-discriminant analysis (PLSDA). Sensitivities and specificities 
were produced of up to 86% and 89% for benign neoplasm classification, 82% 
and 92% for secondary neoplasm classification, and 81% and 93% for primary 
neoplasm classification. However, whilst 18 patients had benign lymph node 
neoplasms, only 6 had secondary lymph node neoplasms and 3 had primary 
lymph node neoplasms.  
 
Bird et al.206 reported a “superior sensitivity” for cellular classification of 
breast micro-metastases in axillary lymph nodes, through the production of 
infrared micro-spectral images of 20 tissue specimens from different patients. 
They note that 7.33% of lymph nodes diagnosed as negative are later diagnosed 
as positive after re-examination; the detection of micro-metastases and isolated 
tumour cells (less than 0.2 mm in diameter) is difficult, yet vital for correct 
diagnostic staging of disease. Additionally, the ability of FTIR spectroscopy as a 
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diagnostic tool was demonstrated by Liu et al.207 They reported a classification 
accuracy of 81.82% for papillary thyroid carcinoma micro-metastases in cervical 
lymph nodes, through the analysis of 184 lymph nodes from 22 patients, of which 
14 were positive and 8 negative.    
 
Isabelle et al.208 measured 78,624 spectra from 9 benign lymph nodes and 
11 cancerous lymph nodes to analyse the discriminatory power of both infrared 
and Raman spectroscopy. A training performance was reported of 98% and 94% 
for infrared and Raman spectroscopy respectively. They report an increase in 
nucleic acid concentrations in cancerous tissue when compared to benign tissue, 
in Raman spectra at peak 724 cm-1 attributed to CH2 bonds and 1125 cm-1 
attributed to C-C bonds. They state that the increase in nucleic acid 
concentrations support increased nuclear-to-cytoplasmic ratios and mitotic 
activity observed in neoplastic cells. A decrease in lipid and carbohydrate 
concentrations was observed in cancerous tissue compared to benign 
neoplasms. This was seen in Raman spectra at peak 1303 cm-1, attributed to the 
CH bond and 1442 cm-1, attributed to CH2 bond of lipids, and peak 1084 cm-1, 
attributed to the C-C bond in carbohydrates. It was also seen in the IR spectra at 
peak 1745 cm-1, attributed to the C=O bond in lipids, and peak 1165 cm-1, 
attributed to the C-O bond, and 1400 cm-1, attributed to the COO- bond in 
carbohydrates. They state that the decrease in lipids and carbohydrates support 
the use of these molecules as energy providers for proliferation in carcinogenesis.   
 
Andrus and Strickland209 reported that as the pathological grade of non-
Hodgkin’s lymphomas increased so did the intensity ratio of peak 1121 cm to 
1020 cm-1 representing cellular RNA and DNA respectively. Their observations 
were made through the collection and analysis of FTIR spectra from nine snap-
frozen sections of non-Hodgkin’s lymphomas. They also found collagen peaks to 
increase, present between 1200 cm-1 -1700 cm-1, relative to the 1084 cm-1 peak 
as the pathological grade of the lymphoma increased.   
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Chapter 2: Materials and Methods 
 
2.1 Tissue Samples 
 
Oesophageal, head and neck, and femoral lymph node samples were 
collected by surgeons at Gloucester hospitals NHS foundation trust, after ethical 
approval by the Gloucestershire local research ethics committee (REC 
references: 02/112G, 15/LO/1345 and 14/SW/1077 respectively). 
 
Immediately after biopsy a portion of lymph node or an extra lymph node, 
not required as for diagnostic purposes, was placed in a cryovial and snap frozen 
using liquid nitrogen. The bulk lymph node sample was then stored in -80oC 
freezers until tissue sectioning. The tissue samples were sectioned using a 
freezing microtome by an experienced histopathology technician. For the 
oesophageal and femoral samples two sections were cut from each bulk tissue 
block, one for spectroscopic analysis and another for pathologist diagnosis. The 
tissue section for spectroscopic analysis was cut at 8 µm onto calcium fluoride 
CaF2 substrate (Crystran, UK). The CaF2 substrates are circular windows with a 
20 mm diameter and 1 mm thickness. The tissue section for pathological 
diagnosis was cut at 4 µm thick onto a glass microscope slide and stained with 
haematoxylin and eosin (H&E) in order to better show the tissue architecture and 
cells. For the head and neck lymph nodes three sections were cut for 
spectroscopic analysis. The first at 8 µm onto calcium fluoride CaF2 for 
spectroscopic analysis. The second at 4 µm thick onto a glass microscope slide 
for histopathological review. And a third section cut at 15 µm for spectroscopic 
analysis to compare with the results from the needle probe measurements. The 
remaining node was used for needle probe measurements. The tissue sections 
on the CaF2 slides were returned to the freezer and stored at -80oC until required. 
Prior to measurement, the tissue sections were removed from the freezer and left 
to thaw for at least a half-hour before analysis. For FTIR spectroscopy, the 
sections were left for an hour to ensure any water had evaporated prior to 
measurements taking place.  
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2.1.1 Histopathological Analysis 
 
 Two pathologists from Gloucestershire Hospitals NHS Foundation Trust, 
Dr Suzanne Hopcroft and Dr Chandima de Cates, gave their expertise to this 
study to enable the pathological identification of the H&E stained tissue sections. 
The H&E stained tissue sections, adjacent to those spectrally measured, were 
microscopically examined in order for a diagnosis to be made. In cases of 
lymphoma it is difficult to make a definitive decision for frozen sections. In these 
cases the other half of the lymph node, taken by the surgeon and formalin fixed 
for a clinical decision, was paraffin set, sectioned and stained for analysis by the 
pathologist. Thus, the section looked at was not adjacent, however in cases of 
lymphoma, the cancer cells are not as localised as in metastatic and the 
lymphoma cells are expected to be throughout the tissue. Also, for samples 
where the pathologist was not completely sure, the section was taken to other 
pathologist to form a consensus.  
 
 
2.1.2 Sample and Acquisition Numbers 
 
The total number of samples collected for this study can be seen in Table 
2.5. Twenty-two oesophageal lymph node samples were collected from fifteen 
patients: Fifteen nodes were identified as non-cancer (benign) from nine patients, 
and seven samples were identified to contain metastatic adenocarcinoma from 
six patients. Twenty-two femoral lymph node samples were collected from eight 
patients: sixteen were identified as non-cancer from five patients, and six were 
identified to contain squamous cell carcinoma metastases from four patients. A 
total of seventy-five head and neck lymph node samples were collected from 
sixty-three patients: forty-eight classified as non-cancer from thirty-nine patients, 
six as containing squamous cell carcinoma metastases from six patients, one as 
containing papillary carcinoma metastases from the thyroid, one as containing 
infiltrating adenocarcinoma from the breast, one as Hodgkin lymphoma, fifteen 
as non-Hodgkin lymphoma from fourteen patients and three reactive nodes from 
three patients caused by toxoplasmosis, cat-scratch and Castleman’s disease. 
Some of the patients in this study had both non-cancer lymph nodes and 
metastatic ones.  
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Table 2.5- Total number of lymph node samples and patient numbers from the whole study. 
 Head and Neck Oesophageal Femoral 
 Non- 
cancer 
Metastatic Lymphoma 
Other 
Non- 
cancer 
Metast
atic 
Non- 
cancer 
Metasta
tic 
 SCC PC AC HL NHL AC SCC 
Sample 
Number 
48 6 1 1 1 15 3 15 7 16 6 
Patient 
Number 
39 6 1 1 1 14 3 9 6 5 4 
Total 
Patients 
63 15 8 
 
 
 
Not all the samples that were collected for this study were used for analysis. 
Reasons for this exclusion were: a patient infected by MRSA, poor 
measurements, nodes with too much adipose content leading to intense 
contributions of lipid peaks and the need for a more equal balance between the 
pathology groups. In the final situation, only one or two nodes would be used per 
patient to optimise patient numbers whilst trying to balance the pathology groups. 
A random selection of the nodes were chosen to represent the patient. Table 2.6 
and Table 2.7 show the sample and patient numbers alongside the number of 
spectra used for the analysis of the 8 µm and 15 µm sections.  
 
 
Table 2.6- Sample numbers and corresponding pathologies used for the 8 µm samples. 
 
 
 
 
 
 
 Head and Neck Oesophageal Femoral 
 Non cancer SCC Non cancer AC Non cancer SCC 
Samples 13 5 6 6 8 6 
Patients 13 5 6 5 5 4 
Total Patients 18 11 6 
Point spectra 260 100 120 120 160 120 
Map spectra 131738 44802 - - - - 
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Table 2.7- Total number of lymph node samples used for the 15 µm study. 
 Head and Neck 
 
Non cancer 
Metastatic Lymphoma 
Other 
 SCC PC AC HL NHL 
Sample 
Number 
39 6 1 1 1 14 3 
Patient 
Number 
38 6 1 1 1 13 3 
Total Patients 62 
Map Spectra 53879 10330 714 1076 2690 30511 5151 
 
 
2.2 Raman Spectroscopy      
 
2.2.1 The Raman Spectrometer System 
 
Raman measurements were taken using a Renishaw inVia confocal 
spectrometer system (Renishaw, UK) shown in Figure 2.23. The system employs 
an eyepiece with a magnification power of 10x/20 N.A. (numerical aperture) and 
also uses a camera in order to display the picture on the PC monitor. Spectra 
were generated using a long working distance NPlan objective (Leica, Germany) 
with a magnification power of 50x/0.5 N.A. A Leica NPlan objective with a 
magnification power of 5x/0.12 N.A. was used to locate areas of interest for 
measurements. Samples were excited using an 830 nm laser with an output 
power of around 300 mW at the source and approximately 150 mW at the sample. 
Laser wavelengths were chosen to minimise fluorescence and sample burning. 
A grating of 600 lines mm-1 was employed to collect spectra over wavelengths in 
the region of 460-2400 cm-1. The system is equipped with a charge coupled 
device (CCD) detector to detect the scattered photons from the sample. The 
Raman system is controlled through a computer using the Renishaw software 
WIRE. A motorised XYZ stage provides ease for streamline mapping of samples.  
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Figure 2.23-Renishaw in Via Raman spectrometer at the University of Exeter. 
 
 
2.2.2 System Calibration and Standards Measurements 
 
The system was offset against the 520 cm-1 peak of silicon (Si) prior to 
measurements taking place. Calibration is not ensured across the whole 
wavenumber range and therefore a Neon Argon lamp was measured also to 
evaluate the position of the emission bands.  A measurement from green glass 
was also collected to correct for the energy sensitivity of the system. There is a 
known fluorescence for this glass and therefore the sensitivity of the CCD can be 
corrected using a transform function. An assignment table for biological signals 
frequently detected was collated and displayed in Table 2.8.    
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Table 2.8- Tentative assignment table for peaks observed in tissue spectra. 
Tentative assignment Peak position 
(cm-1) 
Ref. 
Vibration Biochemical 
C-C twsit Phenylalanine 622 6,153,190,21
0 
C-C twsit Tyrosine 645 6,190,210,21
1  
C-S Amino acid (cystine) 665 6,190,210,21
2 
C-S Cystine 694  213 
C-N DNA adenine/phospholipidhead 723 85,214 
Ring breathing DNA 748 215 
Symmetric 
breathing 
Tryptophan 755 6,85,190,204  
Ring breathing Pyrimidine base  784 6,58,85  
 
Phosphodiester (Z-marker) 809 212 
PO2- stretch Nucleic acids 827 6,85,215  
Ring breathing  Tyrosine 851 155,214 
C-C stretch Collagen, hydroxyproline  874(w) 215  
C-O-C Adenine 899 6 
C-C stretch Protein backbone (α-helix 
conformation) 
936 6,85,140  
 
Hydroxapatite, cholesterol 957 85,212  
ν(C-C) wagging Collagen 970 212  
Ring breathing Phenylalanine 1001 6,85,140,190  
C-H in-plane 
bending 
Phenylalanine 1033 6,85,199  
 
Glycogen 1047 212,216  
C-C stretch  Lipids 1060 85,212  
C-N, C-C stretch Protein, lipid, glycogen  1082 6,85,190,204
,216,217  
ν(C-N) DNA 1095 212 
ν(C-C), C-N Lipid, proteins 1125 6,85,190,215  
C-C, C-N stretch  Proteins/carotenoid 1154 6,155,190,21
4  
C-H in-plane bend Tyrosine 1172 6,190,212  
ν(C-C6H5)  Protein (tryptophan, phenylalanine) 1207 6,190,212 
 
Amide III 1261 6,85,215,218  
CH2 wag Collagen 1282 219 
CH3/CH2   Lipid/collagen  1302 85,199,212  
CH deformation  Collagen  1320 214 
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CH deformation  Amide III 1338 214 
CH Tryptophan 1365 220 
CH Protein  1391(w) 221 
CH2 CH3 Proteins, phospholipids 1445 6,190,212 
CH DNA 1490 217 
r-C=C-r Carotenoid 1527 85 
C=C Tryptophan 1551 204 
Ring Nucleic acids- Pyrimidine 1581 6,85 
C=C bend  Amino acids (phe, tyr)/amide I 1604 6,155,190,21
8,222 
C=C stretch Amino acids (tyr, tryp)/amide I 1617 6,85,190,204
,218,223 
C=O/C=C stretch Amide I: alpha helix (1650-57) 
Antiparallel beta sheet (1612-40) 
Parallel beta sheet (1626-40) 
Turn (1655-75, 1680-96) 
Unordered(1640-51) 
1656 6,85,190,212
,224 
C=O Ester Lipids 1733 214,225  
C=O, C=C  Lipid 1747 85,204,226 
 
 
2.2.3 Raman Measurements 
 
Both point measurements and streamline maps were acquired for this 
project. Point measurements were acquired for 15 seconds at various locations 
after identification by the pathologist within the lymph node to ensure a 
representative area was sampled. Raman images were produced through 
streamline mapping of the sample with an acquisition time of 30 seconds per 
spectrum. In streamline mode, the time spent illuminating an area on the sample 
is the equivalent to the time divided by the fraction of the laser line that the 
mapping pixels approximate to. The streamline laser line used was 50 µm in 
length by 4 µm wide. Measurements of the 15 µm sections for pathological 
discrimination had a step size of 7.1 µm x 7.1 µm, and those at 8µm for 
comparison with FTIR images had a XY step size of 5.7 µm x 5.7 µm, in order to 
be more comparable to the FTIR step size of 5.5 µm x 5.5 µm. Therefore, the 
time the laser line illuminated the sample for are 4.2 seconds for the former and 
3.4 seconds for the latter measurements.  
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2.2.4 Raman Needle Probe 
 
 The Raman needle probe that was employed in this study is described by 
Iping Petterson et al.147 developed from an earlier probe by Day and Stone146. 
The probe used employs multiple optical fibres to enable maximum collection of 
scattered light. The optical fibres are composed of low-OH silica, with six 
collection fibres situated around one central delivery fibre. The fibres are 125 µm 
in diameter with a core of 105 µm and are all polished at the tip. The excitation 
wavelength employed in the system was 830 nm, delivered using a spectrum-
stabilised laser module (FatBoy, Innovative Photonic Solutions, USA). A patch 
cable directs the excitation light through two collimating lenses surrounding two 
bandpass filters (BrightLine FF01-830/2-25, Semrock, USA) to the the needle tip. 
Maximum power at the sample was measured to be 230 mW, however the power 
was altered depending on the tissue type being measured. The scattered light is 
then collected and directed to collimating lenses (Thorlabs, F220FC-780 nm) to 
pass the light through two long-pass filters (RazorEdge, LP02830RU-25, 
Semrock, Rochester, NY, USA) and then to the spectrometer (RamanExplorer 
830, 1002A-00465, Headwall Photonics, Fitchburg, MA, USA). A back 
illuminated, deep depletion charged-coupled device camera (iDus, DU420A-BR-
DD, Andor, Belfast, UK) is coupled to the spectrometer for detection of the Raman 
scattering. The tip of the probe is a 22 gauge stainless steel tube 7 cm in length, 
to allow lymph nodes in the head and neck to be reached through the skin. The 
fibres are fixed in place in the tube using medically approved epoxy resin (Opti-
tec 5007, INTERTRONICS, UK). A 19 gauge hypodermic needle acts as a sleeve 
around the tube to allow insertion of the needle prior to insertion of the fibre-
containing stainless steel tube in order to minimise fibre damage and tissue 
debris building up before it reaches the target tissue. The filters and expensive 
optics are incorporated outside the needle probe tip to allow it to be disposable 
and thus sterile for each patient use. The probe tip is optically coupled to the 
handle using ceramic ferules (Alker Optical Equipment, UK). Figure 2.24 shows 
the schematic setup of the needle probe instrumentation design. 
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Figure 2.24- Schematic of needle probe instrumentation taken from reference.147 
 
 
2.2.5 Tissue Simulating Phantoms 
 
Intralipid and India ink phantoms were used as tissue simulating 
phantoms, due to their scattering and absorbing properties, to assess the 
performance of the needle probe. A phantom was prepared of 1% intralipid (20% 
emulsion, Sigma) and 0.005% India ink (Histology Stain, American MasterTech). 
The reduced scattering coefficient is calculated using the following equation: 
µs’=a(λ(nm)/500)-b   
 
 From Jacques,227 the ‘a’ and ‘b’ for soft tissue, such as lymph nodes and 
the surrounding tissue, is 18.9 and 1.286. With a laser wavelength of 830 the 
reduced scattering coefficient equals 9.8422 cm-1. Vardaki et al.228 show that 1 % 
intralipid is acceptable for a reduced scattering coefficient of 9.2 cm-1.   
 
 Polytetrafluoroethylene (PTFE) was submerged in a bath of the intralipid 
and ink solution and a micrometre was utilised with the probe attached whilst 
enabling accurate alteration of the distance for every measurement. For the initial 
measurement the probe tip was in contact with the PTFE and then the distance 
between the two was increased by half a millimetre for each subsequent 
measurement.    
 
 Prior to acquisition of sample measurements, standards were taken. 
These included NeAr to calibrate the instrument, silicon for a reference peak, 
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stainless steel and green glass to later correct for instrumental contributions.
  
 
The remaining bulk head and neck nodes were measured using the 
Raman needle probe at 150mW of power at the sample. Once defrosted, the 
sample was placed on a CaF2 window and the Raman needle probe was clamped 
in position above the node ready for measurement. The needle probe would then 
be lowered and 10 continuous 1 second measurements would be taken. This was 
then repeated at various locations on the sample so at least 10 areas were 
measured.   
 
 
2.3 Fourier Transform Infrared (FTIR) Spectroscopy  
 
 2.3.1 The FTIR Spectrometer System 
 
Infrared measurements were taken using an Agilent Cary 600 series 
Fourier transform-infrared imaging (FTIR) spectrometer system, coupled with an 
FTIR microscope (Agilent Technologies, USA), and shown in Figure 2.25. The 
microscope system consists of a wide field eyepiece magnification power of 
10x/0.18 N.A and measurements were taken using an Agilent objective with a 
magnification power of 15x/0.62 N.A. A 128 x 128 liquid nitrogen cooled focal 
plane array (FPA) detector was employed in the instrument, which allows 
simultaneous detection of spectra. Transmittance mode was utilised for this study 
and an under-sampling ratio (UDR) of 4 was included to filter the stray light. 
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Figure 2.25- Agilent Technologies Cary 600 series Fourier Transform Infrared Spectrometer and 
microscope system at the University of Exeter. 
 
 
2.3.2 FTIR Measurements 
 
The spectral resolution of 4 cm-1 was selected for the FTIR measurements. 
256 scans were summed for the background spectrum and 64 scans were co-
added for each tissue spectra. FTIR images were acquired to measure a large 
proportion of the tissue sections. The tissue sections used were those cut at 8 
µm rather than 15 µm, so the light could be transmitted through the sample more 
readily. The pixels in the image are 5.5 µm x 5.5 µm. The FPA camera pixels are 
40 x 40 µm2 in size, internal microscope objectives change the magnification of 
the sample that is passed onto the camera and results in the image magnification 
of approximately seven times in standard magnification mode with the 15 x 
objective.  
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2.4 Data Analysis 
 
Analyses of the data were carried out using the computer software Matlab 
R2015b (The MathWorks, Inc, USA). The analytical methods for the data was 
chosen to both align with literature58 and also as a result of tested algorithms with 
research group. 
 
 
2.4.1 Pre-processing  
 
The signal-to-noise ratio (SNR) is used to characterise the noise of the 
spectrometer system being used and is especially important for in vivo application 
where the integration time is limited for clinical practice. The following equation 
was used to calculate the signal-to-noise in order to assess the quality of the 
signal collected.  
 𝑆𝑁𝑅 = 𝑆/𝜎𝑦 Eq. 2.4.1 
 
 
Where: 
𝜎𝑦 = Standard deviation of the peak height,  𝑆 = Average peak height of a peak  
 
 
Spectral wavelengths were cut down to only include the fingerprint region 
over 600-1800 cm-1, to speed up analysis but retain a reasonable amount of 
spectral information. Pre-processing was carried out on the data initially to correct 
for unwanted spectral features. Raman data were green glass corrected, and 
vector normalised. Median filtering was also applied on map data to remove 
unwanted cosmic rays, where each acquisition is not visually checked for these 
contributions. Green glass acquisitions are taken after calibration and prior to 
every image, or set of sample measurements, to enable correction of the 
instrument response function (which can change subtly when the system self-
aligns, moving the edge filter set). For Raman maps, median filtering was applied 
across three pixels. The median was calculated where the two adjacent pixels, to 
the pixel of interest, are used to replace the pixel to remove the unwanted cosmic 
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ray whilst not losing that pixel from analysis. The data were finally vector 
normalised to account for intensity differences caused by variations during data 
collection. For visualisation of the spectra, baseline subtraction and smoothing 
was applied to the data, but this method was not used for multivariate analysis. 
A third order polynomial fit was applied for baseline subtraction in this study as it 
was observed to be the optimum for reducing the baseline without altering the 
spectral features. The Savitzky-Golay algorithm was employed to smooth the 
data, using a 3rd order polynomial fitted across 7 wavenumbers, to reduce the 
noise contributions. A region of interest (ROI) was selected from the spectral 
maps based on pathological review of the adjacent H&E section.  
 
For the FTIR data the only pre-processing that was carried out was vector 
normalisation and mean centring prior to multivariate analysis. 
 
2.4.2 Multivariate Analysis 
Once pre-processed, the data were mean-centred before any further 
analysis. Principal component analysis (PCA) and for maps K-means cluster 
analysis was applied to observe unsupervised spectral grouping and assess the 
peaks in the spectra that contribute to variation of the dataset. Multivariate 
analysis was then carried out to create and evaluate classification models for 
identifying pathological groupings of the dataset. Partial least squares-
discriminant analysis (PLSDA) was employed to create the classification model 
and a leave-one-sample-out cross-validation was carried out to assess the 
accuracy of the model. The components selected for the models were between 
3 and 7, depending on when performance of the model was at an optimum. A 
majority wins approach was used, similar to how it would be classified in a clinical 
setting, to identify groups depending on all the measurements from one sample. 
Figure 2.26 shows the flow diagram for the data analysis of the spectral 
measurements.   
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Figure 2.26- Flow diagram of the order of pre-processing and methods of data analysis. 
 
 
2.4.3 Data Analysis of Needle Probe Measurements. 
 
 The green glass measurements provided a calibrated fluorescence 
spectrum to correct for instrumental response. The green glass could also be 
used to correct for etaloning of the CCD. The data were then cropped to 575-
1800 wavenumbers and interpolation was carried out. Any spectra that were 
above the overall mean plus 1 standard deviation was removed from analysis in 
order to identify and eliminate saturated spectra. The data were then normalised 
and mean centred. Orthogonal partial least squares (OPLS) was carried out to 
identify components in the spectrum that cause variation, yet are not as a result 
of biochemical changes. Four components were identified, these included 
spectral features present as a result of fibre signal, etaloning, background and 
intense lipid peaks. Hoteling T-squared (a t-test in multiple directions) was 
performed to remove outliers outside an ellipse calculated from the scores at 95% 
(2 standard deviations). PLSDA was then carried out on OPLS dataset and a 
leave-one-out cross-validation was performed to predict classification accuracy.   
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For visualisation, the data were baseline corrected and the etaloning was 
corrected using a 2nd order polynomial fit of the stainless steel measurement 
using the etaloning shape from the green glass.      
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Chapter 3. Raman Spectroscopy of Metastatic and Non-
Cancer Lymph Nodes from Different Anatomical Locations 
 
 
 The lymph nodes collected and measured for this study were from the 
oesophageal, head and neck and femoral regions and consisted of a variety of 
pathologies. Lymph nodes are frequently some of the first organs metastatic 
cancer cells will travel to and therefore it is of interest to assess the spectroscopic 
differences between the metastatic and non-cancer lymph nodes in this study, to 
evaluate the clinical abilities of Raman spectroscopy for this application. In this 
chapter, the identification of secondary cancers from benign tissue will be 
assessed, both as lymph nodes from their individual regions and also as lymph 
nodes combined.  
 
3.1 Results  
 
3.1.1 Raman Spectroscopy of Oesophageal Lymph Nodes 
 
During experimentation it was observed that oesophageal lymph node 
measurements possessed much higher lipid signal than many other biological 
tissue samples. Measurements were acquired of the surrounding fat tissue in 
order to obtain its spectral signature and clearly observe the lipid peaks that 
contribute. Figure 3.27 shows the spectrum of fat averaged across four 
measurements for more accurate representation of the signal. Lipid peaks are 
seen at 1080 cm-1 with a shoulder at 1065 cm-1, 1119 cm-1, 1300 cm-1, 1439 cm-
1 and 1745 cm-1, attributed to C-C, CH2, C=C and C=O molecules within the 
tissue.      
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Figure 3.27- A spectrum from the adipose tissue surrounding the lymph nodes averaged across 
four acquisitions with lipid peaks labelled. 
 
 
Dark coloured microscopic particles were seen in most of the oesophageal 
lymph node tissue sections, shown in the images of an H&E stained section and 
an unstained section in Figure 3.28. These particles are carbon pigments which 
pathologists diagnose as anthracosis.  
 
 
 
Figure 3.28- H&E (left) stained section of a lymph node section and a white light (right) image of 
the subsequent section from the same lymph node exhibiting anthracosis in the form of black 
pigmentation. 
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These heavily pigmented areas in the section would often result in a very 
strong spectral background when acquired for the time needed to get a biological 
spectrum with an acceptable signal to noise ratio. Hence the acquisition of 
spectra was more difficult, especially when streamline mapping, where 
measurements are acquired whilst the stage is moving in order to reduce the time 
taken to map a sample. Thus, one spectral measurement is a combination of 
scattered light from all the tissue illuminated within the set acquisition time. If a 
fluorescing particle is illuminated it will cause an intense spectral background of 
that measurement, often masking the biological peaks of interest. Figure 3.29 
shows a spectrum from the carbon pigments measured for just 1 second in order 
not to flood the detector. Due to poor signal-to-noise, as a result of the limited 
acquisition time, the spectrum was smoothed using a Savitsky-Golay filter over 
10 wavenumbers. The graphite peak (G band) and disordered carbon peak (D 
band) are displayed at 1583 cm-1 and 1300 cm-1 respectively, attributed to the C-
C bonds that make up the molecule.   
 
 
Figure 3.29- Carbon spectrum in a lymph node acquired for 1 second exhibits the D and G bands 
at ~1300 cm-1 and ~1583 cm-1. 
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Frozen samples can often result in scoring marks across the tissue section 
from the blade when they have been cut using a cryo-microtome. These scoring 
patterns can often make direct comparison difficult between the H&E stained 
sections and their subsequent spectroscopic section. An example of typical 
scoring patterns often seen on a tissue section is shown in Figure 3.30. Samples 
that have been formalin fixed and paraffin embedded prior to sectioning, are 
much less damaged and striated by the sectioning process. However, for 
spectroscopic analysis it is preferred for tissue samples to be in a state similar to 
how they would be in vivo. Therefore, the samples are put in liquid nitrogen in 
order to snap-freeze them, to avoid crystallisation of the tissue, and preserve 
them through low temperatures rather than external chemicals, even at the 
expense of striated sections.   
 
 
 
Figure 3.30- H&E section of lymph node tissue exhibiting diagonal scoring patterns caused by the 
blade of the microtome. 
 
 
101 
 
 To assess the spectral heterogeneity of lymph node samples, a Raman 
map was acquired in order to produce a spectral image. A section of lymph node 
excised from underneath the diaphragm, where carbon pigmentation is less 
common, and possessing identifiable nodal regions was measured using Raman 
streamline mapping. Figure 3.31 shows the microscopic image of the H&E 
stained tissue adjacent to the section mapped. The measured area is highlighted 
by the black box on the image and the various nodal regions are labelled.   
 
 
 
Figure 3.31- H&E stained tissue section showing the different regions within the oesophageal 
lymph node. The region in the black square represents the area mapped using Raman and FTIR 
spectroscopy. 
 
 
 Raman spectroscopy was utilised to collect a spectral map to produce a 
pseudo-coloured image, shown in Figure 3.32, through 6-cluster k-means 
analysis, an unsupervised technique where clusters are formed based on 
spectral similarities. Each pixel on the image represents a different spectrum. 
Using the H&E section, the colours from the k-means image can be assigned to 
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the various regions of the lymph node. It would appear that the follicles containing 
B-cells are represented in yellow, the surrounding T-cells in turquoise, the 
capsule in light blue, missing tissue in orange, lipid in maroon and dark blue 
represents the subcapsular sinus and other areas that are not as densely 
populated with lymphocytes. In order to see the spectral differences, the 
averaged spectra of the T-cell and B-cell regions are displayed in Figure 3.33.  
 
   
 
Figure 3.32- Pseudo-coloured image of 6 cluster K-means analysis on a Raman mapped non-
cancerous lymph node section (right) with the corresponding region of the H&E stained tissue.  
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Figure 3.33- Mean spectra of the T cell area (blue) and the B cell area within the follicles (yellow) 
from the correlating colour on the k-means cluster image in figure 6. 
 
 
The oesophageal lymph node samples only consisted of non-cancerous 
tissue and metastatic adenocarcinoma originating from primary cancers in the 
oesophagus. Therefore, the spectra from only two cell types were analysed: non-
cancerous lymphocytes and cancerous epithelial cells of glandular origin. A 
pathologist highlighted any metastatic cells and the nodal regions on the adjacent 
H&E stained section. This enabled spectral acquisition of the specific metastatic 
areas when measuring from the cancerous lymph nodes. When collecting point 
spectra from the non-cancerous sections, spectral measurements from different 
areas within the lymph node were taken to have a representative dataset of the 
whole lymph node.  
 
Due to heavy lipid and carbon contributions in the samples, spectral maps could 
not be acquired from many samples without their spectral contamination. 
Therefore, point spectra were taken in order to avoid areas that did not yield the 
appropriate biochemical information in their spectra. Samples that were heavily 
contaminated by lipid or carbon, that affected the resulting spectra, were left out 
of analysis. Also, there is a large discrepancy between the sample sizes of 
groups. To avoid a group being too over-represented, samples were sometimes 
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omitted from groups if there were multiple biopsies from the same patient, to only 
include one lymph node per patient.    
 
To aid visualisation of the spectral differences between measurements 
from non-cancerous lymph nodes and those with adenocarcinoma (AC) 
metastases, the mean spectrum was calculated for each pathology and displayed 
in Figure 3.34. In typical spectra from biological tissue, the main peak 
contributions are a result of molecular bonds within amino acid, protein, lipid, 
nucleic acids and carbohydrate groups.  
 
 
 
Figure 3.34- Spectra averaged across 140 AC met point measurements (red) and 280 non-
cancerous point measurements (green) from 7 metastatic nodes from 6 patients and 14 non-
cancerous nodes from 9 patients. The spectra are pre-processed and vector normalised and the 
band assignments are labelled. 
 
 
Visual spectral differences between the two pathologies are primarily due 
to a variation in peak intensities. The protein, nucleic acid and amino acid peaks, 
found at wavenumbers 600 cm-1 to 810 cm-1, 1336 cm-1, 1365 cm-1, 1513-1617 
cm-1, are more intense in the spectra from non-cancerous tissue than metastatic 
AC tissue. Lipid peaks are conversely more intense in metastatic AC than non-
cancerous tissue, seen at 1061 cm-1, 1078 cm-1, 1298 cm-1, 1439 cm-1 and 1743 
cm-1.  The amide III peak at 1261 cm-1 and the amide I peak at 1654 cm-1 are also 
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more intense in the metastatic tissue measurements than in the non-cancerous 
sample measurements along with the collagen peak at 872 cm-1. A carotenoid 
peak at 1523 cm-1 is seen to be more intense in the spectra of healthy tissue 
than that of metastatic tissue.  
 
To show the variation between measurements from the same pathological 
group, the standard deviation is plotted around the mean in Figure 3.35. Although 
there is a large amount of variation between the dataset, the DNA peaks seem to 
be consistently more intense in non-cancer tissue measurements whilst those 
assigned as lipid peaks are always much more intense in metastatic tissue 
measurements. The signal-to-noise ratio was most commonly between 11 and 
13 and greater than 5.71 in all measured cases. Therefore, most variation is 
attributed to biochemical differences between the samples rather than noise. The 
spread of data appears to be greater in the metastatic LN measurements than 
the non-cancer LN measurements. The dataset is balanced between the two 
groups so this may suggest a larger amount of biochemical heterogeneity 
between metastatic samples.   
 
 
 
Figure 3.35- Averaged AC met (red) and non-cancerous (green) spectra. The shaded area 
flanking the spectra represents 2 standard deviations from the mean. Note that when both green 
and red overlap they are shown in brown.  
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The variations between spectra from metastatic AC tissue and non-cancer 
tissue are visually subtle and multivariate analysis was needed to identify spectral 
differences between the two pathological groups. Biochemical differences exist 
between pathological groups, therefore a supervised technique was employed to 
help identify the differences between the groups as oppose to the dataset as a 
whole. PLSDA was carried out to identify the components in the spectra that lead 
to the most variation between groups. The scores plot is displayed in Figure 3.36 
based on the first three components. Analysis focused on where the scores were 
plotted, as either on the positive axis, above 0, or on the negative axis, below 0. 
In the first PLS component, the metastatic scores are generally negative whilst 
those from non-cancer measurements are more often positive. For PLS 
component 2 the non-cancer scores are more frequently positive and the 
metastatic, whilst more heavily negative, have a much broader distribution across 
the component. For PLS component 3 the metastatic scores are primarily 
negative and the non-cancer scores positive.   
 
 
 
Figure 3.36- PLS score plot showing the grouping of AC met lymph node measurements (120 
spectra), in red, and non-cancerous lymph node measurements, (120 spectra) in green, based 
on PLS components 1, 2 and 3.  
 
 
Using a ‘leave one sample out’ cross-validation, the pathological group of 
the blind dataset were estimated. Classification sensitivities and specificities were 
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calculated between 50-83% for identifying metastatic lymph node data correctly 
from non-cancer measurements using a majority wins approach per sample. The 
optimal number of PLS components was calculated to be primarily 5 for this 
cross-validation. Table 3.9 shows the confusion matrix for this cross validation 
which uses a majority wins approach for measurements per node.   
 
 
Table 3.9- Table displaying the confusion matrix and calculated sensitivity and specificity from 
blind classification using the PLS model from figure 10. 
 Confusion matrix True group 
Metastatic AC Non-cancer 
Predicted 
group 
Metastatic AC 3 1 
Non-cancer 3 5 
Total LN Samples                                      6 6 
Sensitivity 0.5000 0.8333 
Specificity 0.8333 0.5000 
 
 
 
The PLS weights from the components were analysed in order to gain 
more information regarding the biochemicals responsible for the variation 
between the metastatic and benign tissue. Figure 3.37 shows the spectra of these 
weights and Table 3.10 lists the main peaks as either a positive or negative band. 
These weights can be compared to the scores on the PLSDA plot which represent 
the component weights based on the level of peak contribution in the spectrum. 
Therefore the direction of the peak, either positive or negative, can be compared 
to the PLSDA scores of the data, in order to identify which pathological group it 
is more characteristic of.  
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Figure 3.37- Spectra representing the weights of PLS components 1 (blue), 2 (purple) and 3 
(green). 
 
 
 The weights from PLS component one support the observation that there 
are more intense lipid peaks in metastatic AC LN tissue, seen by peaks in the 
negative direction at 1062, 1076, 1296, 1437 and 1743 cm-1, resulting from the 
C-C, CH2CH3, C=O and C=C bonds. Amide III is assigned to the 1263 cm-1 peak, 
present as a negative band in component 1 along with a peak at 1652 cm-1 
assigned as amide I, supporting the observation of higher levels in metastatic AC 
tissue. Peaks assigned to DNA and amino acids are observed in the positive 
direction, such as at Raman shifts of 669, 731, 750, 781, 1553 and 1557 cm-1 
caused by vibrations of C-N bonds and aromatic ring structure, which are 
components of DNA molecules and nucleic acids. This is also in agreement with 
the observations that the DNA seems to be present in lower quantities in the 
metastatic AC LN tissue than compared to the non-cancer LN samples. Table 
3.10 lists the main peaks from the component weights with their tentative 
biochemical assignments.   
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Table 3.10- Table of positive and negative bands from the weights of PLS components 1, 2 and 
3 in figure 11. 
Component 1 Component 2 Component 3 
-ve band +ve band -ve band +ve band -ve band +ve band 
8
5
1
 
Tyr 
6
6
9
 
Cystine 
9
7
4
 
Collgen 
7
3
1
 
DNA 
1
1
2
3
 
Lipid/protein 
7
3
1
 
DNA 
8
6
5
 
Collagen, 
hydroxyproline 
7
3
1
 
DNA 
9
8
2
 
Collagen 
7
8
1
 
Pyrimidine base 
1
4
3
7
 
Protein/ 
phospholipid 
7
8
1
 
Pyrimidine base 
1
0
6
2
 Lipid 
7
5
0
 
Tryp 
 
 
1
1
5
2
 Protein/carotenoid 
1
4
5
6
 Protein/ 
phospholipid 
1
1
5
2
 Protein/caroteno
id 
1
0
7
6
 
Protein, lipid 
7
8
1
 
Pyrimidine 
base 
 
 
1
2
9
4
 
Cytosine229 
 
 
1
2
9
4
 
Cytosine229 
1
2
6
3
 Carb/amide III 
1
1
3
3
 Protein, lipid   
1
4
2
9
 Protein/ 
phospholipid 
  
1
4
2
9
 Protein/ 
phospholipid 
1
2
9
6
 Lipid/ collagen 
1
2
1
2
 Protein   
1
4
8
9
 DNA   
1
4
8
9
 DNA 
1
4
3
7
 Protein/ 
phospholipid 
1
5
5
3
 Tryp   
1
5
2
3
 Carotenoid   
1
5
2
3
 Carotenoid 
1
6
5
2
 Amide I 
1
5
7
6
 Nucleic acid   
1
6
5
0
 Amide I   
1
6
5
0
 Amide I 
1
7
4
3
 Lipid 
 
         
 
 
 
 In the weights of PLS component two, negative bands at 974 cm-1 and 982 
cm-1 are assigned to collagen due to vibrations of C-C and CH2 bonds within the 
molecule, implying higher collagen in the LN with metastatic AC. The band at 
1523 cm-1, caused by r-C=C-r bond, assigned to carotenoid molecules is also 
present in PLS component two in the positive direction belonging mainly to the 
non-cancerous lymphocyte group, which is also seen to be different between the 
two pathologies in the mean spectra. In the positive direction a peak present at 
781 cm -1 is attributed to the ring structure of the pyrimidine bases, further 
supporting their stronger presence in non-cancerous tissue. In the weights of PLS 
component three, lipid peaks seen at 1123, 1437 and 1456 cm-1 are negative and 
peaks at 781 and 1489 cm-1 are positive, and indicative of the vibrations of DNA 
molecules. Carotenoid assigned peaks at 1152 and 1523 cm-1 are also positive, 
along with an amide I assignment at 1650 cm-1.   
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Figure 3.38- Bar plot showing the selection frequency of bands using VIP overlaid on the mean 
spectrum of both metastatic and non-cancerous data. 
 
 
 VIP was used to identify the important Raman shifts for discriminating 
between the groups. Figure 3.38 shows the selection frequency of these 
wavenumbers. Table 3.11 shows the bands that were selected 100% of times in 
the PLSDA model. The 781 cm-1 band, attributed to the ring structure of 
pyrimidine bases, is identified as important for delineating non-cancer from 
metastatic AC tissue. Other bands recognised as important for characterising 
include: 1003 (phenylalanine), 1152 (protein, carotenoid), 1288, 1304, 1320 
(collagen), 1338 (amide III), 1445 (phospholipid, protein), 1527 (carotenoid), 
1551 (tryptophan), 1581 (nucleic acid), 1604, 1617 (amino acids), and 1656 cm-
1 (amide I).  
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Table 3.11- Raman shifts selected 100% of times from the VIP.  
Bands selected for classification 100% of the time 
Band Wavelength Tentative assignment  
781.2-783.3 Pyrimidine base 
1003 Phe 
1152 Protein/carotenoid 
1288 Collagen  
1294-1338 Lipid/collagen, Amide III 
1429-1460 Protein, phospholipid 
1536-1600 Nucleic acid, amino acid 
1603 Amino acid 
1613-1620 Amino acid 
1654-1666 Amide I 
1670-1672 Amide I 
1676-1677 Amide I 
 
 
 The VIP plot was compared to the analysis of the PLSDA weights in order 
to identify the biochemicals that were identified as important and which pathology 
they are characteristic of. It was found that the peaks more indicative of 
metastatic AC LN measurements include 1296 cm-1, assigned to lipid/collagen, 
1437 and 1456 cm-1 assigned to phospholipid/protein. Whilst those more 
indicative of non-cancer LN tissue are peaks at 781 cm-1, assigned as pyrimidine, 
1152 cm-1,assigned as protein/carotenoid, 1294 cm-1,assigned as cytosine, 1559 
cm-1, assigned as tryptophan and 1576 cm-1 assigned as nucleic acid.  
 
 
3.1.2 Raman Spectroscopy of Femoral Lymph Nodes  
 
This study also measured femoral lymph nodes to assess the use of 
Raman spectroscopy for differentiation between non-cancer samples and those 
with metastatic squamous cell carcinoma from cervical cancers. Femoral lymph 
nodes are found in the groin and often referred to as inguinal nodes.  
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Figure 3.39- Mean spectra of metastatic SCC and non-cancer femoral lymph node measurements 
from 120 and 160 acquisitions respectively.   
 
 
 Figure 3.39 shows the resulting mean spectra from measurements of the 
metastatic and non-cancer femoral lymph nodes. Similarly to the oesophageal 
LN data, differences are mainly present as a result of intensity variation as 
oppose to changes in peak position. Visual differences appear most noticeably 
at 784 cm-1, assigned as pyrimidine, 1261 cm-1, assigned as amide III, 1365 cm-
1, assigned as tryptophan, 1527 cm-1, assigned as carotenoid and 1581 and 1617 
cm-1, assigned as amino acid, where they appear less intense in the metastatic 
mean spectrum than the non-cancer. 
113 
 
 
Figure 3.40- Standard deviation plotted around the mean spectra of metastatic SCC and non-
cancer femoral lymph node measurements from 120 and 160 acquisitions respectively.   
 
 
 To evaluate the variation of the dataset the standard deviation was plotted 
around the mean, displayed in Figure 3.40. It can be seen that variation is higher 
in both the groups, mainly in the DNA regions of the spectra between 600–900 
cm-1 and the amide III peak and lipid region of 1200–1400 cm-1. The level of 
variation seems to be similar across both the metastatic and non-cancer LN 
measurements except at the amide III peak (1261 cm-1) and the nucleic and 
amino acid peaks around 1500-1620 cm-1. This could be due to a higher number 
of samples, and hence measurements, in the non-cancer LN group leading to a 
higher chance of variation within the dataset.      
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Figure 3.41- PLS scores plot of the metastatic SCC and non-cancer femoral lymph node 
measurements. 
 
 
 The subtlety in differences between the metastatic and non-cancer 
measurements requires multivariate analysis to identify significant variations 
between the two groups and cross-validation to evaluate the ability for 
classification. PLSDA was performed and cross-validated using leave-one-
sample-out. Through a majority wins approach, a sensitivity and specificity of 
83% and 75% respectively for the identification of metastatic SCC in femoral 
lymph nodes was calculated. The confusion matrix for the validation is seen in 
Table 3.12. 
 
 
Table 3.12- Confusion matrix for the classification of metastatic SCC in femoral lymph nodes. 
  True group 
Metastatic SCC Non-cancer 
Predicted group 
Metastatic SCC 5 2 
Non-cancer 1 6 
Total LN samples 6 8 
Sensitivity 0.8333     0.7500 
Specificity 0.7500 0.8333     
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The scores plot displayed in Figure 3.41 shows the clustering of the two 
datasets. The scores for PLS components 1, 2 and 3 are generally more negative 
in the metastatic group and more positive in the non-cancer group. The PLSDA 
weights for the first three components are presented in Figure 3.42 and Table 
3.13 lists the main negative and positive peaks with their tentatively assigned 
biochemicals. 
 
 
 
Figure 3.42- PLS weight spectra of the first three PLS component. 
 
 
 The peaks in the negative direction are more representative of the scores 
that are also negative, and thus metastatic LN measurements. Those that are in 
the positive direction are more characteristic of scores also positive, and therefore 
non-cancer LN measurements for the first three components. Negative peaks 
include 899.7 cm-1, assigned as adenine, 935.9 cm-1, assigned as protein, 1003 
and 1032 cm-1, assigned as phenylalanine, 1123, 1445 and 1078 cm-1, assigned 
as lipid peaks, 1318 cm-1, assigned as collagen and 1654 cm-1, assigned as 
amide I. Positive peaks, thus those that are more indicative of non-cancer 
measurements, include 728, 781, 1094 and 1480 cm-1, assigned as DNA, 753, 
853, 1375 and 1559 cm-1, assigned as amino acid, 1521 cm-1,  assigned as 
carotenoid and 1570 cm-1, assigned as nucleic acid. Component three slightly 
conflicts with the other two as the phenylalanine peak is positive, but with a small 
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shift in wavenumber at 1001 cm-1 as opposed to 1003 cm-1. This might suggest 
that the phenylalanine is slightly altered, perhaps by the microenvironment, in 
metastatic tissue causing a shift in the wavelength of the scattered light. 
Furthermore, a peak assigned as collagen/lipid at 1302 cm-1 is present in the 
positive direction. However, in the other two components the lipid and collagen 
peaks appear to be present more often in the negative direction.          
 
 
Table 3.13- Main peaks and their biochemical assignments from the PLS component weights.  
Component 1 Component 2 Component 3 
-ve band +ve band -ve band +ve band -ve band +ve band 
9
0
0
 Adenine 
7
2
9
 DNA 
9
0
0
 Adenine 
6
7
4
 Cystine 
9
0
0
 Adenin
e 6
4
2
 Tyr 
9
3
6
 
Protein 
7
5
3
 
Tryp 
9
3
6
 
Protein 
7
3
1
 
DNA 
 
 
6
7
4
 
Cystine 
1
0
0
3
 
Phe 
7
7
7
 
Pyrimidine  
9
5
1
 
Hydroxyapatite
, cholesterol  
7
8
1
 
Pyrimidine  
 
 
7
8
6
 
Pyrimidine 
1
0
3
2
 
Phe 
1
0
9
4
 
DNA 
1
0
0
3
 
Phe 
1
0
9
4
 
DNA 
 
 
8
5
3
 
Tyr 
1
1
2
3
 
Lipid, protein  
1
1
5
6
 
Protein, 
carotenoid 
1
0
3
2
 
Phe 
1
1
5
6
 
Protein, 
carotenoid 
 
 
1
0
0
1
 
Phe 
1
4
4
5
 
Phospholipid
, protein  
1
2
5
7
 
Carb, 
amide III 
1
0
7
8
 
Lipid, protein  
1
2
4
9
 
Carb, 
amide III 
 
 
1
0
9
4
 
DNA 
1
6
5
4
 
Amide I 
1
3
7
5
 
Tryp 
1
1
2
3
 
Lipid, protein  
1
3
6
5
 
Tryp 
 
 
1
1
5
4
 
Protein, 
carotenoid 
 
 
1
4
9
0
 
DNA 
1
2
0
6
 
Protein  
1
4
8
1
 
DNA 
 
 
1
2
5
7
 
Carb, amide 
III 
 
 
1
5
2
1
 Carotenoi
d 
1
3
1
8
 Collagen  
1
5
2
1
 Carotenoi
d  
 
 
1
3
0
2
 Collagen, 
lipid 
 
 
1
5
5
9
 Tryp 
1
4
4
5
 Phospholipid, 
protein  
1
5
7
0
 Nucleic 
acid  
 
 
1
3
7
5
 Tryp 
 
 
1
6
1
7
 Amino 
acid  1
6
5
2
 Amide I 
 
 
 
 
1
4
4
6
 Phospholipid
, protein  
 
 
 
   
 
   
1
5
1
7
 Carotenoid 
 
 
 
   
 
   
1
5
7
4
 
Nucleic acid 
 
 
 
   
 
   
1
6
5
7
 Amide I 
 
 
 Identification of the important peaks for discrimination by VIP, suggests 
that the wavenumbers where amino acids, nucleic acids, collagen, amide I and 
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III, lipid and carotenoid peaks are useful for delineation of metastatic SCC from 
non-cancer LN measurements. The VIP bar plot is shown in Figure 3.43 and the 
wavenumbers with 100% selection are listen in Table 3.14 with the tentative 
assignments for the peaks present within the bands. Through comparison of the 
VIP with the PLSDA weights it can be seen that metastatic SCC LN can be 
identified from non-cancer LN measurements from a higher intensity of peaks 
assigned as lipid and collagen. This also indicates a higher content of these 
biochemicals within the tissue. Moreover, metastatic LN also appears to have 
less intense peaks assigned as DNA, nucleic acids, amino acid and amide III than 
non-cancer LN measurements.        
 
  
 
Figure 3.43- VIP bar plot overlaid onto a mean spectrum of the dataset to show the proportion of 
times specific Raman bands were included in classification. 
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Table 3.14- Table of the Raman shifts that were selected 100% of the time for classification with 
their biochemical assignments. 
Bands selected for classification 100% of the time 
Band Wavelength Tentative assignment  
631.1 Amino acid 
776.9-781.3 Pyrimidine base 
1001-1003 Phe 
1150-1158 Carotenoid, protein  
1224 Protein, amide III, carb 
1228 Protein, amide III, carb 
1233-1258 Protein, amide III, carb 
1262-1264 Amide III, carb 
1268-1270 Amide III, carb 
1292 Collagen 
1298-1304 Collagen, lipid 
1334-1336 Amide III 
1371 Tryp 
1375 Tryp 
1431-1456 Protein, phospholipid 
1509-1527 Carotenoid  
1644-1654 Amide I 
1749 Lipid 
  
119 
 
 
3.1.3 Raman Spectroscopy of Head and Neck Lymph Nodes 
 
 
The averaged spectra for measurements from metastatic squamous cell 
carcinoma (SCC) and non-cancer lymph nodes of the head and neck are 
displayed in Figure 3.44. Similarly to the oesophageal lymph node data the main 
differences between the spectra are peak intensities as oppose to position. Visual 
differences include less intense peaks assigned as DNA and nucleic acid and 
more intense peaks assigned as lipid, amide I and amide III in the metastatic 
data.  
 
 
Figure 3.44- Mean spectra of metastatic SCC and non-cancer data from head and neck lymph 
nodes averaged across 100 and 260 measurements respectively. 
 
  
 The standard deviation was plotted around the averaged spectra and 
shown in Figure 3.45 to show the variation of the dataset. The non-cancer LN 
data appear to exhibit much more variability than the metastatic SCC data, unlike 
the oesophageal dataset. However, in this dataset there are more non-cancer 
samples included than metastatic samples which may lead to this increase in 
deviation. The peaks characteristic of DNA and amino acids are still typically 
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lower and those characteristic of lipids higher in the metastatic measurements 
even in the standard deviation.       
 
 
 
Figure 3.45- Standard deviation plotted around the mean spectra of SCC metastatic and non-
cancer data from head and neck lymph nodes averaged across 100 and 260 measurements 
respectively.  
 
Multi-variate analysis was carried out to assess if the two groups could be 
distinguished from one another analytically and also to reveal the main 
wavenumber regions in the spectra for this discrimination. PLSDA, a supervised 
technique was employed and a leave-one-sample-out cross validation used to 
quantify the classification capabilities in the form of sensitivities and specificities 
using a majority wins approach.   
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Figure 3.46- PLSDA scores plot showing clustering of the metastatic and non-cancer 
measurements from head and neck lymph nodes. 
 
  
 The PLSDA scores plots shown in Figure 3.46 displays the dataset scores 
depending on the first three PLS components. The scores plot enables 
visualisation of the dataset clustering. It is seen that the metastatic and non-
cancer lymph node measurements typically cluster with others from the same 
group with a slight amount of overlap. PLS component 1 has mainly positive 
scores pertaining to the non-cancer LN group and negative belonging to the 
metastatic SCC LN group. In PLS component 2 it is more difficult to discern 
between the groups, as the non-cancer scores are spread widely across both the 
negative and positive directions on the axis. However, metastatic scores are more 
frequently negative than positive. PLS component 3 is seen to separate primarily 
negative metastatic scores from the more positive non-cancer LN scores.     
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Table 3.15- Confusion matrix for the classification of Metastatic SCC in head and neck lymph 
nodes. 
 Actual group 
Metastatic SCC Reactive 
Predicted group 
Metastatic SCC 4 1 
Reactive 1 12 
Total LN samples 5 13 
Sensitivity 0.8000     0.9231 
Specificity 0.9231 0.8000     
 
 
A leave-one-sample-out cross-validation resulted in a sensitivity of 80% 
and specificity of 92% for the identification of metastatic SCC LN from non-cancer 
LN tissue, when employing a majority wins approach (Table 3.15). 
 
The PLSDA weights from the first three components, displayed in Figure 
3.47, show the peaks that contribute to the component, and the direction in which 
they are present indicate whether they are more indicative of the negative or 
positive scores. The main peaks from the weights spectra of the first three PLSDA 
components are listed in Table 3.16 and show the tentative biochemical 
assignments. 
 
 
 
Figure 3.47- Weight spectra of the top three components in PLSDA. 
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Table 3.16- Main peaks from PLS weights with tentative biochemical assignments.   
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 The negative peaks from the three components are more representative 
of the negative scores, and thus metastatic SCC measurements. These include 
peaks at 698 and 848 cm-1 assigned as the amino acids cysteine and tyrosine, 
assigned protein peaks at 938 and 1204 cm-1, phenylalanine at 1001 and 1030 
cm-1, collagen at 1278 cm-1, and peaks at 1061, 1080, 1123, 1308 and 1440 cm-
1, assigned as lipid. An amide I peak at 1654 cm-1 is also present negatively in 
the weights of component 1. The positive peaks, and thus more indicative of the 
positive scores which are primarily more characteristic of non-cancer LN 
measurements include DNA and nucleic acids, amide III and nucleic acids. Peaks 
assigned as DNA and nucleic acids comprise 709, 727, 749, 781, 1090, 1481 
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and 1574 cm-1, amide III at 1257 cm-1 and amino acid at 1330 cm-1. Conflicting 
peaks include a peak at 1300 cm-1 assigned as collagen/lipid which is positive in 
the weights for component 2 and 3 however negative in component 1 at 1308 cm-
1. Also an assigned amide I peak is positive in components 2 and 3 at 1661 cm-
1, yet negative in component 1 at 1654 cm-1 and a peak at 1440 cm-1, assigned 
as phospholipid/protein, is negative in component 1 and positive in components 
2 and 3 at 1439 cm-1. These discrepancies between components could be 
highlighting a difference in the Raman shift of the collagen and amide I peaks 
rather than an alteration between the intensities of the peaks.  
 
 
 
Figure 3.48- Bar chart of the VIP results plotted in front of the mean spectrum showing the 
wavelengths and the proportion of times they were selected for classification. 
 
 
 VIP was carried out to identify the important peaks for classification, shown 
as a bar chart in Figure 3.48. Table 3.17 displays the wavelengths that were used 
100% of the time for helping discriminate between the two groups, these include 
peaks assigned as DNA components, phenylalanine, lipid, collagen and amide I 
and III. Comparison of the VIP results and the PLSDA weights enabled the 
recognition of peaks contributing most to variation, and which group they are 
indicative of. A peak at 781 cm-1, assigned as pyrimidine, is supposedly more 
indicative of non-cancer LN measurements and was found to be important for 
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classification of metastatic nodes as the peak appears at a lower intensity in these 
samples’ spectra. This is also seen for peaks at 1300, 1439, 1574 and 1661 cm-
1, assigned as lipid/collagen, amide III, phospholipid/protein, nucleic acids and 
amide I respectively. These are all present at lower intensities in the metastatic 
SCC measurements compared to the non-cancer LN measurements. Peaks 
identified as important by VIP and are supposedly more characteristic of 
metastatic SCC include 1001, 1278, 1308, 1440 and 1654 cm-1 assigned as 
phenylalanine, collagen/lipid, collagen, phospholipid/protein and amide I 
respectively. Again, the phospholipid/protein and amide I peak could represent a 
change in Raman shift rather than intensity.  
 
 
Table 3.17- Table of Raman bands selected 100% for classification identified through VIP along 
with their biochemical assignments.  
Bands selected for classification 100% of the time 
Band Wavelength Tentative assignment  
776.9-796.5 Pyrimidine base 
999-1003 Phenylalanine 
1292-1312 Lipid/collagen, Amide III 
1316 Collagen 
1334-1338 Amide III 
1431-1462 Protein, phospholipid 
1570-1575 Nucleic acid 
1644 Amide I 
1652-1661 Amide I 
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 Point measurements from all the three LN regions were acquired, after the 
oesophageal lymph node samples were found to be largely affected by carbon 
particles, to keep continuity and to enable the comparison of the measurements. 
However, maps were also acquired from the head and neck nodes in order to 
evaluate if there was a loss in performance and thus classification accuracy when 
only analysing point measurements. The results from the maps were analysed in 
the same way as the point measurements, so that a comparison could be made. 
Figure 3.49 shows the non-baseline corrected averaged spectra of the metastatic 
SCC and non-cancer LN Raman maps. Visually the spectra are alike to that of 
the point data in Figure 3.44 and the differences between the two LN groups are 
similar. Such as, in the mean metastatic SCC spectrum, less intense peaks in the 
DNA region of 600-900 cm-1, in the nucleic acid and carotenoid regions between 
1500-1620 cm-1, and more intense phenylalanine, amide, collagen and lipid 
peaks between 1000-1440 cm-1 and 1654 cm-1.  
 
    
 
Figure 3.49- Mean spectra for metastatic SCC and non-cancer head and neck lymph node 
measurements from Raman maps resulting in 44802 and 131738 spectral measurements.  
 
 
 PLSDA was carried out on the data for comparison with the point data. 
The scores plot is shown in Figure 3.50 and resembles that of the point 
measurements in Figure 3.46 where the scores for the non-cancer 
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measurements are more frequently positive whilst that of the metastatic SCC are 
more often negative in the first three components. 
  
 
 
Figure 3.50- PLSDA scores plots for metastatic SCC and non-cancer head and neck LN 
measurements for the first three components. 
 
 
 Cross validation was also performed and produced a classification 
sensitivity of 80% and a specificity of 92% for the identification of metastatic 
cancers using a majority wins approach for spectra per sample, the same results 
calculated in the point spectra dataset. The confusion matrix for this analysis is 
shown in Table 3.18.     
  
 
Table 3.18- Confusion matrix for classification of metastatic SCC in head and neck LN. 
 True group 
Metastatic SCC Non-cancer 
Predicted group 
Metastatic SCC 4 1 
Non-cancer 1 12 
Total LN samples 5 13 
Sensitivity 0.8000     0.9231 
Specificity 0.9231 0.8000     
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The spectra for the weights of the first three components are displayed in 
Figure 3.51 and are also similar to that of the point spectra data set in Figure 
3.47. The main peaks listed in Table 3.19 also align with those of the point spectra 
dataset in Table 3.16, such as positive assigned DNA and nucleic acid peaks at 
727, 748, 779, 792, 1090, 1485 and 1575 cm-1, amino acids at 667, 675, 707, 
1188, 1617 cm-1 and amide III at 1260 and 1334 cm-1. Negative peaks assigned 
as collagen are present at 876 and 1314 cm-1, lipid at 1059, 1082 and 1445 cm-
1, and phenylalanine at 1001 cm-1. Similarly, the phospholipid/protein peak is 
present in the positive weights but at a lower Raman shift of 1439 cm-1 and 
collagen at 1300 cm-1 but again at a lower Raman shift. 
 
 
 
Figure 3.51- PLSDA weight spectra of the first three components. 
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Table 3.19- Table of the main peaks from the PLSDA weights with biochemical assignments. 
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 VIP was again performed to compare the results to the point spectra 
dataset. The plot displayed in Figure 3.52 shows the regions of the spectra that 
were used for classification and the proportion of times. Those used 100% of 
times for classification are listed with their biochemical assignments in Table 3.20. 
Although certain spectral bands were found to be important for both the mapped 
dataset and the point spectra dataset, differences included no collagen bands 
and the inclusion of the lipid peak area at 1745 cm-1 in the mapped dataset. 
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Figure 3.52- VIP plot to show the proportion of times bands were selected for classification. 
 
 
Table 3.20- Table of bands selected 100% of times for classification identified through VIP along 
with their biochemical assignments. 
Bands selected for classification 100% of the time 
Band Wavelength Tentative assignment  
777-792 Pyrimidine base 
1158-1160 Carotenoid, protein  
1433-1460 Protein, phospholipid 
1562-1581 Nucleic acid 
1654-1655 Amide I 
1723-1801 Lipid 
 
 
After the adjacent H&E sections were analysed the pathologist identified 
regions that were of interest. These regions were then spectrally mapped in order 
to create a spectral image representing biochemical content. Figure 3.53 shows 
the white light image of the H&E stained sample and the k-means clustered image 
of the adjacent mapped section. The images are labelled to show the areas of 
keratinocytes, SCC cells and non-cancer lymphocyte cells. Visually the areas 
look distinct and therefore Raman was used to assess if they could be spectrally 
delineated based on the biochemicals in the tissue that contribute to the 
scattering detected. K-means clustering was applied to create a pseudo-colour 
image of the map, categorised based on similar spectral components. From 
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visual evaluation it is clear that the regions are spectrally distinct. The 
keratinocytes are shown as dark blue, the SCC as cyan and the lymphocytes as 
red. The image shown is a 6 cluster image however, and it can be seen that there 
is a yellow border between the keratinocytes and the SCC and also a lighter blue 
and dark red within the keratinocyte region. The lymphocyte cells and the SCC 
cells appear to have a clear separation between the groups whereas the border 
between the SCC cells and the keratinocytes is less clear. Possibly as a result of 
diffusion of the cells between the different areas.  
 
  
 
Figure 3.53- K-mean cluster image from a Raman map (right) from the area highlighted in the 
white light image (left).  
 
  
 The centroid spectra (Figure 3.54) exhibit visual differences between the 
measurements. Particularly in the non-cancer lymphocytes spectra where there 
appears to be a stronger amide III (1261 cm-1) and DNA and nucleic acids (723, 
784, 827, 1095 and 1581 cm-1) peaks and weaker amide I (1747 cm-1) and 
collagen (1320 cm-1) assigned bands than in the SCC and keratinocyte spectra. 
Another variation between the spectra is the lack of a 784 cm-1 peak, assigned 
as pyrimidine base, in the keratinocyte spectrum.  
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Figure 3.54- Centroid spectra from the Raman map of the SCC, keratinocyte and non-cancer 
lymphocyte lymph node regions.  
 
 
FTIR was carried out on the same area and section of head and neck 
lymph node samples, to compare the spectroscopic techniques. The averaged 
FTIR spectra of the data taken from maps are displayed in Figure 3.55. The noise 
is much less in FTIR, but there are not as many spectral peaks. Visually there is 
a slight intensity decrease in signal around the nucleic acid assigned peaks at 
1086 and 1236 cm-1 and around the lipid assigned peak at 1741 cm-1, and a slight 
increase at the amide II assigned peak230 at 1547 cm-1 in the metastatic averaged 
measurement compared to the non-cancer. PLSDA was carried out on the 
dataset using the FTIR data and the scores plot (Figure 3.56) showed the 
grouping of the data. Cross-validation carried out resulted in a sensitivity of 60% 
and sensitivity of 69% for the identification of head and neck lymph nodes with 
metastatic SCC (Table 3.21).   
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Figure 3.55- Mean FTIR spectra of metastatic SCC and non-cancer LN averaged over 3942 and 
5621. 
 
 
 
Figure 3.56- PLSDA scores plots of the top three components. 
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Table 3.21- Confusion matrix for the cross validation of the PLSDA model using a majority wins 
approach. 
 True group 
Metastatic SCC Non-cancer 
Predicted group 
Metastatic SCC 3 4 
Non-cancer 2 9 
Total LN samples 5 13 
Sensitivity 0.6000     0.6923 
Specificity 0.6923 0.6000     
 
 
3.1.4 Raman Spectroscopy of Combined Lymph Nodes 
 
In the three lymph node regions looked at the number of metastatic 
samples was limited, hence the ability to distinguish metastatic from non-cancer 
lymph nodes of the three lymph node regions combined was investigated. The 
mean spectra of the metastatic and non-cancer lymph node measurements are 
displayed in Figure 3.57 to visually assess any obvious spectral differences.   
 
 
 
Figure 3.57- Mean spectra of metastatic (red) and non-cancer (green) lymph nodes averaged 
across 340 and 540 measurements respectively. 
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Although biochemical differences are expected between metastatic and 
non-cancer tissue, PCA was carried out to not only assess if separation was 
present based on pathology but also between data from the various lymph node 
regions, as the technique does not require prior information. The PCA scores plot 
in Figure 3.58 shows the clustering of the measurements based on the top four 
principal components calculated using ANOVA.   
 
 
 
Figure 3.58-PCA plots of measurements from metastatic (red) and non-cancer (green) lymph 
nodes. 
 
 
 From ANOVA and through visually assessing the scores plot it is clear that 
the main component for separation of the metastatic and non-cancer LN data 
groups is PC7. It can be seen that in PC7 the metastatic LN data congregate 
mainly on the negative axis whilst the non-cancer LN data are mainly plotted on 
the positive. The separation for the next three components is not visually as clear. 
However, looking at the average and median values for the dataset, it can be 
seen that for PC5 the metastatic scores are generally negative whilst the non-
cancer scores are positive. For PC2, the metastatic scores seem to be both 
positive and negative and are seen to be dispersed across the whole axis, whilst 
the non-cancer visually congregate closer to 0. For PC10, the metastatic are 
primarily negative whilst the non-cancer are slightly more positive. The loadings 
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of the components are displayed in Figure 3.59 and the main peaks and their 
assignments are listed in Table 3.22.  
 
 
Figure 3.59-PCA loadings highlighting the variability between metastatic and non-cancerous 
lymph node tissue measurements. 
 
 
Through comparing the loading peaks to the PCA scores plot (Figure 3.60) 
it can be deduced that in PC7, peaks more indicative of metastatic data include 
those assigned as amino acids (640, 698, 1001, 1170 and 1609 cm-1), collagen 
(1278 and 1322 cm-1) and protein (1406 cm-1). The PC7 loading peaks more 
indicative of non-cancer include those in the positive direction, such as those 
assigned as, Nucleic acids and DNA (784, 804, 1092 and 1576 cm-1) and Amide 
III and I (1249 and 1678 cm-1 respectively). The negative peaks in PC5, are more 
indicative of metastatic samples and are assigned as amino acids (855, 1555 and 
1620 cm-1), and the positive peaks, more indicative of non-cancer samples, are 
assigned as DNA and nucleic acids (727, 781, 1092, 1334 and 1483 cm-1), 
protein and lipid (1334 and 1483 cm-1), carotenoid (1513 cm-1) and amide I (1659 
cm-1). The loading spectrum of PC2 largely consists of positive bands that make 
up the majority of the peaks belonging to lymph node spectra. The only potentially 
negative peak was at 1530 cm-1 assigned as carotenoid. This might support the 
observation in the PCA scores plot, where metastatic and non-cancer scores are 
both more positive.     
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Table 3.22-Positive and negative bands from the PCA loadings with their tentative assignemnts. 
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PLSDA was then carried out on the dataset to evaluate the capabilities of 
the supervised method to classify metastatic lymph nodes from reactive lymph 
nodes, from the three anatomical locations. Figure 3.60 shows the supervised 
clustering of the two groups of the dataset, although visually not overly distinct 
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from each other, cross-validation resulted in a sensitivity of 71% and specificity 
of 89% for the identification of metastasis in lymph nodes (Table 3.23).   
 
 
 
Figure 3.60-PLSDA scores plot for the first three components, showing the distribution of 
metastatic (red) and non-cancer (green) LN measurements. 
 
 
Table 3.23- Confusion matrix for the classification of metastatic LN from non-cancer LN. 
 True Group 
Metastatic  Non-cancer 
Predicted group 
Metastatic 12 3 
Non-cancer 5 24 
Total LN 17 27 
Sensitivity 0.7059     0.8889 
Specificity 0.8889 0.7059     
 
 
The PLS scores plot for component 1 and 2 was plotted, Figure 3.61, and 
labelled with the anatomical location of the LN as well as the pathology, to assess 
if clustering between lymph nodes of the same location, but different pathology, 
was occurring. From the plot it does not seem like this is taking place, as the LN 
data from the different locations are intermingled with each other. 
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Figure 3.61- PLSDA scores plot of component 1 and 2 and labelled by both pathology and 
location. 
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 The VIP plot displayed in Figure 3.62 shows the most important spectral 
wavenumbers for distinguishing metastatic LN from non-cancer nodes and Table 
3.24 lists those selected 100% of the time for cross validation with their 
corresponding tentative assignments. Comparing this to the PCA component 
loadings, the peaks primarily indicative of metastatic LN are those assigned as 
amino acids (645, 695, 1001, 1549, 1620 cm-1), lipid and protein (1129 cm-1), 
collage (1322 cm-1) and carbohydrate (1340 cm-1). Those mostly indicative of 
non-cancer nodes consist of those assigned as DNA and amino acids (784, 1094 
and 1579 cm-1), carbohydrate (1334 cm-1), protein and phospholipid (1483 cm-1) 
and carotenoid (1513 cm-1). 
 
 
 
Figure 3.62- VIP plot showing the proportion of times specific Raman shifts were selected to 
discriminate between the groups of the dataset in PLSDA cross-validation. 
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Table 3.24- Spectral regions from VIP selected 100% of times for cross-validation of PLSDA 
model. 
Bands selected 100% of time for classification Tentative assignment 
599.7-657.9 Phe, Tyr 
697.9 Glycine 
774.7 Pyrimidine base 
1001 Phe 
1086-1099 Protein, lipid, DNA 
1121-1125 Lipid, protein 
1152-1154 Protein 
1316 Collagen 
1322-1345 DNA, nucleic acid 
1433-1452 Protein, phospholipid 
1477-1490 Protein, phospholipid  
1511 Carotenoid 
1515-1523 Carotenoid 
1542-1575 Tryp, Nucleic acid 
1587 Nucleic acid 
1592-1605 Amino acid 
1613-1620 Amino acid 
1657-1665 Amide I 
1725-1788 Lipid 
1792-1797 - 
1801 - 
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3.2 Discussion 
 
Lymph nodes are primarily located within and attached to adipose 
tissue.231 Adipose tissue is loose connective tissue that stores energy in the form 
of lipids. Lipids, along with proteins and carbohydrates, are the main constituents 
of the human body, hence is stored in many cells throughout different tissue types 
in different quantities. Lymph fluid contains a high concentration of lipids and fat 
deposition often occurs in the lymphatic structures. Also, the leakage of lymphatic 
fluid from its vessels appears to promote the accumulation of fat.232 High 
concentrations of adipocytes surrounding lymph nodes has been found to be 
related to chronic lymphadenopathy, inflammation, of peripheral lymph nodes.233 
A high fat content was observed in the oesophageal lymph nodes and all were 
typically surrounded by adipose tissue, shown through its spectrum in Figure 
3.27. As well as the lymph nodes possessing a naturally higher lipid cell content 
than other tissue, some sections exhibited pools of fat. Suggesting that in some 
sections, surrounding adipose might have been dragged across the tissue during 
the sectioning process. This creates a challenge in obtaining biochemical signal 
from the lymph node tissue that is not overwhelmed by intense lipid peaks. This 
especially causes problems when mapping areas of the tissue sample.   
 
The carbon particles that pigment the lymph node sections produce 
challenges for spectral acquisition. Anthracosis of lymph nodes is caused as a 
result of the inhalation of carbon particles into the lungs followed by their removal 
via macrophages in the lymphatic system and transportation to the lymph 
nodes.234 Anthracosis is a form of pneumoconiosis, a benign disease with 
unknown clinical implications, associated with tuberculosis, infection, smoking, 
air pollution and biomass.235 The histiocytes that engulf the carbon pigments 
situate in the medulla of the lymph node. Metastatic cancers also infiltrate into 
the lymph node via the afferent lymphatics. The tumour cells then spread 
throughout the subcapsular and medullary sinuses and eventually to the whole 
node. Thus, tumour cells are initially seen in the subcapsular and medulla 
regions. However, these carbon particles cause difficulty when measuring the 
medulla of the nodes, where the metastatic cancer often presents, far more 
difficult and limits the number of areas where viable spectra can be measured. 
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Severe anthracosis has been reported to reduce the lymph nodes ability to 
efficiently trap antigens which can eventually pass straight through the node and 
can also cause false positive diagnosis using PET scans during the staging of 
lung cancer.236 Lymph nodes from below the diaphragm have lower carbon 
particle content than nodes above due to reduced drainage from the lungs, hence 
spectral measurements are more representative of biochemical information of the 
lymph nodes and do not result in intense spectral backgrounds as a result of 
carbon particles. Therefore the lymph nodes from these locations were acquired 
when possible for spectroscopic analysis of oesophageal nodes in this study, to 
enable better measurements of nodal tissue.  
 
The challenges of fat deposits, carbon pigmentation and tissue scoring of 
the oesophageal tissue led to the need for the primary acquisition of point spectra 
in this part of the study as opposed to tissue mapping. This method of spectral 
acquisition resulted in lower spectral acquisitions but ensured spectra weren’t 
affected by fat or carbon contributions as the quality of each were visually 
checked. Point collection also more closely resembles how measurements would 
be taken in vivo. Only a few sections from the sample set produced sufficient 
Raman maps to permit evaluation of digital staining shown in Figure 3.32.  
 
Primary cancers of the lymph node are diagnosed based on the 
lymphocyte they originate from, either B-cell or T-cell, and the location in the 
lymph node. Therefore the ability to distinguish between these two cell types is 
important for diagnosis of the pathology of a tissue sample. The diagnosis may 
also influence the treatment and thus an accurate diagnosis is vital for the 
understanding of the treatment available for a patient and their prognosis. The 
Raman map, Figure 3.32, shows that the T-cells and B-cells in one sample can 
be identified and distinguished from one another using K-means clustering, 
demonstrating that the two cells must be spectrally different from one another 
based on the biochemicals detected. Romeo and Diem237 were able to 
discriminate the regions within the lymph node based on clustering of the infrared 
spectral map.  
 
Many studies looking at Raman spectroscopy as a diagnostic technique 
have found that the intensity of the lipid bands are lower and the protein bands 
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higher in cancerous tissue compared to non-cancerous tissue.199 This is 
attributed to the replacement of tissue lipids with rapidly dividing tumour cells, 
causing an increase in protein and a decrease in lipid concentrations. The 
measurements from this study show the opposite however, with an increase in 
lipid and a decrease in protein in metastatic AC tissue. Adipocytes are a major 
constituent in the tumour microenvironment and a positive relationship between 
obesity and cancer, especially oesophageal cancers, has been observed by 
many epidemiological studies.238 Renehan et al.239 found that oesophageal 
adenocarcinoma is the highest cancer in males and the third highest in females 
associated with obesity. This may provide an explanation for the increased lipid 
peak intensities in measurements from nodes with metastatic AC from 
oesophageal tumours compared to non-cancer lymph nodes. Furthermore, the 
adipose deposits surrounding lymph nodes respond directly to stimulation from 
the immune system to provide a store of energy when needed. The lymphatic 
fluid also has a strong pro-adipogenic effect and adipose progenitor cells can be 
reprogrammed into lymphoid organiser cell to contribute to stroma.240      
 
Lloyd et al.58 note that metastatic invasion can reduce the number of 
nucleic acids due to a higher cytoplasm to nucleus ratio in epithelial cells 
compared to lymphocyte cells and note that lymphocytes have been shown to 
display strong nucleic acid signals241 which may offer an explanation for the 
decrease in DNA peak intensity in the metastatic than the non-cancer sample 
measurements. However, this decrease in DNA content does disagree with the 
study by Isabelle et al.208 where they found lipid concentration and carbohydrate 
at lower signals in benign tissue measurements and DNA higher. 
 
During tumour progression the secretion of type VI collagen is 
upregulated.242 Amide III is a component of collagen within tissues. Higher 
collagen peak intensities in the cancerous lymph nodes may be attributed to the 
desmoplastic response which is induced by malignancy. Growth factors that are 
secreted by cancer cells activate fibroblasts to synthesise collagen.243 The 
apparent increase in collagen that was observed in the metastatic lymph node 
measurements of this study is also frequently seen in breast tissue with 
malignancy and is consistent with other Raman spectroscopy studies. This 
increase is attributed to fibrosis associated with lesion formation.244 Denser 
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breast tissue is associated with increased collagen content as a result of breast 
cancer and also aids mammography in identifying tumours. Additionally, women 
with dense breast tissue are found to have an elevated chance of developing 
breast cancer at some point during their lives.245 Therefore, whether the collagen 
increase is caused by cancer, the collagen increase aids the progression of 
cancer, or they are both positively related, would be of interest in better 
understanding the development of cancer and its diagnosis.   
 
The health benefits of carotenoids have been reported for preventing a 
variety of diseases, such as cancers and cardiovascular diseases.246 A decrease 
in carotenoid levels in the metastatic samples observed in this study was also 
reported by Bakker-Schut et al.247 They found carotenoid concentrations in 
lymphocyte tissue at decreased levels in cancer samples than compared to 
healthy. However, they also saw carotenoid levels decrease with age and found 
that while there was a significant difference between all their ‘healthy’ and ‘lung 
cancer’ samples, there was not a significant difference between the ‘healthy old’ 
and ‘lung cancer’. Therefore, it would only be reliable to take this into 
consideration and compare the carotenoid levels within age groups. When 
producing classification models for clinical diagnosis, it could be more reliable to 
have a number of different models trained based on age range that a blind sample 
could be tested against depending on the patient demographics. Hata et al.248 
also reported carotenoid signals at a decreased level in neoplastic and 
precancerous human skin when compared to healthy tissue.   
 
The glycine assigned peak seen in the metastatic spectrum may be the 
result of elevated levels of glycine when a tissue becomes necrotic. Sitter et al. 
(2007)249 also observed an increase in glycine levels in tissue samples from large 
breast tumours using MRI and attributed this increase to a connection with the 
synthesis of collagen, which is also found in higher concentrations in cancerous 
tissue.  
 
PLSDA, an unsupervised method, was used immediately without a prior 
unsupervised technique. This was done as biochemical differences between 
cancer and non-cancer samples are already known to exist and have previously 
been detected using Raman spectroscopy. 
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The PLSDA scores plot for the oesophageal lymph node tissue, Figure 
3.36, shows the grouping of the data based on the top three components and 
shows slight separation of the groups. Cross validation of the PLSDA model 
produced a sensitivity of 50% and specificity of 83% for the identification of 
oesophageal lymph node samples with adenocarcinoma metastases. The 
weights further show that there are stronger DNA and carotenoid peaks 
associated with non-cancer measurements, and stronger collagen and lipid 
peaks associated with metastatic adenocarcinoma in oesophageal nodes.  
 
A positive peak present at 1296 cm-1, attributed to CH2 vibrations, 
exhibited in the weights of PLS component 2 indicates more intense presence in 
non-cancerous tissue spectra than those from metastatic cancer. Whilst other 
lipid signal produced also from CH2 bonds as well as C=C and C=O bonds are 
as a whole more intense in metastatic tissue measurements. Malini et al.217 also 
reported the stronger presence of this peak at 1301 cm-1 when measuring the 
signal from inflamed oral tissue samples than when compared to malignant and 
premalignant tissue. The non-cancerous tissue samples used in this study were 
often diagnosed as minimally reactive where, like inflammation, they are 
responding to infection. This may provide an explanation for the peak’s stronger 
presence in non-cancerous tissue, whilst lipid molecules as a whole are still more 
abundant in metastatic tissue, and why it may aid discrimination between the 
pathological groups.  
 
A hydroxyproline peak at 865 cm-1 was identified as important by VIP for 
identifying metastatic AC in lymph node tissue. Hydroxyproline is an amino acid 
unique to collagen which was also found to be at elevated levels in met AC tissue, 
observed by an increase in the associated Raman bands. Studies have found 
that patients with bone metastases had elevated levels of excreted 
hydroxyproline.250,251 Li et al.252 observed a higher level of hydroxyproline in blood 
samples of patients with ovarian cancer than those without the disease or other 
benign conditions. They found that the level of hydroxproline was not affected by 
age, but pregnant women can have levels higher than usual. The tryptophan 
assigned peak is observed at lower levels in met AC tissue seen in the PLS 
weights in component 1 at 1551 cm-1 and component 3 at 1559 cm-1 in the 
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positive direction. Krishna et al.253 also observed a decrease in these peaks in 
FTIR spectra in malignant and benign ovarian tissue. 
 
VIP identified the pyrimidine bases of DNA, phenylalanine, carotenoid, 
lipid, collagen, nucleic acids, amino acids and amide I regions as important for 
classification. Amide I appears in both the positive and negative weights and 
therefore may suggest the presence of a peak shift between the cancer and non-
cancer group as oppose to a difference in its intensity between the two. In the 
metastatic cancer tissue it appears to be detected at a slightly higher 
wavenumber than in the non-cancer. This could be suggestive of a change in 
microenvironment, resulting from the infiltration or development of cancer, which 
may lead to slightly altered Raman scattering.   
 
Visually a notable difference between the femoral and oesophageal lymph 
node measurements is much less lipid contribution in the femoral LN samples.  
 
The PLSDA model was cross-validated resulting in a sensitivity and 
specificity of 83% and 75% for the identification of femoral lymph nodes with 
squamous cell carcinoma metastases. Like the oesophageal lymph node 
measurements, DNA and carotenoid peaks were observed to be more 
characteristic of non-cancer LN measurements than cancer. Lipid, phenylalanine 
and collagen peaks were similarly found to be more indicative of the metastatic 
LN measurements. Amide I was again observed in both the negative and positive 
weights and might further indicate a difference in Raman shift rather than 
quantities in the samples. The amide I appears to be present in the metastatic 
samples at a decreased Raman shift to the non-cancer samples, unlike the 
oesophageal metastatic samples. The assigned amide III peak appears more 
intense in the non-cancer samples, suggesting its presence at a decreased level 
in femoral LN samples that are metastatic.  
 
A hydroxyapatite/ cholesterol peak is present in the negative weights and 
more indicative of the metastatic measurements. Sathyavathi et al.254 observed 
the presence of hydroxyapatite, at 960 cm-1, and found it to be related to 
microcalcifications in both malignant and benign tissue. This suggests that both 
cancer and non-cancer tissue may exhibit a more intense hydroxyapatite peak in 
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relation to the presence of calcifications. However, a strong indication of a 
malignancy is the presence of microcalcifications and thus provides an 
explanation for why in this study stronger hydroxyapatite peaks are indicative of 
the metastatic samples.   
 
 Again, the lipid contributions appear much less in the head and neck LN 
measurements than those of the oesophageal LN. The initial visual differences 
coincide with the other two lymph node areas where DNA and nucleic acid peaks 
are less intense in the metastatic measurements and lipid is stronger.  
 
 The scores plot of PLSDA was able to visually separate the two groups of 
the dataset better than either the femoral LN or the oesophageal LN data. This 
better separation was reflected in the cross-validation of the model where a 
sensitivity of 80% and specificity of 92% was calculated for the identification of 
head and neck lymph nodes with SCC metastases.  
 
 The weights from the PLSDA, highlighting peaks in the spectra 
contributing to variation between the groups, include peaks more representative 
of non-cancer, assigned as DNA, carotenoid, nucleic and amino acids and amide 
III. Peaks more representative of metastasis primarily include those assigned as 
lipid, phenylalanine, collagen and hydroxyapatite. These results support those 
observed in the previous oesophageal and femoral LN PLSDA models.  
 
 The VIP also highlighted similar areas of the spectrum as important for 
classification as the oesophageal and femoral LN dataset. Areas of the spectrum 
that were identified that were also in the VIP of the femoral and oesophageal LN 
consisted of the areas around the following assigned peaks: the pyrimidine base 
of DNA (784 cm-1), phenylalanine (1001 cm-1), collagen (1302 cm-1), amide III 
(1338 cm-1), protein/phospholipid (1444 cm-1) and amide I (1656 cm-1). These 
areas of the spectrum could be where the general variation between metastasis 
and non-cancer lymph nodes occur, and also where the similarities between the 
three non-cancer lymph node areas exist. 
 
 The PLSDA of the mapped data resulted in a lot of similarity to the point 
measurement data, and the cross-validation carried out achieved the exact same 
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sensitivity and specificity. This result shows that a high number of measurements, 
that causes a long overall acquisition, is not necessarily needed for improved 
classification and that just a few measurements are sufficient to get an 
appropriate spectral representation of the sample. This result also gives further 
support to real time diagnosis and the feasibility of only taking point 
measurements in vivo. The main difference between the point and mapped 
datasets is the decrease in noise in the PLSDA component weights in the 
mapped dataset, although the main peaks are the same. A difference in the VIP 
is seen with the mapped data which includes the carotenoid peak (1154 cm-1) 
and lipid (1723-1801 cm-1) as important for classification, and lacks the 
wavenumber regions of the phenylalanine and amide III assigned peaks.  
 
It is clear from the k-mean cluster image, Figure 3.53, that ‘digital staining’ 
could be a possibility for samples that have metastatic cells present, to remove 
the need and expense of physically staining the samples. Diem et al.255 shows 
the ability for “molecular pathology” using vibrational micro-spectroscopy for the 
identification of metastases in lymph nodes, early morphological changes in oral 
and cervical tissue and distinguishing between SCC and AC metastases through 
the recognition of different cell types. Nallala et al.256 also report their ability to 
use FTIR for spectral histopathology to aid standard approaches through analysis 
of the same tissue section using digital dewaxing257. Although the collection of 
spectral maps is a much more lengthy process than taking point acquisitions, this 
method could increase sample throughput compared to the current methods that 
can take days to produce stained sections. Fernandez et al.258 suggest three 
aspects to be considered for the implementation of digital staining: rapid and 
reliable data acquisition, the development of robust algorithms and testing its 
validity. The clear margin between the non-cancer lymphocytes and the SCC 
cells also supports the potential for tumour margin delineation which has the 
ability to aid surgery in real-time. Diem et al.255 state that brain metastases have 
well defined tumour margins and reports the ability to use spectroscopy for aiding 
tumour removal in the brain, where only removing necessary tissue is essential 
for preserving brain function of the patient after the operation. The figure also 
shows the heterogeneity of the samples and the difficulty that can be experienced 
in measuring similar regions for each sample.  
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Keratinocytes are often present in the tissue of SCC metastases in lymph 
nodes and its presence often can confirm diagnosis. Kim et al.259 observed that 
changes to vitamin A sensitivity in malignant cells causes a decreased 
differentiation of these cells and thus keratin synthesis. They also noted that there 
was an alteration between the synthesis of type I and type II keratin between 
healthy and malignant cells. The three different clusters, seen by the three 
colours, in the k-means image could perhaps represent different keratinocyte 
types and a better understanding may be important in recognising SCC cells.  
   
FTIR was conducted to compare it to Raman spectroscopy and enable 
analysis of the two techniques using the same samples and region of interest 
(ROI). For in vivo analysis Raman spectra are not affected by water contributions 
where FTIR spectra are. However, if FTIR is a much better technique than Raman 
for classification when used ex vivo, it could be more important to focus on 
developing the appropriate pre-processing techniques that help combat the 
spectral water features, to enable in vivo use of FTIR. However, this research 
found that FTIR actually had a lower sensitivity and specificity than Raman 
spectroscopy for classifying lymph nodes with SCC metastases from non-cancer 
samples. The FTIR spectra are in agreement with the Raman, regarding less 
intense nucleic acid assigned peaks in the averaged metastatic data compared 
to the non-cancer.     
 
PCA of the combined sample set of oesophageal, femoral and head and 
neck lymph node data enabled the analysis of the unsupervised separation that 
occurs. The PCA scores plot did not give any indication of data groupings other 
than pathologically. PCA recognised many of the same peaks as the previous 
PLSDA models did, as variation between the metastatic cancer and non-cancer 
measurements. These include collagen, DNA, amide I and III and lipid assigned 
peaks.  
 
The PLSDA scores plot did not show separation of the data based on 
anatomical location or metastatic type. Cross-validation of this model produced a 
sensitivity of 71% and specificity of 89% for identifying metastatic measurements 
from non-cancer. This shows that potentially metastatic lymph node cancers can 
be differentiated from non-cancer lymph nodes when in a combined model. 
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Although, the accuracy has decreased for that of the head and neck where the 
sensitivity and specificity was much better. Therefore, for these samples it might 
be more beneficial to have a separate classification model. The VIP showed the 
majority of spectral variation was in the DNA and nucleic acid, collagen, lipid and 
carotenoid regions.  
 
 
3.3 Conclusion  
 
 Overall this study has demonstrated the use of Raman spectroscopy for 
analysing lymph node tissue from three different anatomical locations.  
 
It has been observed that lymph nodes from the oesophagus can contain 
anthracosis that cause difficulty when measuring certain areas within the tissue, 
and can even result in overwhelmed signal to the spectrum. The lymph nodes 
from this location also appear to have a larger amount of adipose tissue 
surrounding and embedding it, observed through strong lipid peaks that can also 
affect resulting Raman spectra. Therefore, these lymph nodes are difficult to 
measure however point spectra were produced with avoidance of areas affected 
by anthracosis and adipose tissue. The difficulty to measure these lymph nodes 
were perhaps reflected by poor sensitivities and specificities of just 50% and 83% 
for the identification of LN with adenocarcinoma metastases from non-cancer 
oesophageal nodes.  
 
Femoral lymph node measurements were far easier to carry out and no 
anthracosis or intense lipid peaks were observed. A sensitivity of 83% and 
specificity of 75% was calculated for identifying squamous cell carcinoma from 
non-cancer femoral nodes. 
 
Head and neck nodes were also easier to acquire spectra from and no 
anthracosis or strong lipid peaks were observed. The resulting sensitivity and 
specificity from both the point measurements and spectral maps were 80% and 
92% for the identification of LN with squamous cell carcinoma metastases from 
non-cancer head and neck nodes. The ability to classify at the same level from 
just 20 spectra per sample, supports the viability for real-time in vivo 
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measurements that rely on just a few measurements to produce representative 
data of a sample. FTIR spectroscopy did not prove to be a better technique for 
disease classification in this study and therefore a focus on Raman could be 
continued in subsequent experiments. Raman spectroscopy has also been 
shown to produce good spectral maps that can be coupled with clustering 
techniques in order to digitally differentiate different regions with the lymph nodes 
and even identify metastatic regions and their border. This result indicates the 
potential for Raman digital staining of lymph node metastases to reduce time and 
expense of diagnosis. The clear cancer borders identified through k-means 
clustering could be a promising indication of its surgical capabilities. A larger 
study based on the analysis of Raman maps would be needed to fully assess its 
clinical capabilities as a histological tool for tissue sections.  
 
The ability to combine lymph node regions for metastatic detection as a 
whole has also been demonstrated. But whilst it helps to improve oesophageal 
classification it would be less beneficial for femoral and head and neck nodes that 
had better sensitivities and specificities in their independent models. Also, the 
differences between the lymph nodes from the different anatomical regions is not 
known and how this would impact on the reliability of the data.    
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Chapter 4: Raman Analysis of Lymph Node Regions  
 
4.1 Results 
 
Initially measurements from the non-cancer lymph nodes of the head and 
neck, oesophageal and femoral regions, were analysed using PCA to assess if 
there were any biochemical differences between the anatomical regions that had 
led to a substantial difference in the Raman signal detected. If all lymph nodes 
are spectrally the same then their analysis can be combined to create a larger 
diagnostic model. If however spectral irregularities are observed between nodes 
from different areas, it may indicate that more specific diagnostic models, of not 
just the tissue type but the anatomical region also, are required for Raman 
spectroscopy to better indicate disease.    
 Figure 4.63 shows the spectra of the mean head and neck, oesophageal 
and femoral lymph node data. Differences between the spectra appear primarily 
due to variation in spectral intensity rather than the shifts in the peak positions.       
 
 
 
Figure 4.63- Spectra averaged from 260 head & neck (red), 120 oesophageal (green) and 160 
femoral (blue) lymph node measurements.  
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Figure 4.64 shows the PCA score plots from the top four components for 
variation between the groups with at least a 99% confidence calculated using 
ANOVA. The scores from the three groups show a large amount of overlap with 
each other. Clustering is present however, and the scores from the groups appear 
to congregate together at similar areas on the component axes. The green 
oesophageal cluster appears the most visibly distinct from the other groups. 
Principal component six is responsible for the most variance between the groups. 
In this component the oesophageal node scores are primarily grouped on the 
negative axis whilst the head and neck and femoral node scores are most 
frequently positive. The scores for PC3 are mainly negative for femoral node data 
and positive for oesophageal node data, whilst the head and neck node scores 
are equally distributed across the component. In PC 9, it appears to separate 
head and neck LN data, distributed more across the negative axis, from data of 
the other two LN regions, which are generally more positive. In PC8 the data from 
all three LN regions are quite dispersed across both the negative and positive 
axis and therefore it is difficult to see a separation between groups. 
 
 
Figure 4.64- PCA scores plots of lymph node measurements from the head and neck (red) 
oesophageal (green) and femoral (blue) regions.  
 
 
 The PCA loadings, displayed in Figure 4.65, show the peaks in the spectra 
that are responsible for the variation between the clusters in the PCA scores plot. 
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The loadings appear to consist of many peaks across the whole of the 600-1800 
cm-1 wavenumber region. The main peaks from the loadings are displayed in 
Table 4.25, separated by their either positive or negative direction to enable 
identification of the possible biochemicals that are more frequent in a particular 
lymph node group.       
 
 
 
Figure 4.65-PCA loadings of the top four components for discriminating head & neck, femoral and 
oesophageal LN data. 
 
 
 In PC 6, positive bands include those assigned to amide I (1631, 1641 cm-
1) and amino acids (999, 1003, 1559, 1562, 1620 cm-1) whilst the predominant 
negative band is assigned to amide III (1268 cm-1). According to the distribution 
of data in the scores plot, amide III peaks appear to be more frequent in spectra 
belonging to oesophageal LN whilst amide I and amino acids, such as 
phenylalanine and tryptophan, bands are more frequent in those from head and 
neck and femoral LN. Also, among the negative bands is a lipid/collagen (1298 
cm-1) peak, suggesting a higher level in oesophageal LN than when compared to 
the other LN locations. In PC 3 the negative bands consist of peaks assigned to 
lipids (1437, 1745 cm-1), whilst the positive bands include those assigned to 
amide III (1231, 1247 cm-1), carbohydrate (1340 cm-1) and nucleic acids (1561 
cm-1). In this component the scores plot suggests oesophageal LN data are 
primarily on the positive axis whilst femoral LN measurements are on the negative 
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axis. Therefore, amide III appears to be more indicative of oesophageal origin, 
along with carbohydrates and nucleic acids, than femoral lymph node data. 
Negative peaks, more indicative of femoral LN, constitute the main lipid peaks. 
PC9 appears to separate head and neck lymph node data, which congregate 
mainly on the negative axis, from the other two lymph node regions. Negative 
peaks from this component include amino acids (619, 640, 750, 1001, 1561 and 
1615 cm-1) and amide I (1648 cm-1) whilst the positive peaks are those of amide 
III (1282 cm-1), lipids (1308 and 1418 cm-1) and carotenoid (1517 cm-1). The 
bands in PC8 are primarily peaks assigned as amino acids and proteins, however 
it is not obvious which clusters positive and which are negative on the PCA scores 
plot. 
 
 
Table 4.25-Positive and negative bands from the PCA weights in Figure 3. 
PC6 PC3 PC9 PC8 
-ve 
Assignments 
+ve 
Assignments 
-ve 
Assignments 
+ve 
Assignments 
-ve 
Assignment
s 
+ve 
Assignments 
-ve 
Assignments 
+ve 
Assignments 
6
9
5
.7
 Cystine 
9
3
3
 
Protein 
backbone 
8
6
9
.8
 Tyrosine 
7
4
8
.5
 DNA  
6
1
9
 
Phe 
8
1
6
 
Phosphodi
ester 
7
8
1
 
Pyrimidine  
6
2
2
.2
 Phe 
1
0
6
1
 
Lipid 
9
9
9
 
Phe  
1
4
3
7
 
Proteins 
phospholipid
s 
 
1
0
0
1
 
Phe 
6
4
0
 
Tyr 
1
1
5
2
 
Proteins  
1
0
8
8
 
Protein, 
lipid 
6
4
4
.6
 
Tyr 
1
2
6
8
 Amide III 
1
0
0
3
 Phe  
1
7
4
5
 Lipid 
1
2
3
1
 Amide III 
7
1
1
.2
 DNA 
1
2
8
2
 Amide III   
6
9
7
.9
 Cystine 
1
2
9
8
 Lipid/collag
en 
1
5
4
7
 Proline    
1
2
4
7
 Amide III 
7
5
0
 
Tryp 
1
3
0
8
 Lipid/collag
en  
  
7
5
5
.1
 Tryp 
1
3
5
9
 
Protein/lipi
d 
1
5
5
9
 
Tryp    
1
3
4
0
 
Amide III/ 
Carbs/ 
Nucleic 
acid 
8
9
9
.8
 
Adenine 
1
4
1
8
 
Protein/pho
spholipid 
  
8
5
2
.7
 
Tyr 
1
4
3
1
 Lipid 
1
5
6
2
 Tryp    
1
3
6
9
 Tryp 
1
0
0
1
 Phe  
1
5
1
7
 Carotenoid   
9
3
5
.9
 Protein 
 
 
1
6
2
0
 
Amide I/ 
Amino 
acid 
  
1
5
6
1
 
Nucleic 
acid 
1
0
8
0
 
Phosphol
ipid 
    
1
0
0
3
 
Phe ring 
 
 
1
6
3
1
 Amide I   
1
5
7
7
 Nucleic 
acids  
1
1
2
3
 Protein, 
lipid 
    
1
1
5
2
 Protein 
  
1
6
4
1
 Amide I   
1
5
9
8
 Amino acid 
(phe, tryp) 
1
5
6
1
 Tryp     
1
2
7
8
 Protein 
  
1
6
6
7
 
Amide I   
1
6
1
7
 
Amino acid 
(tyr, tryp) 
1
6
1
5
 
Amide I/ 
Amino 
acid (tyr, 
tryp) 
    
1
4
4
8
 
Protein, 
phospholipid 
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1
6
4
8
 Amide I     
1
4
5
8
 Protein 
phospholipid 
        
 
     
1
4
6
4
 Lipid 
        
 
     
1
5
1
9
 Carotenoid 
              
1
6
6
7
 Amide I 
 
 
The clustering between the groups in PCA suggested that biochemical 
differences existed between the lymph nodes from different anatomical regions 
potentially allowing them to be identified from one another. Lloyd et al. found that 
PLSDA should produce either better or the same classification accuracies as 
PCA-LDA as PLSDA chooses the number of components at its optimum 
performance. Therefore, PLSDA, a supervised technique, was applied in order to 
assess if the differences were substantial enough to enable classification into 
specific groups. The PLSDA scores plot in Figure 4.66 show the data clustering 
of the three groups. A leave-one-sample-out cross-validation was carried out and 
produced sensitivities between 63-92% and specificities between 71-100% for 
classification of the measured lymph node regions, shown in Table 4.26. Model 
performance should increase with a greater number of samples. Cross validation, 
where one sample is removed from the training set and blind tested, ensures that 
the model’s performance when a sample is removed is accounted for.   
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Figure 4.66- PLSDA scores plot showing clustering of data from the different lymph node regions. 
 
 
Table 4.26- Confusion matrix for the classification of head and neck, oesophageal and femoral 
LN data. 
 True group 
Head & Neck Oesophageal Femoral 
Predicted 
group 
Head & Neck 12 1 3 
Oesophageal 0 5 0 
Femoral 1 0 5 
Total LN samples 13 6 8 
Sensitivity 0.9231     0.8333     0.6250 
Specificity 0.7143     1.0000     0.9474 
 
 
VIP was carried out to assess which bands in the spectrum are important 
for classification through quantifying the proportion of times those wavenumbers 
were selected in the cross validation of the PLSDA model. The VIP plots in Figure 
4.67 highlight the spectral regions that have been used in cross validation for 
delineating between the groups and the proportion of times they have been 
selected. Several bands across the spectrum were selected for cross validation 
therefore, Table 4.27 displays only the wavenumbers of the bands selected 100% 
of the time for classification.   
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Figure 4.67- VIP plots to show the proportion of times specific Raman shifts were selected during 
PLSDA cross validation. 
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Table 4.27- Table of bands from VIP that were selected 100% of the time for the PLSDA cross 
validation.  
Bands selected for head & 
neck classification 100% of the 
time 
Bands selected for oesophageal 
classification 100% of the time 
Bands selected for femoral 
classification 100% of the time 
779.1-787.8 Pyrimidine 779.1 Pyrimidine 779.1-790 Pyrimidine 
852.7-859.1 Tyrosine 783.4 Pyrimidine  1001-1003 Phenylalanine 
1146-1156 Protein 787.8 Pyrimidine 1020  
1260 Amide III 852.7-863.4 Tyrosine 1146 Protein 
1266 Amide III 994.8-1003 Phenylalanine 1150-1154 Lipid, collagen 
1294-1316 Lipid, collagen 1148-1154 Protein 1251 Amide III 
1322-1345 Carbohydrate 1262-1272 Amide III 1316 Collagen 
1369 Tryp 1276 Amide III 1322-1345 Collagen/carbohydrate 
1429-1460 Protein, 
phospholipid 
1282 Amide III/collagen 1365 Tryp 
1511-1527 Carotenoid 1286 Cytosine 1427-1462 Protein, phospholipid 
1538 Tryptophan 1288 Cytosine 1511-1523 Carotenoid 
1544 Tryptophan 1302 Lipid/collagen 1547 Tryptophan 
1547 Tryptophan 1326-1328 Nucleic acids 1551-1564 Tryptophan, nucleic 
acid 
1555-1564 Nucleic acid 1332-1342 Carbohydrate 1575-1579 Nucleic acid 
1659-1678 Amide I 1367-1371 Tryp 1617-1622 Amino acid (tyr, tryp) 
1747 Lipid 1433-1454 Protein, 
phospholipid 
1630 Amide I 
1761 Lipid 1517-1525 Carotenoid 1633 Amide I 
  1538 Tryptophan 1648-1676 Amide I 
  1542-1547 Tryptophan 1679 Amide I 
  1551-1579 Nucleic acid 1725-1758 Lipid 
  1602 Amino acid 1761-1767 Lipid 
  1613-1618 Amino acid 1772-1776 Lipid 
  1641 Amide I 1785 Lipid 
  1655-1668 Amide I   
  1734-1743 Lipid   
  1749 Lipid   
 
 
VIP identified a large number of peaks selected 100% of the time for 
classification from across the whole measured wavelength range. However, it 
only identifies them based on their importance for variability and cannot identify 
which peaks are characteristic of which groups. Thus, the bands selected 100% 
of the time were compared to the PCA loadings in order to assess which groups 
the peaks are more frequent in, hence leading to their importance for 
classification. In head and neck LN data the biochemical assignments of the 
peaks that are the most indicative of the group are tryptophan (1547 cm-1), nucleic 
acids (1561 cm-1) and amide I (1655 cm-1). For oesophageal LN, the biochemical 
assignments of the peaks most suggestive of the dataset are phenylalanine (1001 
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cm-1), amide III (1257 cm-1), lipid/collagen (1302 cm-1), carbohydrate (1338 cm-
1), protein/lipid (1367 cm-1), proteins/phospholipid (1446 cm-1), tryptophan (1551 
cm-1), nucleic acid (1581 cm-1) and amino acid (1617 cm-1). The most indicative 
peaks from femoral LN data are assigned as phenylalanine (1001 cm-1),  
proteins/phospholipid (1446 cm-1), tryptophan (1551 cm-1), amino acid (1617 cm-
1), amide I (1655 cm-1) and lipid (1745 cm-1). 
 
 
The ability to distinguish between the metastatic cancers that are found in 
the LN from the three anatomical regions was also of interest, to determine how 
identifiable their Raman spectra are in comparison to each other. Figure 4.68 
shows the mean spectra of the three metastatic types found in the LN of the three 
regions. The metastatic cancers in the study were mouth and throat SCC found 
in head and neck nodes, AC from oesophageal cancers and cervical SCC in 
femoral nodes. 
 
 
 
Figure 4.68- Mean spectra of SCC mets in head & neck LN (red), AC mets in oesophageal LN 
(black) and SCC mets in femoral LN (blue), averaged across 100, 120 and 120 measurements 
respectively. 
 
 
 PCA carried out shows unsupervised clustering of data from the three 
metastatic groups. The PCA scores plot in Figure 4.69 shows the results from the 
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top four components selected through ANOVA. PC4 and PC3 appear to separate 
the femoral and head and neck metastatic LN data, primarily plotted on the 
negative axis, from the oesophageal metastatic LN data, primarily plotted on the 
positive axis. Separation in PC 1 and PC5 are harder to discern, however it can 
be seen that metastatic data from the head and neck LN are more frequently 
plotted on the negative axis in PC1 and the metastatic data from the femoral LN 
are more heavily distributed on the positive axis in PC5.  
 
 
 
Figure 4.69- PCA scores plot showing the distribution of measurements from SCC in head & neck 
LN (red), AC in oesophageal LN (black) and SCC in femoral LN (blue) across the top four 
components. 
 
 
The PCA loadings for the top four components are displayed in Figure 4.70 
and the main peaks and correlating biochemical assignments are shown in Table 
4.28. Through comparison of the loadings with the scores plot, the spectral peaks 
indicative of specific groups were identified and their biochemicals tentatively 
assigned. In PC4 and PC3 peaks in the negative direction, and thus suggestive 
of SCC metastases in femoral LN and head and neck LN, were those assigned 
as protein (938 cm-1), lipids (1435, 1752 cm-1) and amide I (1641, 1670 cm-1). 
Those peaks in the positive direction, and thus more indicative of AC metastases 
in oesophageal LN, were assigned as amide III (1261, 1245 cm-1), protein and 
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lipid (1371, 1369 cm-1), carotenoid (1515, 1527, 1502 cm-1), nucleic acid (1579, 
1577 cm-1) and amino acid (1618 cm-1). The loading of PC1 seems to be affected 
largely by the spectral background, with a higher background in positive scores 
around the 600-900 cm-1 range and a higher background in negative scores in 
the 1200-1800 cm-1 range, suggestive of head and neck LN metastasis. In the 
loadings for PC5, peaks indicative of SCC metastases in femoral nodes were in 
the positive direction and consisted of those assigned as amino acid (675.1, 
1545, 1561, 1618 cm-1), DNA (750.7 cm-1), lipids (1302, 1747 cm-1), protein and 
phospholipid (1450 cm-1) and nucleic acid (904, 1576 cm-1). 
 
 
 
Figure 4.70- PCA loadings of the top four principal components for discriminating metastatic 
lymph nodes from the head and neck, oesophagus and femoral regions. 
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Table 4.28- Main peaks and their tentative assignments from the PC loadings. 
PC4 PC3 PC1 PC5 
-ve 
assignments 
+ve 
assignments 
-ve 
assignments 
+ve 
assignments 
-ve 
assignments 
+ve 
assignments 
-ve 
assignments 
+ve 
assignments 
9
3
8
 
Protein  
1
0
7
6
 
Protein, 
lipid 
1
4
3
5
 
Protein, 
phospholi
pid 7
5
0
.7
 
DNA 
 
- 
 
- 
9
9
9
 
Phe 
6
7
5
.7
 
Amino 
acid 
1
0
0
1
 
Phe 
1
2
6
1
 
Amide III 
1
7
5
2
 
Lipid 
1
0
0
1
 
Phe 
 
- 
 
- 
1
0
2
2
 
Phe 
7
5
0
.7
 
DNA 
1
3
3
6
 
Carb, 
Nucleic 
acid 
1
3
0
0
 
Lipid, 
collagen 
  
1
2
4
5
 
Amide III 
 
   
1
0
5
9
 
Lipid 
9
0
4
 
Adenine 
1
6
4
1
 
Amide I 
1
3
7
1
 
Tryp   
1
3
4
0
 
Carb, 
Nucleic 
acid 
 
   
1
0
8
8
 
Lipid, 
DNA 
9
2
9
.5
 Protein 
1
6
7
0
 
Amide I 
1
4
3
7
 
Protein, 
phospholi
pid 
  
1
3
6
9
 
Tryp     
1
1
4
2
 
Protein 
1
3
0
2
 
Lipid, 
collagen 
  
1
5
1
5
 
Carotenoi
d 
  
1
5
0
2
 
Carotenoi
d 
    
1
1
5
2
 
Protein 
1
3
1
4
 
Collagen 
  
1
5
2
7
 
Carotenoi
d 
  
1
5
7
7
 
Nucleic 
acid 
    
1
3
7
9
 
Tryp 
1
4
5
0
 
Protein, 
phosphol
ipid 
  
1
5
7
9
 
Nucleic 
acid 
  
1
6
1
8
 
Amino 
acid 
    
1
6
7
0
 
Amide I 
1
5
4
5
 
Tryp 
  
1
7
4
7
 lipid           
1
5
6
1
 Tryp 
              
1
5
7
6
 
Nucleic 
acid 
              
1
6
1
8
 
Amino 
acid 
              
1
6
4
8
 Amide I 
              
1
7
4
7
 Lipid 
 
 
 PLSDA and cross validation was carried out on the data. The PLSDA 
scores plot, Figure 4.71, shows the clustering of the groups using the first three 
PLS components. It appears that the oesophageal AC and femoral SCC data are 
more delineated from each other than the head and neck SCC data, especially in 
PLS3. The sensitivities and specificities were calculated from the cross validation 
using a majority wins approach for the data per lymph node. Sensitivities and 
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specificities were calculated between 60-67% and 73-91% for metastatic lymph 
nodes from the three anatomical regions studied (Table 4.29). 
 
 
 
Figure 4.71- PLSDA scores plot for the first three components, showing the distribution of head 
& neck SCC (red), oesophageal AC (black) and femoral SCC (blue) measurements. 
 
 
Table 4.29- Confusion matrix for the classification of head & neck SCC, oesophageal AC and 
femoral SCC LN data. 
 True group 
Head & Neck 
SCC 
Oesophageal AC Femoral SCC 
Predicted 
group 
Head & Neck SCC 3 1 1 
Oesophageal AC 0 4 1 
Femoral SCC 2 1 4 
Total LN 5 6 6 
Sensitivity 0.6000     0.6667     0.6667 
Specificity 0.8333     0.9091     0.7273 
 
 
 VIP was used to identify the important spectral bands for delineating 
between the three metastatic groups. The VIP plot, in Figure 4.72, highlights the 
bands used for cross validation and the proportion of the times those bands were 
selected. Those that were selected 100% of the time were tentatively assigned 
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biochemicals and are displayed in Table 4.30. These bands were compared to 
the PCA weights, in order to assess which peaks are primarily indicative of the 
certain groups.  
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Figure 4.72- VIP plot highlighting the spectral bands that were selected for classification of the 
head & neck SCC, oesophageal AC and femoral SCC. 
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The peaks that are mainly suggestive of head and neck SCC are those 
assigned as phenylalanine (1001 cm-1), carbohydrate and nucleic acid (1336 cm-
1) and amide I (1655 cm-1). Those that are indicative of oesophageal AC are 
assigned as amide III (1261 cm-1), collagen and lipid (1300 cm-1), protein and lipid 
(1367 cm-1), proteins and phospholipids (1445 cm-1), carotenoid (1523 cm-1) and 
nucleic acid (1581 cm-1). The spectral peaks that are most indicative of the 
femoral SCC are assigned as carbohydrate and nucleic acid (1336 cm-1), protein 
and phospholipid (1446 cm-1), tryptophan (1547 cm-1), nucleic acid (1581 cm-1), 
amino acid (1617 cm-1) and amide I (1655 cm-1). 
 
 
Table 4.30- Table of bands selected 100% of PLSDA cross validations with their tentative 
assignments. 
Bands selected 100% of times 
for head & neck SCC 
classification  
Bands selected 100% of times for 
oesophageal AC classification  
Bands selected 100% of times for 
femoral SCC classification 
626.6-633.4 Phe 657.9 Amino acid 1239 Amide III 
644.5-693.4 Tyr, amino 
acid, glycine 
1249 Amide III 1243 Amide III 
787.8 Pyrimidine 
base 
1253 Amide III 1247-1249 Amide III 
1001 Phe 1256-1262 Amide III 1260 Amide III 
1260-1264 Amide III 1298-1302 Lipid, collagen 1330-1332 Carb, nucleic acid 
1292-1316 Lipid, collagen 1365-1375 Tryp 1369-1375 Tryp 
1336 Carb, nucleic 
acid 
1431-1458 Protein, 
phospholipid 
1435-1464 Protein, phospholipid 
1429-1466 Protein, 
phospholipid 
1515-1598 Carotenoid, tryp, 
nucleic acid 
1538-1592 Tryp, nucleic acid 
1577-1579 Nucleic acid 1617 Amino acid 1596 Amino acid 
1641-1690 Amide I 1643-1661 Amide I 1615-1618 Amino acid 
  1665-1687 Amide I 1643-1679 Amide I 
  1690 Amide I 1683 Amide I 
  1696-1700 Amide I   
 
 
  
The metastatic data can be grouped into both AC, found in the 
oesophageal LN, and SCC, found in the head and neck and femoral nodes. The 
ability to differentiate between these two cancer types was of interest in assessing 
the capability to distinguish between two types of metastatic carcinomas. PLSDA 
was carried out again as a two group model, grouping the metastatic femoral and 
head and neck LN data as one group, and the metastatic oesophageal LN as 
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another. Cross validation resulted in sensitivities and specificities between 83-
91% using a majority wins approach per node for classification of the two 
metastatic carcinoma types. Table 4.31 displays the confusion matrix for the 
cross-validation of the PLSDA model.   
 
 
Table 4.31- Confusion matrix for the classification of AC and SCC data. 
 True Group 
AC SCC 
Predicted Group 
AC 5 1 
SCC 1 10 
Total LN 6 11 
Sensitivity 0.8333     0.9091 
Specificity 0.9091 0.8333     
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Discussion 
 
The initial finding of the study was that there are biochemical differences 
between benign lymph nodes from different regions that lead to spectral 
variations. The three lymph node regions included in this study were head and 
neck, oesophagus and femoral. The lymph nodes from these regions drain 
different locations of the body. The head and neck drain lymph found in the head, 
neck and upper oesophagus. The oesophageal lymph nodes primarily drain the 
mid portion of the oesophagus260 and other upper abdominal regions. The 
femoral lymph nodes drain lymph from the lower portion of the abdomen and 
upper legs. The anatomy of lymph nodes are supposedly the same throughout 
the body. Therefore, the regions they drain may be responsible for the 
biochemical differences observed in the spectral measurements and analysis of 
the non-cancer LN from the different regions. This could suggest that combined 
LN models, like that in the previous chapter, may be less accurate than 
independent models for specific regions. The peaks at 1260 cm-1 and 1336 cm-1 
assigned as amide III, appears to be more distinctive of oesophageal lymph node 
spectra, seen across the component loadings, and also highlighted as important 
by VIP for the identification of measurements belonging to this group. The peak 
at 1655 cm-1, assigned as amide I, however seems to be more characteristic of 
femoral and head and neck lymph node measurements. Amides are compounds 
derived from fatty acids where the carboxyl group (COOH) is replaced by an 
amino group (NH2). The differences between the amide groups will be as result 
of the structure of the molecule which leads to various Raman shifts and thus 
detection of varying concentrations between the three lymph node region groups.  
 
The peaks that appear to be more indicative of femoral lymph nodes are 
1745 cm-1 assigned as lipid and 1437 cm-1 assigned as protein and phospholipid. 
The majority of the lymph node samples had fat deposits seen either 
microscopically or through their Raman spectra. However, the results from the 
analysis suggest that the lipid content in the femoral lymph nodes was slightly 
higher in order to delineate them from the other lymph node regions.  Isolated fat 
cells and small areas of adipose tissue are often found in lymph nodes after 
childhood and lymph node tissue can even be replaced by adipose tissue in the 
elderly, obese or as a result of chronic infection, preserving very little of the 
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original node structure. It is common for any lymph nodes to show a degree of 
lipomatosis. However, inguinal and axillary lymph node regions have the highest 
fat abundance.261 The inguinal lymph node region include those that are femoral 
and their high fat abundance may explain the higher detected levels in their 
Raman measurements. Weiss et al.262 explain that lipid lymphadenopathy, 
caused by lipid deposition from outside the lymph node, is often associated with 
tumour tissue and commonly occur in abdominal nodes. Furthermore, Meksiarun 
et al.263 showed the difference in visceral and subcutaneous adipose tissue and 
highlight the main variation around the spectral regions 974, 1230 and 1655 cm-
1. Therefore, alterations amongst the lipid peaks may be influenced by this 
difference between fat types across different anatomical regions.      
 
As well as the amide I peak, head and neck lymph node measurements 
also appear to have higher intensities of peaks assigned as amino acids. In 
particular tryptophan, with assigned peaks at 1559 and 1562 cm-1, were found to 
be characteristic of the lymph nodes from this group. Amino acids play an 
important role in immunity aiding the activation of B cells, T cells, natural killer 
cells and macrophages, regulating redox state, lymphocyte proliferation and gene 
expression and producing antibodies and cytokines. The immune system relies 
heavily on the availability of amino acids for the production of proteins and 
polypeptides as well as individual molecules that control metabolites.264 Amino 
acids can also be used for fuelling the immune system and the production of new 
cells either directly or through conversion to other amino acids or glucose.265 
Tyrosine is directly involved in phosphorylation and the production of 
neurotransmitters, such as dopamine, and melatonin, an antioxidant, and its 
precursor phenylalanine is responsible for the activation of Tetrahydrobiopterin. 
Tryptophan, another amino acid, produces inhibitors along with serotonin, a 
neurotransmitter, and melatonin, an antioxidant.266 It is a possibility that head and 
neck nodes require higher levels of specific amino acids in their lymph nodes, 
maybe due to their location, which could explain why these peaks in the spectra 
tend to be more indicative of head and neck nodes.  
 
Good cross-validation sensitivities and specificities of the three group 
PLSDA model, further supported characteristic differences between the 
measurements of the lymph node tissue from the three regions. 
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The metastatic lymph node measurements from the three regions also 
showed clustering in their PCA and PLSDA score plots. Through analysis of both 
the scores plots and loadings, it can be seen that many peaks responsible for 
variation between the measurements of the metastatic lymph node region are the 
same as those that were most responsible for variation between the regions of 
the non-cancer samples. For example the amide I peaks (1641, 1670 cm-1) are 
apparently more indicative of metastases in head and neck and femoral nodes, 
whilst the amide III (1261, 1245 cm-1) appears to be more characteristic of the 
metastatic oesophageal LN. Lipids (1435, 1752, 1302 and 1747 cm-1) also seem 
to be present in higher concentrations in metastatic femoral nodes than the other 
regions.  
 
Peaks assigned as carotenoids (1515, 1527 and 1502 cm-1) were also 
associated more with metastatic oesophageal LN than those from the other 
regions. Carotenoids are pigmented compounds that are only synthesised by 
plants and micro-organisms and humans obtain them through diet. A higher level 
of carotenoids was also seen in the non-cancer lymph nodes where both femoral 
and oesophageal nodes were observed to have higher levels than head and neck 
lymph nodes. This implies that the differences in carotenoid content is not isolated 
to the development of carcinoma tissue in the nodes. An explanation for this 
higher carotenoid level in oesophageal lymph nodes could be as a result of a 
positive relationship with the lipid content. Carotenoids are known to be fat 
soluble and rely on dietary fat for absorption.267 Therefore, as the oesophageal 
lymph node samples comprise a larger amount of adipose tissue, the number of 
carotenoids may also be higher as a result. Another reason for the observed 
regional differences may be the proximity of femoral and oesophageal lymph 
nodes to the intestines, when compared to the head and neck nodes, where 
carotenoids are absorbed from food sources and initially enter the bloodstream.  
 
A peak assigned as amino acid at 1618 cm-1 was identified as being 
indicative of head and neck nodes in non-cancer samples study, yet indicative of 
oesophageal samples in the metastatic LN study. This shows that not all 
differences between the metastatic samples must be similar to those between the 
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non-cancer samples and suggests that variations may be altered in metastatic 
tissue as a result of tumour tissue and not just lymphoid tissue.    
 
Cross validation shows that the metastatic node measurements are 
analytically more similar to each other than those from non-cancer nodes seen 
through their cross-validation results. This may suggest that metastasis in lymph 
nodes, regardless of location, has dominant and related biochemicals that cause 
their Raman signature to resemble each other. As the biochemicals that lead to 
the differences between the LN regions are very similar in both the non-cancer 
and cancer samples, yet with a drop in sensitivity to predict, there is an implication 
that metastasis leads to a reduction in variation between LN from different 
regions. However, all the metastases in this study were carcinomas, originating 
from epithelial tissue. Therefore, there may be a higher level of homogeneity 
between epithelial tissues than lymphoid. As a result, the reduction in variation 
would probably arise due to the introduction of new biochemicals from the 
epithelial cells, masking the important identifying features between lymph node 
regions. It would be of interest to measure a variety of healthy epithelial tissue in 
order to spectrally assess any similarity to each other and whether this could be 
responsible for lack of region identification, or whether metastatic tissue as a 
whole is more similar to each other and causing this reduction in variation of 
lymph node regions.    
 
Both the femoral and head and neck lymph node metastases were 
squamous cell carcinomas. Similarities between these groups may have resulted 
in decreased sensitivities for the identification of the different lymph node regions 
when invaded with metastasis. When grouping the squamous cell carcinoma 
data, from both the head and neck and femoral node measurements, together as 
one pathology and leaving the adenocarcinoma as another, the classification 
sensitivities and specificities greatly improve. It is understood that the reduction 
of the model to just two groups will contribute to this improvement as a result of 
the 50% baseline classification of 2-group models. However, the greater 
sensitivities may also be due to similar biochemicals being present between the 
two SCC groups that allow its better identification from AC measurements when 
grouped together. Such as, the SCC groups both have a more intense 1336 cm-
1 peaks assigned as a combination of nucleic acid and carbohydrate. It may also 
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be possible though, that non-cancer femoral and head and neck lymph nodes 
already share more similarities, such as a stronger amide I peak, than with 
oesophageal lymph nodes and that is what is leading to the better classification. 
A further investigation using samples with both AC and SCC metastases from the 
three lymph node regions would be a more accurate way to determine whether 
SCC and AC metastases can truly be identified from one another. It is especially 
of interest in determining the ability to clinically diagnose a patient more 
accurately, or even potentially primary site identification, rather than grouping 
metastasis or cancer as a whole.    
 
   
Conclusion 
 
 It has been determined that spectral changes exist between the regions of 
head and neck, oesophageal and femoral lymph nodes in both non-cancer and 
metastatic samples. The classification ability for the various lymph node regions 
is higher in the non-cancer sample measurements than those of the metastatic. 
However, the biochemicals that appear to cause the differences between the 
three lymph node regions, regardless of pathology, remain similar. These 
variations between the regions appear to be primarily because of amide I and III, 
lipids, amino acids and carotenoids peak intensities. The ability to potentially 
identify SCC from AC metastasis was also observed and would be extremely 
useful for clinical diagnosis. Further studies with larger sample sizes and a larger 
range of pathologies would be required in order to assess the source of variability 
between the metastatic groups however. 
 
 These findings suggest that lymph nodes from different locations within 
the body may contain too many varying biochemical features to allow them to be 
treated as one single tissue group. When analysing lymph nodes it might be more 
appropriate to consider individual regions, comparing like samples, for 
discrimination and identification of pathological groups.    
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Chapter 5: Raman Analysis of Primary and Secondary 
Cancers in Head and Neck Lymph Node Tissue 
 
5.1 Results 
 
 Inflammation of head and neck lymph nodes are more noticeable due to 
their superficial anatomy in many cases. Whilst inflammation is often the result of 
benign conditions, it can also be caused by primary and secondary malignancy, 
and in such cases the node may also feel harder than usual. Lymphomas and 
metastases are amongst the many diseases frequently diagnosed in the head 
and neck. From the samples collected for this study, the head and neck lymph 
nodes contained the widest array of pathologies. This part of the research 
spectrally examined 15 µm sections of head and neck lymph nodes to assess 
detectable biochemical differences between diseased lymph nodes and those 
without any diagnosed pathological abnormalities. An area of the section was 
mapped after reviewing the adjacent H&E with the pathologist to identify key 
areas, the Raman images were then examined and the spectra from a region of 
interest (ROI) was used for analysis. 
 
 
 
Figure 5.73- Mean spectra of lymphoma, metastatic, other and non-cancer maps, averaged 
across 33201, 12120, 5151 and 53879 acquisitions respectively. 
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The average spectra of the four histological groups, lymphoma, 
metastatic, other and non-cancer, are displayed in Figure 5.73. The most visually 
evident difference between the spectra appears to be in the 1515 cm-1 region 
assigned as carotenoid, where the peak is much less intense in the averaged 
metastatic and lymphoma samples’ measurements than in the non-cancer and 
other spectra.  
 
The intensity of these spectral peaks seem to contribute the most to 
differences seen visually, rather than spectral shift which may be subtly present 
and require further multivariate analysis to detect. As expected, the two benign 
groups, non-cancer and other, are apparently more spectrally similar to one 
another. The metastatic mean spectrum looks the most dissimilar to the other 
groups, whilst the averaged lymphoma spectrum shares similarities with and 
exhibits differences between all the groups over the measured wavenumbers. 
Multivariate analysis was then employed to mathematically analyse further 
variations between the dataset.    
 
To provisionally assess if cancer could be distinguished from non-cancer 
in this investigation, the metastatic and lymphoma data were classed as one 
group, cancer. The non-cancer and other data was classed as another group, 
non-cancer. A two group model is faster to initially identify differences between 
the groups and assess classification capability.  
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Figure 5.74- PLSDA scores plot for cancer (45321 acquisitions) and non-cancer (59030 
acquisitions) measurements  
 
 
 The PLDA scores plot, Figure 5.74, shows the clustering of the data 
according to the top three components, of the malignant groups and benign 
groups combined. The cancer group consists of lymphoma and metastatic, and 
the non-cancer is both the other and non-cancer groups. Whilst there is no distinct 
separation between the data, the groups cluster with their own more readily. In 
the first two components the cancer scores are more negative whilst the non-
cancer scores more positive. The third component also clusters the data the 
same with a slight few outliers in the non-cancer group. The lack of distinction 
between the groups could be due to the combination of a wide variety of 
pathologies within both the groups. This can cause difficulty for differences 
between the groups to be identifiable and representative of the whole group. A 
leave-one-sample-out cross-validation was carried out on the PLSDA model and 
a sensitivity of 81% and a specificity of 90% was calculated for identifying cancer 
tissue from non-cancer tissue in the lymph nodes using a majority wins approach 
(Table 5.32). 
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Table 5.32- Confusion matrix from the cross-validation of the PLSDA model for cancer and non-
cancer LN measurements using a leave-one-sample out majority wins approach. 
  True group 
  Cancer Other & Non-
Cancer 
Predicted group 
Cancer 18 4 
Non-Cancer 4 36 
 Total Samples 22 40 
 Sensitivity 0.8182     0.9000 
 Specificity 0.9000 0.8182     
 
 
The group labelled other, which are samples that were found to be reactive 
as a result of a disease other than cancer were then removed from the dataset 
and the PLSDA model was run again. Cross validating this model produced a 
sensitivity and specificity of 77% and 89% respectively (Table 5.33). Surprisingly, 
one more cancer lymph node was incorrectly identified as non-cancer in this 
PLSDA model than in the previous. Also, in the previous model none of the three 
other lymph nodes were identified as cancer but it was instead four of the 
diagnosed non-cancer lymph nodes.     
 
 
Table 5.33- Confusion matrix from the cross-validation of the PLSDA model for cancer and non-
cancer LN measurements using a leave-one-sample out majority wins approach excluding the 
‘other’ group. 
  True group 
  Cancer Non-Cancer 
Predicted group 
Cancer 17 4 
Non-Cancer 5 33 
 Total Samples 22 37 
 Sensitivity 0.7727 0.8919 
 Specificity 0.8919 0.7727 
  
 
Though the model without the other group did not have quite as high 
sensitivities and specificities than the one that included it, the non-cancer group 
should theoretically provide a more representative sample set of non-diseased 
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tissue as no abnormal pathology was identified, and therefore this model was 
further analysed.  
 
 
Figure 5.75- ROC curve for the PLSDA model delineating cancer from non-cancer. 
  
 
 The ROC curve in Figure 5.75 shows the relationship between the 
sensitivity and specificity of the PLSDA model for identifying cancer tissue from 
non-cancer tissue by sample. It shows how the specificity or sensitivity can be 
compromised in order to improve the other. For example, it may be more 
important to have a higher sensitivity at the expense of a lower specificity when 
identifying cancer tissue, so not to incorrectly diagnose a patient as healthy. In 
this model, to achieve a sensitivity of 90%, 95% and 98% a specificity of 58%, 
48% and 38% respectively would follow. In order to get a 100% sensitivity where 
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you would expect no false negatives, a specificity of just 28% would occur with 
this model.  
 
The PLSDA weights spectra are displayed in Figure 5.76 for the first three 
PLS components. The weight from the first component is clearly affected by 
background and therefore negative and positive peaks were categorised based 
on their direction as oppose to their peak weight.   
 
 
Figure 5.76- PLSDA component 1, 2 and 3 weight spectra. 
 
 
 Across the three components, peaks in the negative direction, and thus 
more indicative of the cancer lymph node measurements, include: peaks 
assigned to DNA and nucleic acid (1498 cm-1 and 1594 cm-1) amino acids (620, 
640, 695, 704, 848, 999, 1030, 1545, 1553, 1609 cm-1) lipids and phospholipids 
(1061, 1076, 1121, 1437 cm-1, amide I, 1652 cm-1) and proteins including collagen 
(1076, 1121, 1298, 1412, 1437 cm-1). Peaks in the positive direction, and thus 
more indicative of the non-cancer lymph node measurements, include: those 
assigned to DNA and nucleic acids (727, 746, 781, 811, 1094, 1487, 1574 cm-1) 
amino acids (669, 682, 1188, 1206 1214, 1373, 1562, 1622 cm-1) amide III (1253, 
1338 cm-1) glycogen (1047 cm-1) and carotenoid (1521 cm-1). A full list of the main 
peaks and their tentative biochemical assignments are displayed in Table 5.34. 
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Table 5.34- List of positive and negative peaks from the PLSDA component weights. 
PLS component 1 PLS component 2 PLS component 3 
-ve  +ve  -ve  +ve  -ve  +ve  
6
9
3
.5
 
Cystine 
7
2
6
.6
 
DNA 
6
2
0
 
Phe 
6
2
4
.4
 
Phe 
6
9
5
.7
 
Cystine 
6
2
2
.2
 
Phe 
8
2
4
.7
 
Nucleic acid 
7
4
6
.3
 
DNA 
6
4
0
.1
 
Tyr 
6
8
0
.2
 
Aino acid 
7
0
4
.5
 
Cystine 
6
4
4
.6
 
Tyr 
8
4
8
.4
 
Tyr 
7
8
1
.3
 
Pyrimidine 
base 
9
9
9
 
Phe 
7
2
6
.6
 
DNA 
1
2
9
4
 
Collagen 
6
6
9
.1
 
Amino acid 
9
9
9
 
Phe 
8
1
1
.7
 
Phosphodie
ster 
1
0
6
1
 
Lipid 
7
4
6
.3
 
DNA 
1
4
1
0
 
Protein 
6
8
2
.4
 
Amino acid 
1
0
3
0
 Phe 
8
3
3
.3
 Protein 
1
0
7
6
 Lipid, 
protein 
7
8
1
.3
 Pyrimidine 
base 
1
4
3
1
 Phospholipi
d, protein 
7
2
6
.6
 DNA 
1
0
6
1
 
Lipid 
1
0
9
4
 
DNA 
1
1
2
1
 
Lipid, 
protein 
8
3
3
.3
 
Protein 
1
4
9
8
 
DNA 
7
4
6
.3
 
DNA 
1
0
7
6
 
Protein, lipid 
1
1
5
6
 
Lipid 
1
2
9
8
 
Collagen  
1
0
4
7
 
Glycogen 
1
5
4
4
 
Tryp 
7
8
1
.3
 
Pyrimidine 
base 
1
1
2
1
 
Lipid, protein 
1
1
8
8
 
Protein, 
amino acid 
1
4
1
2
 
Protein 
1
0
9
4
 
DNA 
1
5
5
7
 
Tryp 
8
5
2
.7
 
Tryp 
1
2
9
8
 Collagen 
1
2
1
4
 Protein, 
amino acid 1
4
3
7
 Phospholipi
d, protein 1
1
5
6
 Lipid 
1
5
9
4
 Nucleic acid 
9
3
8
 
Protein 
1
4
3
7
 
Protein, 
phospholipid 
1
2
5
3
 
Amide III 
1
4
9
8
 
DNA 
1
1
8
8
 
Protein, 
amino acid 
1
6
0
9
 
Amino acid 
1
0
0
3
 
Phe 
1
4
9
6
 
DNA 
1
3
7
1
 
Tryp 
1
5
4
4
 
Tryp 
1
2
1
4
 
Protein, 
amino acid 
  
1
0
4
7
 
Glycogen 
1
5
4
7
 
Tryp 
1
5
2
1
 
Carotenoid 
1
5
5
3
 
Tryp 
1
2
5
3
 
Amide III   
1
0
9
4
 
DNA 
1
6
0
9
 
Amino acid 
1
5
6
2
 
Amino acid 
1
6
0
2
 
Amino acid 
1
3
7
3
 
Tryp   
1
1
2
7
 
Lipid, 
protein 
1
6
5
2
 
Amide I 
1
5
7
4
 
Nucleic acid 
1
6
5
2
 
Amide I 
1
4
8
7
 
DNA   
1
1
5
6
 
Lipid 
 
 
 
   
1
5
2
1
 
Carotenoid   
1
2
0
6
 
Protein, 
amino acid 
      
1
5
7
4
 
Nucleic acid   
1
2
5
3
 
Amide III 
      
1
6
2
2
 
Amino acid   
1
3
3
8
 
Amide III 
      
 
   
1
3
7
3
 Tryp 
          
1
4
4
8
 Phospholipi
d, protein 
          
1
4
6
0
 Phospholipi
d, protein 
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1
4
8
1
 
DNA 
          
1
5
2
1
 Carotenoid 
          
1
5
7
4
 Nucleic 
acid 
          
1
6
6
1
 Amide I 
 
 
 VIP was carried out to identify the wavenumber regions in the spectrum 
that contribute to the most variation between the groups. The VIP plot, Figure 
5.77, shows the proportion of times certain wavenumbers were chosen based on 
their ability to aid classification of the two groups. Important peaks which are 
apparently more indicative of the cancer group measurements include: those 
assigned to cystine, phenylalanine, collagen, other proteins, phospholipid, lipid 
and amide I. Important peaks which are apparently more indicative of the non-
cancer group measurements include: DNA, amide III, nucleic acid and 
carotenoid.   
 
 
Figure 5.77 Cancer v non-cancer VIP plot with mean spectrum 
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Table 5.35- Table of bands selected 100% of the time for classification with their tentative 
biochemical assignment. 
Bands selected 100% of times Tentative biochemical assignment  
693.5-695.7 Cystine  
704.5 Cystine 
774.8-796.5 Pyrimidine base 
938 Protein backbone  
1001-1003 Phenylalanine  
1090-1099 DNA 
1152-1160 Proteins 
1322-1346 Collagen, amide III 
1367-1375 Tryptophan, protein  
1398-1418 Protein 
1425-1439 Protein, phospholipid 
1445-1450 Protein, phospholipid 
1479-1485 DNA 
1508-1528 Carotenoid 
1570-1577 Nucleic acid 
1618-1674 Amino acid, amide I 
1707-1799 Lipid  
 
 
Combining metastatic with lymphoma and non-cancer with the other 
measurements and classifying them as one pathology is flawed however. The 
other samples were still diagnosed as diseased and therefore still classified as 
pathological where the non-cancer group samples were not. Also the metastatic 
samples contained malignant cells from different organs whereas the lymphoma 
samples only contain malignant lymphocytes. Therefore it was essential to further 
analyse the lymphoma and metastatic measurements as individual classifications 
to ensure the differences between the two are identified and assessed. When 
included, the other group was also considered a separate group, however there 
are only three samples within the group and the pathologies are different from 
one another. Therefore, the results from such analyses were for interest and 
treated more cautiously.    
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Figure 5.78- PLSDA scores plot showing the clustering of lymphoma (33201 acquisitions), 
metastatic (12120 acquisitions) other (5151 acquisitions) and non-cancer (53879 acquisitions) 
lymph nodes. 
 
 
The PLSDA scores plot, Figure 5.78, shows the distribution of the 
lymphoma, metastatic, other and non-cancer measurements. As this is a four 
group model and there are also a large number of measurements involved it is 
difficult to discern whether certain group scores are more positive or negative. 
Visually it would appear that PLS component 1 separates lymphoma 
measurements, which look to be more negative, from the rest of the groups, whilst 
PLS component 2 separates metastatic and other measurements, which look to 
be more negative, from the rest of the groups. PLS component 3 looks more 
difficult to deduce, which is expected as the variation between groups decrease 
with ascending component. The weights will not be analysed in this four group 
model, but will be in subsequent two group models as they provide more clarity. 
Cross validation of the model resulted in sensitivities of 50%, 25%, 33% and 92% 
and specificities of 90%, 94%, 94% and 68%, for classification of lymphoma, 
metastatic, other and non-cancer lymph nodes from their spectra using a majority 
wins approach. Through analysis of the confusion matrix, Table 5.36, lymphoma 
samples are most frequently misclassified as non-cancer, metastatic data are 
more often misclassified as lymphoma, the samples in the other group are 
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identified as everything but lymphoma and the non-cancer group are more likely 
to be falsely identified as lymphoma or other.  
 
 
Table 5.36- Confusion matrix from cross validation of the PLSDA model showing classification of 
lymphoma, metastatic, other and non-cancer data. 
  True group 
  Lymphoma Metastatic Other Non-
cancer 
Predicted 
group 
Lymphoma 7 3 0 2 
Metastatic 1 2 1 0 
Other 1 1 1 1 
Non-cancer 5 2 1 34 
 Total Samples 14 8 3 37 
 Sensitivity 0.5000  0.2500 0.3333 0.9189 
 Specificity 0.8958 0.9444 0.9492 0.6800 
 
 
When the other group was combined with the rest of the non-cancer group, 
cross-validation produced slightly better sensitivities for lymphoma and 
metastatic lymph node classification of 57% and 38%. Sensitivities should 
already start higher in a three group model than a four-group model, and looking 
at the confusion matrix, Table 5.37, one more lymph node in both the lymphoma 
and metastatic group were identified correctly. The misclassifications have 
remained fairly similar to the four-group model.     
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Table 5.37- Confusion matrix from the cross-validation of the PLSDA model or classifying 
lymphoma, metastatic and other combined with non-cancer data. 
  Actual group 
  Lymphoma Metastatic Other & Non-
cancer 
Predicted 
group 
Lymphoma 8 3 3 
Metastatic 1 3 1 
Other & Non-
cancer 
5 2 36 
 Total LN Samples 14 8 40 
 Sensitivity 0.5714     0.3750     0.9000 
 Specificity 0.8750     0.9630     0.6818 
 
 
When removing the other group entirely from the analysis, the results of 
the cross-validation are similar to the previous model. It can be assumed from 
this confusion matrix, Table 5.38, that the three samples from the other group 
were classified correctly as non-cancer in the previous model as the only 
difference in this model is three less true positive identifications. This may imply 
that the lymph nodes classified as other are more similar to the lymph nodes 
grouped as non-cancer.     
 
Table 5.38- Confusion matrix from the cross-validation of the PLSDA model for the classification 
of lymphoma, metastatic and non-cancer data.  
  Actual group 
  Lymphoma Metastatic Non-cancer 
Predicted 
group 
Lymphoma 8 3 3 
Metastatic 1 3 1 
Non-cancer 5 2 33 
 Total LN Samples 14 8 37 
 Sensitivity 0.5714     0.3750     0.8919 
 Specificity 0.8666   0.9607  0.6818 
 
 
To better evaluate the differences between the specific pathology groups 
a two-group model was produced including just the lymphoma and metastatic 
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measurements. The PLSDA scores plot, Figure 5.79, shows the clustering of the 
data of the two groups. The two groups however do not show any distinct 
separation. The lymphoma scores appear slightly more negative in all the PLS 
components and the metastatic scores are more often positive for the 
components, apart from PLS component 2 where it appears fairly distributed 
across the axis and a more neutral scores on average.   
 
 
 
Figure 5.79- PLSDA scores plot of the lymphoma (33201 acquisitions) and metastatic (12120 
acquisitions) lymph node Raman map data. 
 
 
 Cross-validation was performed on the PLSDA model and a sensitivity and 
specificity of 86% and 63% respectively for the identification of lymphoma 
measurements and 63% and 85% for metastatic measurements was calculated. 
Using these measurements and this model there is a higher ability of recognising 
a lymphoma lymph node than a metastatic one, the confusion matrix is displayed 
in Table 5.39. A slight unbalance of sample and spectrum numbers may 
contribute to this shift towards better lymphoma classification. It also supports the 
findings of the three and four group model where lymphomas were more 
accurately classified than metastatic based on their measurements.  
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Table 5.39- Confusion matrix for the cross-validation of lymphoma and metastatic measurements. 
  Actual group  
  Lymphoma Metastatic 
Predicted group Lymphoma 12 3 
 Metastatic 2 5 
 Total Samples 14 8 
 Sensitivity 0.8571     0.6250 
 Specificity 0.6250 0.8571     
 
 
 Although there is no definite separation between the two groups, the 
weights of the components were analysed (Figure 5.80) to evaluate if certain 
biochemical contributions were more indicative of specific groups. A list of the 
main peaks and their tentative biochemical assignments are displayed in Table 
5.40. Peaks assigned as DNA and nucleic acids are overall more prevalent in the 
negative direction, and thus appear to be more indicative of lymphoma 
measurements, include 727, 749, 786, 833, 1092, 1487 and 1574 cm-1. Also, a 
peak at 1257 cm-1 assigned as amide III and peaks at 1150, 1160 and 1513 cm-
1 assigned as carotenoid also is apparently more indicative of lymphoma 
measurements. Peaks in the positive direction, and thus more characteristic of 
metastatic measurements, include amino acid assigned peaks at 620, 642, 696, 
755, 851, 1001, 1026, 1551, 1602 and 1613 cm-1  and also peaks assigned as 
lipid and proteins at 936, 1061, 1076, 1123, 1394 and 1445 cm-1.  
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Figure 5.80- Weight spectra for the first three PLS components.  
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Table 5.40- List of the main negative and positive peaks for the weights of the three components 
with their tentative biochemical assignment. 
PLS component 1 PLS component 2 PLS component 3 
-ve  +ve  -ve  +ve  -ve  +ve  
7
2
7
 DNA 
6
2
0
 Phe 
6
4
5
 Tyr 
6
2
0
 Phe 
6
4
5
 Tyr 
6
9
6
 Cystine 
7
4
9
 
DNA 
6
4
2
 
Tyr 
7
2
7
 
DNA 
6
4
2
 
Tyr 
7
2
7
 
DNA 
8
4
8
 
Tyr 
7
8
6
 
Pyrimidine  
7
5
5
 
Tryp 
7
8
4
 
Pyrimidine 
6
9
6
 
Cystine  
7
8
6
 
Pyrimidine  
9
3
8
 
Protein 
8
3
3
 
Nucleic acid 
8
5
1
 
Tyr 
8
2
9
 
Tyr 
8
5
1
 
Collagen 
8
2
9
 
Nucleic acid 
1
0
0
1
 Phe 
1
0
9
2
 DNA 
9
3
6
 
Protein 
1
0
9
2
 DNA 
9
3
6
 
Protein 
1
0
0
5
 Phe 
1
0
2
6
 Phe 
1
1
5
0
 
Protein, 
carotenoid  
9
5
7
 
HA, 
cholesterol 
1
1
5
0
 
Protein, 
carotenoid 
1
0
0
1
 
Phe 
1
0
9
2
 
DNA 
1
1
2
1
 
Lipid, 
protein 
1
4
8
7
 
DNA 
1
0
0
1
 
Phe 
1
2
5
7
 
Amide III 
1
0
2
6
 
Phe 
1
1
5
2
 
Protein, 
carotenoid  
1
3
9
4
 
Protein  
1
5
1
3
 Carotenoid 
1
0
2
6
 Phe 
1
3
7
1
 Tryp 
1
1
2
3
 Lipid, 
protein 1
2
5
7
 Amide III 
1
5
5
1
 Tryp 
 
 
1
0
6
1
 Lipid 
1
4
8
7
 DNA 
1
1
6
0
 Protein, 
carotenoid  
1
3
0
2
 Lipid, 
collagen 
 
 
 
 
1
0
7
6
 Protein, lipid 
1
5
1
3
 Carotenoid  
1
2
0
2
 Protein 
1
4
8
1
 DNA 
 
 
 
 
1
1
2
3
 Lipid, 
protein 
1
5
7
4
 Nucleic acid 
1
3
9
4
 Protein 
1
5
1
3
 Carotenoid  
 
 
 
 
1
1
6
0
 Protein, 
carotenoid  
 
 
1
4
4
6
 Phospholipi
d, protein  
1
5
7
4
 Nucleic acid 
 
 
 
 
1
2
0
4
 Protein 
 
 
1
5
5
1
 Tryp 
1
6
5
9
 Amide I 
 
 
 
 
1
2
6
8
 Amide III 
 
 
1
6
0
2
 Amino acid 
 
 
 
 
 
 
1
3
1
2
 Collagen   
1
6
4
8
 Amide I   
 
 
  
1
3
3
4
 Amide III   
 
   
 
 
  
1
3
9
4
 Protein   
 
   
 
 
  
1
4
4
5
 Phospholipi
d, protein 
  
 
   
 
 
  
1
5
5
3
 Tryp       
 
 
  
1
5
8
1
 Nucleic acid       
 
 
  
1
6
0
2
 Amino acid       
 
 
  
1
6
1
3
 Amino acid       
 
 
  
1
6
4
8
 Amide I       
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 VIP was carried out to ascertain the peaks of most importance for 
delineating between the two groups during cross-validation (Figure 5.81). Peaks 
selected 100% of the times for cross-validation are listed in Table 5.41 and 
include regions of DNA, amides, proteins, lipids and amino acids. Through 
comparison to the weights it can be deduced that DNA (724-729 cm-1, 1086-1101 
cm-1, 1487 cm-1), pyrimidine (773-801 cm-1) and amide III (1257 cm-1) are most 
important for being characteristic of the lymphoma measurements. Whilst those 
most important for being indicative of the metastatic measurements include: 
protein backbone (934-940 cm-1), lipid and collagen (1296-1347 cm-1 and 1729-
1799 cm-1), protein and phospholipid (1435-1473) except in component 3, 
tryptophan (1538-1542 cm-1 and 1549-1555 cm-1) and amide I (1655-1659 cm-1).
  
 
 
Figure 5.81- VIP plot identifying the regions of the spectrum and proportion of times selected for 
classification, overlaid on the dataset mean spectrum. 
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Table 5.41- Wavenumbers selected 100% of the time for classification and their tentative 
assignments for the peaks within those regions. 
Bands selected 100% of times Tentative biochemical assignment  
724-729 DNA 
773-801 Pyrimidine 
934-940 Protein backbone 
999-1001 Phenylalanine 
1086-1101 DNA 
1257 Amide III 
1296-1347 Lipid, collagen, Amide III 
1435-1491 Protein, phospholipid, DNA 
1538-1542 Tryptophan  
1549-1555 Tryptophan 
1620-1648 Amino acid 
1655-1659 Amide I 
1729-1799 Lipid 
 
 
 PLSDA was carried out on just the lymphoma and non-cancer data and 
the scores plot is displayed in Figure 5.82. The clustering shows that the 
measurements group together with their own, with the exception of a few outliers. 
The outliers appear more frequent within non-cancer and may be so, due to more 
measurements representing this group. Overall the lymphoma scores are 
generally more negative and the non-cancer scores more positive across the 
three components. In component three the non-cancer scores are distributed 
across the axis more than in the first two components, however the majority are 
still positive.    
 
 
193 
 
 
Figure 5.82- PLSDA scores plot of lymphoma (332013) and non-cancer (53879) measurements.  
 
 
Cross validation was carried out to assess the classification capability of 
the model, the confusion matrix is presented in Table 5.42. A sensitivity and 
specificity of 64% and 86% for the identification of lymphoma samples from non-
cancer lymph nodes was calculated. There appears to be a better ability of 
classifying the non-cancer samples correctly than the lymphoma, and again the 
unbalance between the group sizes may contribute to this.   
 
 
Table 5.42- Confusion matrix for the cross-validation of the PLSDA model for classification of 
lymphoma and non-cancer measurements using a majority wins approach. 
  Actual group  
  Lymphoma Non-cancer 
Predicted group Lymphoma 9 5 
 Non-cancer 5 32 
 Total Samples 14 37 
 Sensitivity 0.6429     0.8649 
 Specificity 0.8649 0.6429    
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The spectra of the first three components are displayed in Figure 5.83. The 
first component is obviously influenced by the difference in spectral background 
between the groups and do not have as many spectral peaks as the other two 
components. Table 5.43 lists the main peaks from the PLS weights with their 
tentative assignments. Peaks in the negative direction, and thus more frequently 
observed in lymphoma measurements are those assigned as amino acids (656, 
694, 705, 1594 and 1605 cm-1), lipids and protein (1061, 1129, 1298, 1437, 1455 
cm-1), collagen (872 and 1298 cm-1), protein (1410, 1429 and 1437 cm-1) and 
amide I (1655 and 1659 cm-1). Peaks in the positive direction, and thus more 
associated with non-cancer measurements are those assigned as DNA and 
nucleic acids (727, 746, 781, 1489 and 1624 cm-1), carotenoid (1158 and 1521 
cm-1), phenylalanine (623 and 1001 cm-1), tryptophan (1371, 1551, 1562 cm-1), 
tyrosine (642 and 853 cm-1), amide III (1253 and 1338). In component 3 
phospholipid and protein peaks are seen in the positive direction at 1448 and 
1460 cm-1. There is also a putative glycogen peak at 1047 cm-1, and a possible 
1084 cm-1 peak further supports the assumed assignment. A hydroxyapatite and 
cholesterol peak is also present in the positive direction in component 3 at 953 
cm-1.  
 
 
Figure 5.83-Spectra of the PLS weights of the first three components. 
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Table 5.43- Main peaks and their tentative assignments from the PLS weights. 
PLS component 1 PLS component 2 PLS component 3 
-ve  +ve  -ve  +ve  -ve  +ve  
6
5
6
 
Amino acid 
1
0
0
1
 
Phe 
8
7
2
 
Collagen 
6
8
0
 
Amino acid 
6
9
4
 
Cystine 
6
2
3
 
Phe 
8
0
7
 
Phosphodiest
er 
1
1
1
7
 Lipid, 
protein 
1
0
6
1
 Lipid 
7
2
7
 
DNA 
7
0
5
 
Cystine 
6
4
2
 
Tyr 
1
1
2
9
 Lipid, protein 
1
1
5
8
 Protein, 
carotenoid 
1
2
6
1
 Amide III 
7
4
6
 
DNA 
8
7
2
 
Collagen 
6
8
0
 
Amino acid 
1
2
9
8
 Lipid, collagen 
1
2
5
3
 Amide III 
1
2
9
8
 Lipid, 
collagen 
7
8
1
 
Pyrimidine 
base 
1
0
6
1
 Lipid 
7
2
7
 
DNA 
1
4
1
0
 Protein 
1
3
3
8
 Amide III 
1
4
0
8
 Protein 
9
3
8
 
Protein 
backbone 
1
2
9
8
 Lipid, 
collagen 
7
4
6
 
DNA 
1
4
3
7
 Phospholipid, 
protein 1
3
7
1
 Tryp 
1
4
5
5
 Phospholipi
d, protein 1
0
0
1
 Phe 
1
4
0
8
 Protein 
7
8
1
 
Pyrimidine 
base 
1
5
4
7
 Tryp 
1
3
8
7
 Protein 
1
6
5
5
 Amide I 
1
0
4
7
 Glycogen 
1
4
2
9
 Protein 
8
5
3
 
Tyr 
1
5
9
4
 Amino acid 
1
4
8
3
 DNA 
 
 
1
1
5
6
 Protein, 
carotenoid 1
5
4
4
 Tryp 
9
3
8
 
Protein 
backbone 
1
6
0
5
 Amino acid 
1
5
2
1
 Carotenoid 
 
 
1
2
5
1
 Amide III 
1
5
4
9
 Tryp 
9
5
3
 
HA 
cholesterol 
1
6
5
9
 Amide I 
1
5
6
2
 Tryp 
 
 
1
3
3
8
 Amide III 
1
5
9
0
 Amino acid 
1
0
0
1
 Phe 
 
 
1
6
1
7
 Amino acid  
 
 
1
3
7
1
 Tryp 
 
 
1
0
4
7
 Glycogen 
 
 
 
 
 
 
1
4
8
9
 DNA 
 
 
1
0
9
4
 DNA 
 
 
 
 
 
 
1
5
2
1
 Carotenoid  
 
 
1
1
2
7
 Lipid, 
protein 
 
 
 
 
 
 
1
5
5
1
 Tryp 
 
 
1
1
5
6
 Protein, 
carotenoid 
 
 
 
   
1
5
7
4
 Nucleic acid   
1
2
0
6
 Protein 
  
 
   
1
6
2
4
 Amino acid   
1
2
5
1
 Amide III 
  
 
   
 
   
1
3
3
8
 Amide III 
  
 
   
 
   
1
3
7
1
 Tryp 
  
 
       
1
4
4
8
 Phospholipi
d, protein 
  
 
       
1
4
6
0
 Phospholipi
d, protein 
  
 
       
1
4
8
3
 DNA 
  
 
       
1
5
2
1
 Carotenoid 
  
 
       
1
5
5
1
 Tryp 
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1
5
7
4
 Nucleic 
acid 
  
 
       
1
6
6
1
 Amide I 
 
 
 VIP carried out on the cross validation of the PLSDA model suggests that 
the areas of most importance within the spectrum for classification are amino 
acids, DNA, proteins, carotenoid, amides and lipids. The plot in Figure 5.84 
visualises the areas of the spectrum that contribute the most to variability and 
Table 5.43 lists the wavenumbers selected 100% of times along with their 
tentative assignments. A comparison with the weights shows that the peaks 
assigned as DNA (702-713 and 779-787 cm-1), carotenoid (1152-1158, 1510-
1528 cm-1), amide III (1324-1342 cm-1) and phenylalanine (629-638, 999-1003 
cm-1) are more representative of the non-cancer lymph node measurements. 
Whilst the peaks assigned as tyrosine (647-658 cm-1), tryptophan (1552 and 
1557-1564 cm-1), amino acids (1587-1596 and 1617 cm-1), protein (1402-1418) 
and amide I (1617-1678 cm-1) more frequently represent lymphoma based on the 
scores plot.   
 
   
 
Figure 5.84- VIP bar graph showing the proportion of spectral regions selected for cross-
validation, plotted over mean spectrum. 
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Table 5.44- Wavenumbers selected 100% of times for cross-validation with tentative 
assignments. 
Bands selected 100% of times (cm-
1) 
Tentative biochemical assignment  
629-638 Phenylalanine 
647-658 Tyrosine, amino acid 
694-697 Cystine 
702-713 DNA 
779-787 Pyrimidine base 
999-1003 Phenylalanine  
1152-1158 Protein, carotenoid 
1324-1342 Amide III 
1402-1418 Protein 
1429-1460 Protein, Phospholipid 
1510-1528 Carotenoid  
1542 Tryptophan 
1557-1564 Tryptophan 
1587-1596 Amino acid 
1617-1678 Amino acid, Amide I 
1701-1799 Lipid 
 
 
  
The PLSDA scores plot, Figure 5.85, shows the clustering of metastatic 
measurements and non-cancer measurements. The separation between the two 
groups is more distinct than in the lymphoma and non-cancer model, though not 
entirely delineated. Once more, outliers are present in both groups but with a 
higher frequency and at a greater degree in the non-cancer data than the 
metastatic. The non-cancer data is more typically positive across the components 
whilst the metastatic is more often negative across the components.      
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Figure 5.85- PLSDA scores plot for the Raman mapped metastatic (12,120 spectra) and non-
cancer (53,879 spectra) lymph node data. 
 
 
Cross-validating the model produced a sensitivity of 75% and specificity of 
97% for the identification of metastatic lesions in lymph nodes from non-cancer 
lymph nodes, with only one non-cancer lymph node being mistaken for metastatic 
(Table 5.45). From these results it is apparent that the metastatic node 
measurements and those of the non-cancer lymph nodes are expectedly more 
different to one another than the lymphoma and non-cancer measurements, most 
probably as a result of the difference in cell types.  
 
 
Table 5.45- Confusion matrix for the cross-validation of the PLSDA model using a majority wins 
approach. 
  Actual group  
  Metastatic Non-cancer 
Predicted group Metastatic 6 1 
 Non-cancer 2 36 
 Total Samples 8 37 
 Sensitivity 0.7500     0.9730 
 Specificity 0.9730 0.7500     
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Figure 5.86- Spectra of PLS weights from the first three components. 
 
 
The weight spectra in Figure 5.86 were evaluated to gain a better 
understanding of the spectral changes and hence biochemical contributions that 
lead to differences between the two groups. Table 5.46 lists the main peaks from 
the weights along with the tentative biochemical assignments to see what 
molecules are contributing to the variation across the pathological groups.  Those 
consistently observed in the positive direction across all the components, thus 
more indicative of the measurements from the non-cancer lymph node tissue 
include peaks assigned as DNA and nucleic acid (729, 749, 781, 833, 1092, 1487 
and 1574 cm-1), carotenoid (1152 and 1517 cm-1), amide III (1253 and 1338 cm-
1), glycogen (1045 cm-1), tyrosine (1180 cm-1) and tryptophan (1373 cm-1). 
Collagen assigned peaks at 883 and 1278 cm-1 were observed in the positive 
direction although also present in the negative weights, which is more suggestive 
of metastatic measurements, at 872 and 1270 cm-1.   
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Table 5.46- Main peaks from the weights with their tentative biochemical assignments. 
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 VIP on the PLSDA model (Figure 5.87) shows that the bands selected 
100% of times for cross-validation include those assigned to DNA and nucleic 
acids, amino acids, proteins, carotenoids, collagen, amides and lipids. A list of 
these bands is displayed in Table 5.47. Through comparison to the weights, 
important peaks that are characteristic of non-cancer LN measurements 
constitute those assigned as DNA and nucleic acid (784, 1092, 1485 and 1574 
cm-1), protein and carotenoid (1152 and 1517 cm-1), amide III (1346 cm-1). Peaks 
characteristic of metastatic measurements and used 100% of times for cross-
validation include tyrosine (851 cm-1), phenylalanine (1001 cm-1), collagen (1310 
cm-1), protein and phospholipid (1445 cm-1), tryptophan (1551 cm-1) and amide I 
(1650 cm-1).     
 
 
 
Figure 5.87- VIP bar graph plotted over mean spectrum. 
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Table 5.47- VIP regions selected 100% of times for cross-validation with their tentative 
assignments. 
Bands selected 100% of times Tentative biochemical assignment  
774-797 Pyrimidine 
846-853 Tyrosine 
999-1005 Phenylalanine 
1088-1099 DNA 
1150-1156 Protein/carotenoid 
1304-1349 Collagen, amide III 
1367-1375 Tryptophan 
1431-1466 Protein, phospholipid 
1473-1491 DNA 
1506-1530 Carotenoid 
1542-1545 Tryptophan 
1553-1555 Tryptophan 
1570-1579 Nucleic acid 
1652-1670 Amide I 
1712-1799 Lipid 
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  The mean spectra of the metastatic head and neck lymph nodes, SCC, 
AC and PC, are displayed in Figure 5.88. There are no obvious visual differences 
between the three averaged spectra of the metastatic tissue measurements 
although they originate from different cell types.  
 
 
 
Figure 5.88- Mean spectra of measurements from AC (1076 spectra), PC (714 spectra) and SCC 
(10330 spectra) metastases in head and neck lymph nodes. 
 
 
Only one AC and PC sample were collected for this study, as they are not 
as common in head and neck lymph nodes as SCC, and therefore leave-one-
sample-out cross-validation could not be conducted. However, PLSDA was 
carried out and its scores plot is displayed in Figure 5.89 and shows the 
distribution of the data across the components. AC and SCC appear to be the 
most clearly different groups, whilst the PC data appears to be more similar to 
the SCC group as oppose to the AC. As the AC and PC measurements are taken 
from only one node each, separation between the groups may be as a result from 
biochemical differences between the lymph nodes as oppose to biochemical 
alterations between pathologies. However, the data within the AC and PC groups 
do not cluster as tightly as expected, considering they are from single samples.  
Typically the AC scores are more negative across the three components whilst 
the SCC are generally positive and the PC scores more positive in component 
one and negative in components two and three.      
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Figure 5.89- PLS scores plots of AC, PC and SCC met data from the first three components 
 
 
 The weights for the components, displayed in Figure 5.90, show the main 
peaks contributing to the variation between the groups. Their tentative 
biochemical assignments are listed in Table 5.48. The main spectral differences 
lies in the DNA and nucleic acid region of 600-900 cm-1 where there are many 
peak variations. There is also a split peak at 999/1003 cm-1 suggesting a shift in 
the phenylalanine peak between the groups. Amide I (1648 cm-1) and III (1260 
cm-1) also appear to contribute to variation between groups along with proteins in 
general (1074, 1121, 1158, 1200, 1218 and 1433 cm-1).      
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Figure 5.90- Spectra of the PLS weights of the first three components. 
 
 
Table 5.48- The main peaks from the component weights and their tentative biochemical 
assignments. 
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The average spectra of the HL and NHL acquisitions are plotted in Figure 
5.91. The main visual difference between the HL and NHL spectra appear to be 
within in the 770-890 cm-1 wavenumber region. However, the background may 
play a part in this and disguise the peaks that are clearly present in the NHL 
spectrum. The 1152 cm-1 peak assigned as protein and carotenoid also appears 
to be more intense in the HL spectrum than the NHL. 
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Figure 5.91- Mean spectra of HL (2690 spectra) and NHL (30511 spectra) measurements. 
 
  
 The PLSDA scores plot, displayed in Figure 5.92, shows the HL 
measurements to be very negative in the three components. The NHL 
measurements are much more dispersed in the three components although in 
general more positive.  
 
 
 
Figure 5.92- PLSDA scored plot of the HL and NHL data from the first three components. 
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 The weights from the components, Figure 5.93, show the background as 
a heavy influence in the first component. Table 5.49 lists the main peaks from the 
weights and their tentative biochemical assignments. Peaks within the DNA 
region around 600-900 cm-1 do not appear to be contributing to variation, except 
in component 1, but the peaks in this region could be affected by the background 
issue. The phenylalanine assigned peak at 1003 is seen to be contributing to the 
variation between the groups, along with amide III (1261, 1340 cm-1) and I (1655 
cm-1). Peaks assigned as amino acid (1367, 1545, 1602 and 1615 cm-1) are also 
present in the component weights and also lipids and protein (1125, 1204, 1308, 
1414 and 1441 cm-1). The majority of the peaks contributing to the variation 
appear to be present in component 1 however, as component 2 and 3 do not 
seem to have as many spectral peaks present.    
209 
 
 
 
Figure 5.93-Spectra of the PLS weights of the first three components. 
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Table 5.49- The main peaks from the component weights and their tentative biochemical 
assignments. 
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Discussion  
 
Along with metastatic tumours, lymphomas are also frequently diagnosed 
in the lymph nodes of the head and neck. Often discovered due to their visual 
enlargement and hardening, prior to any other symptoms. However, lymph nodes 
are also known to become inflamed after infection as part of the immune 
response. Therefore it is vital that inflammation as a result of a benign condition 
is not mistaken for cancer, and more importantly that a malignancy is not 
incorrectly classified as a reactive node. It is also essential for treatment to 
correctly classify the type of cancer (the treatment for NHL is different to HL), and 
whether it is secondary or primary to further search for the cancer origin and 
subsequent removal if required. Furthermore, lymph nodes are essential organs 
for aiding immunity and tissue drainage and removal of them can cause a host of 
problems for a patient. Therefore in vivo diagnosis of lymph nodes would be 
highly beneficial for both patients and clinical practices, reducing the need for 
surgery and time for diagnosis. 
 
A decreased peak intensity at 1515 cm-1, assigned as carotenoid in the 
measurements of the metastases and lymphoma samples when compared with 
the benign groups aligns with the findings from the LN studies from other 
locations. A decrease of this peak in the lymphoma measurements as well as the 
metastatic, indicates that the decrease in carotenoid is due to the tissue 
becoming cancerous as opposed to a difference in cell type between the groups.  
 
The visual similarity between the two benign groups, labelled non-cancer 
and other, suggest that spectral differences are more prominent between 
malignant and benign measurements than just reactive diseases measured in the 
lymph nodes. Only three samples were in the other group, however and a larger 
investigation into diseased nodes would be beneficial to learn the differences 
between cancer tissues from other diseased tissues.  
 
Surprisingly, a better sensitivity and specificity of 82% and 90% were 
calculated when including the other group in the PLSDA and classifying it 
together with non-cancer as three other nodes were classified correctly as non-
cancer. Also, one more cancer sample was classified correctly in this model than 
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when the other group were excluded, suggesting the presence of this group may 
have helped the classification of cancer samples.   
 
Using an ROC curve would be helpful for clinical settings, especially when 
implementing new technologies, where 100% sensitivity would be desired even 
at the expense of specificity. If this technique was used in vivo, a 100% sensitivity 
could be implemented to initially assess the lymph nodes in situ and still prevent 
a number of biopsies and hence save money and time for both surgeons and 
pathologists. Those that were biopsied could then be assessed by pathologists 
in the usual manner and the reduced number of biopsies could enable more time 
being spent on and more pathologists examining difficult sections. The PLSDA 
model of cancer and non-cancer could achieve a classification with 100% 
sensitivity but with a specificity of just 28%. Even still, this would have clinical 
benefit by reducing unnecessary surgery for many patients whilst still ensuring 
cancer lesions are not missed.    
 
The main differences between the cancer and non-cancer samples appear 
to be as a result of spectral peaks assigned as Lipids, DNA, amino acids and 
proteins. Analysis of the PLS scores plot and weights suggest that the cancer 
samples appear to have more intense lipid, protein (especially collagen) and 
amide I assigned peaks, and a decrease in DNA, amide III, glycogen and 
carotenoid assigned peaks.  
 
Although DNA content is supposed to be consistent across diploid cell 
types at around 7 billion base pairs stored in the nucleus, Gillooly et al.268 
observed a difference in DNA concentration between different cell types related 
to their cell size. They observed a positive correlation between cell volume and 
DNA content. Megakaryocytes were observed to contain both the highest level of 
DNA and have the highest cell volume. Whilst the cell volume of lymphocytes is 
slightly higher than many cells types, its DNA concentration is standard and 
therefore DNA quantity of individual cells does not seem to be contributing to a 
higher DNA quantity measured in the non-cancer samples. As mentioned, Lloyd 
et al.58 explained that lymph nodes contain densely packed lymphocytes that 
have been shown to exhibit much stronger DNA signal than epithelial cells. 
Therefore, it is more likely as a result of a higher quantity of cells and thus overall 
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DNA quantity in the tissue and its stronger signals that are solely contributing to 
this higher detected level in the non-cancer lymphocyte cells. As the metastatic 
and lymphoma samples are classed as one group, lower DNA signals in the 
epithelial cells may affect this difference in the DNA peaks between the non-
cancer and the cancer measurements. Additionally, as Lloyd et al.58 also 
mentioned, metastatic invasion can also reduce the nucleic acid density. 
Although most of the measured DNA peaks are more characteristic of the positive 
scores, and thus primarily non-cancer data, a peak at ~1490 cm-1 was observed 
to be more indicative of the negative scores and thus more often the cancer data.  
 
The tumour microenvironment has a major influence in tumour 
development. The extracellular matrix (ECM) is a vital component of this and not 
only provides the binding scaffold but also influences biochemical and physical 
signalling. Collagen is the most abundant molecule in the ECM and its role in 
tumour development has been well documented.269 Accounting for approximately 
one third of proteins, collagen is the most common, existing in many different 
forms. A higher presence of collagen is usually expected in tumour tissue than 
normal. Sok et al.270 found collagen type XI at elevated levels in patients with 
head and neck SCC and were able to demonstrate that it contributes to 
proliferation, migration and invasion through real-time polymerase-chain-reaction 
(RT-PCR). Type XI collagen is reported to help stabilise collagen II but its exact 
role remains unclear.  
 
A peak at 1045 cm-1 was assigned as glycogen. A peak at 1082 cm-1, 
although not obvious in the weights is seen in the spectrum. This peak further 
indicates this is indicative of glycogen. The Raman spectrum of glycogen also 
have peaks at 854, 939, 1131, 1257, 1336, 1381 and a strong peak at 459 cm-1. 
However, this area of the spectrum was not measured and therefore could not be 
used to help confirm or reject a glycogen assignment. This glycogen peak was 
found to be more indicative of non-cancer measurements than cancer in this 
study. Kamemento et al.216 also observed a reduction of glycogen peaks in 
cancer tissue and noted that Lyng et al.137 reported that glycogen is acquired 
during cell maturation and may disappear when there is a loss of differentiation 
such as in neoplasia.   
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Lipids in adipose tissue are primarily in the form of triacylglycerol (TAG) 
and their main role is to accumulate energy and aid metabolism. Czamara et al.271 
stated that Raman spectroscopy is a useful technique for lipid analysis, especially 
as the spectral profile is significantly different depending on saturation, state, 
isomerism and form. They explain that the most characteristic features are due 
to hydrocarbon chains, and observed in the regions of 1050-1200, 1250-1300 cm-
1 and 1400-1500 due to C-C, CH3 and CH2 bonds respectively. The most 
important marker for TAGs was the C=O vibration between 1720-1750 cm-1. This 
may explain why there are visible shifts between the lipid peaks measured from 
cancer and non-cancer LN tissue and why they are always present in the weights 
and the VIP plots, contributing to the variation. Manabe et al.272 stated that tumour 
mass is controlled by the balance of tumour cell growth and apoptosis of tumour 
cells. They reported that mature adipocytes did not influence apoptosis however 
accelerate growth of tumour cells. Also that a large concentration of adipose 
tissue is associated with high cellular proliferation and poor prognosis in breast 
cancer patients. They suggested that the reason for this could be as a result of 
increased oestrogen produced by the adipose tissue or as a result of a higher 
supply of energy stored in and sourced from the adipose tissue.      
  
Gniadecka et al.187 observed a major decrease in the amide I band in 
malignant melanoma when compared with normal skin tissue. They also reported 
shifts in the amide bands between normal and melanoma. In their study, the 
amide I band appeared at a decreased wavenumber shift whilst amide III is 
observed at a higher shift in the melanoma samples than when compared to 
normal tissue. Whilst the amide I peak is recognised in the weights as more 
indicative of cancer, the mean spectra show that in the individual lymphoma 
spectrum there appears to be a decrease in amide I. Lo et al.273 observed the 
decrease in both amide I and III bands as the keratinocytes measured matured 
whilst the phenylalanine peak remained constant. This could affect the amide 
content in lymph nodes where the infiltration of SCC metastases have resulted in 
keratinocytes. The presence of the amide I peak in the weights could therefore 
be a result of a higher concentration of immature keratinocytes in the metastatic 
samples or perhaps a result of a peak shift to 1652 cm-1 from 1656 cm-1. 
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 The negative correlation between the consumption of foods high in 
carotene and cancer diagnosis has long been reported and the anti-carcinogenic 
effects of carotenoids have been researched.274 Carotenoids’ ability to inhibit 
cancer have been attributed to its pro-vitamin A activity, the anti-oxidant 
properties of the molecules or a combination of both.275 Huang et al.199 also 
observed the decrease of carotenoid attributed peaks in tumour tissue of 
bronchial tissue.  
 
The VIP carried out on the data showed the areas of the spectrum that 
most contributed to variation through the proportion of times it was selected for 
classification. DNA, amino acids, lipids and proteins were the main biochemicals 
assigned to the spectral areas, selected 100% of times for classification and thus 
are important for identifying cancer from non-cancer measurements.  
 
When the cancer and non-cancer groups were separated further into 
pathologies the classification accuracies were worse. In the four group model the 
sensitivities calculated from cross-validation were 50%, 25%, 33% and 92% for 
lymphoma, metastases, other and non-cancer and the specificities calculated 
were 90%, 94%, 95% and 68%. The groups with the worse sensitivities were also 
the two with the least samples. Low sample numbers will likely contribute to a 
poorer sensitivity, especially as the other groups had much larger sample-sets 
leading to an imbalance across the groups. Whilst the non-cancer classification 
had a high sensitivity, its specificity was the worse of the four groups. Evaluation 
of the confusion matrix shows that when misclassification occurs, lymphoma are 
more likely incorrectly identified as non-cancer. Incorrect metastatic and other 
classifications are distributed fairly evenly throughout the various groups and 
non-cancer, although only three nodes misclassified, are only incorrectly 
identified as lymphoma or other. The misclassifications suggest that the 
lymphoma and non-cancer groups are more similar to each other than to the 
metastatic. Although the lymphoma samples contain malignant lymphocytes, 
they may be more similar to the benign lymphocytes than they are to the 
malignant epithelial cells in the metastatic samples.  The non-cancer samples 
also seem to be more similar to the other and lymphocyte group than to the 
metastatic which is also likely as a result of the presence of primarily lymphocyte 
cells as oppose to metastatic from other tissue types. Although the misclassified 
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metastatic samples are more evenly distributed they are more likely classed as 
lymphoma than either other or non-cancer, possibly due to the groups shared 
malignancy. As the other was a small group, of only three samples, it is likely this 
lead to the inability to classify any subsequent samples correctly, as only two 
samples were used for training the model before it was tested for validation. 
Another contributing factor could be as a result of the samples containing different 
benign diseases, and therefore they did not share generic similarities that 
distinguished them from the other groups in the model.   
 
The combination of the other and non-cancer groups led to slightly better 
classification but still poorer for metastatic, maybe again as a result of a small 
sample set. Sensitivities of 57%, 38% and 90% were calculated for classification 
of lymphoma, metastatic and other combined with non-cancer and specificities of 
88%, 96% and 68%, respectively. When misclassified, lymphoma was more likely 
to be identified as non-cancer than the metastatic, and metastatic was more likely 
to be identified as lymphoma.  
When the other group was removed from analysis, PLSDA and cross-
validation led to sensitivities of 57%, 38% and 89% and specificities of 87%, 96% 
and 68% for lymphoma, metastatic and non-cancer classification, respectively. 
The only difference in the confusion matrix is three less correctly identified non-
cancer samples. Thus, suggesting that the three other samples that were 
diseased yet benign were more similar to the non-cancer samples when grouped 
with them than some of the completely non-diseased samples.  
 
A two group model was then carried out with the lymphoma and metastatic 
data to identify if spectral differences could be identified. Sensitivities of 86% and 
63% were calculated for classifying lymphoma and metastatic tissue respectively. 
More metastatic samples were incorrectly identified as lymphoma than lymphoma 
as metastatic. Again, the lack of metastatic samples compared to lymphoma may 
contribute to this. It may also be a result of three different metastatic groups 
where the tumour tissues are all from different primary sites, resulting in more 
difficulty in identifying a relationship between the samples and thus classification. 
Areas of the spectrum identified as important for classification included DNA 
regions, protein, amino acids, lipids and amide III and I. The PLSDA weights 
suggest that DNA peaks and amide III at 1257 cm-1 are more indicative of 
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lymphoma. The 934 cm-1 protein peak, phenylalanine, collagen (1312 cm-1), 
amide III (1334 cm-1), protein and phospholipid (1445 cm-1), amino acids (1553, 
1602 and 1613 cm-1) and amide I (1648 cm-1) are more indicative of metastatic 
measurements. The higher frequency of DNA peaks in the lymphoma 
measurements further indicate the presence of densely packed lymphocytes with 
stronger DNA signals. It would be of great interest to measure and analyse 
normal samples of both lymph nodes and the epithelial tissue from the organs 
where metastases often originate from, to gain a better understanding of whether 
the differences seen between the lymphoma and metastatic samples are as a 
result of different cancers or as a result of different tissue types. The peaks 
related to the biochemical differences between the cancers could then be 
identified more accurately.  
 
When lymphoma samples were identified from only non-cancer samples, 
a sensitivity and specificity of 64% and 86% was calculated. Interestingly, the 
model that included all the data was slightly better at delineating lymphoma from 
non-cancer when grouped as cancer with the metastatic measurements. Peaks 
in the spectra that showed the most variation and were identified by VIP for 
delineating between the groups consisted of those recognised as more indicative 
of lymphoma, amino acid (656 cm-1), cystine, protein (1408 cm-1), protein and 
phospholipid peak around 1450 cm-1, tryptophan (~1542 cm-1), amino acid (1590 
cm-1) and amide I (1655 cm-1). Important peaks more characteristic of non-cancer 
include, phenylalanine (623 and 1001 cm-1), DNA (727, 746 and 781 cm-1), 
carotenoid (1158 and 1521 cm-1), tryptophan (1652 cm-1) and amide I (1661 cm-
1). A higher level of DNA signal in the non-cancer spectra was not expected and 
should be more likely in the cancer samples as a result of increased cell 
production according to most studies. However, the mean spectra shows an 
elevated background in the averaged lymphoma spectrum when compared to 
non-cancer which might mask the DNA peaks also. A better understanding of the 
presence of the background would be needed to ascertain whether it is a useful 
feature for delineation or whether it would need further removal to reliably analyse 
pathological differences, but at the expense of less reproducible data and spectral 
integrity. Protein is recognised at stronger signals in the lymphoma data, 
indicating that perhaps there is a change in the nucleus to cytoplasm ratio. Also, 
there is a peaks in the PLSDA component weights that are both present in the 
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negative and positive direction. Another observation in the PLSDA weights was 
a higher signal of hydroxyapatite and cholesterol associated with calcifications. 
Calcifications are often found in malignant tissue but not as often in benign. 
Although it is reported that calcifications can also occur in the lymph nodes as a 
result of infection and may cause enlargement, leading to their removal. Higher 
carotenoid concentrations are in agreement with other studies and the findings in 
this research also. 
 
Metastatic and non-cancer data were then analysed to assess the spectral 
differences between the two. A sensitivity and specificity were calculated as 75% 
and 97% for the identification of metastatic samples from non-cancer. The ability 
to distinguish metastatic from non-cancer was much better than for either 
metastatic and lymphoma or lymphoma and non-cancer. It is assumed that the 
higher level of variability between these two tissue types, is because of both 
different pathological classification as well as a difference in tissue type. 
Lymphoma and metastatic samples share the pathology of malignancy, though 
broad in its definition, and lymphoma and non-cancer share the same cell type. 
Important peaks for variation between the pathologies are those more attributed 
to metastatic measurements: tyrosine (851 cm-1), phenylalanine (1001 and 1028 
cm-1), collagen (1310 cm-1), the phospholipid and protein peak (~ 1445 cm-1) and 
tryptophan (1551 cm-1). Peaks in the spectrum more indicative of non-cancer 
measurements include: DNA (781, 1092, 1485 and 1574 cm-1), carotenoid (1152 
and 1517 cm-1), tryptophan (1371 cm-1) and amide I (1661 cm-1).  These results 
support the previous metastatic lymph node analysis where metastatic samples 
have less DNA and carotenoid signal and more protein and lipid than non-cancer 
samples.  The weights in this part of the study showed collagen peaks to be 
indicative of both non-cancer and metastatic tissue measurements however. 
Such as at 883 and 1280 cm-1 in non-cancer LN tissue and 1270, 1294 and 1310 
cm-1 in metastatic LN tissue. Nguyen et al.276 show the difference between the 
Raman signals measured from type I and type IV collagen. There is a high degree 
of variability between the collagen types based on their structure. Different 
collagen types between the non-cancer and metastatic samples may lead to a 
variance in the signals measured and hence explain why collagen peaks are 
identified as being indicative of both non-cancer and metastasis.  Alternatively, 
there could be shifts of the collagen peaks between the non-cancer and 
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metastatic measurements that contribute to variation, and thus lead to its 
presence in both the non-cancer and metastatic weights. In addition, Hilska et 
al.277 observed a difference in the distribution of collagen types I, III, and IV, 
especially around glandular structures, between normal and cancerous tissue. 
Another explanation for the collagen presence in both non-cancer and metastatic 
tissue could be because of this change in distribution. This change may lead to a 
difference between the collagen types being detected based on where in the 
lymph node the measurement is taken from. However, only the collagen peak at 
1310 cm-1 was included 100% of the time for classification.   
 
Differences between classification sensitivities and specificities may result 
from a data imbalance between the two groups. A large difference between the 
sizes of datasets can lead to a preference of the model to classify a specific group 
as it is more represented. Thus, this may provide an explanation for the difference 
of 22% between the sensitivity and specificity of this cross-validation as there are 
more than four times the number of non-cancer samples as there are metastatic.    
 
Analysis of the metastatic cancers showed no obvious spectral differences 
between the pathologies. PLSDA indicates there are more spectral differences 
between the AC and the SCC measurements than the PC. However, only one 
sample was measured from both AC and PC and that clearly limits the 
interpretation of this analysis. Whilst measuring the samples a shift in the 
phenylalanine peak was often observed at different pixels in the same map, which 
showed up in the weights. This could be as a result of the silicon offset used, 
where the phenylalanine band is detected between wavenumbers due to the limit 
of spectral resolution. Therefore, it may not be caused by an alteration in 
biochemical contributions although identified in the weights, as there is a limited 
number of samples in the group.  
 
It would be of interest to spectrally compare the metastatic samples to their 
primary cancer sites to see if there are any similarities between them that could 
aid the diagnosis of unknown primary cancers (UPC). Gao and Li278 found that 
the majority of research observed that morphological, cytological and molecular 
features of metastases with their matched primary site usually exhibit little 
differences. They noted that the theories behind the mechanism of metastasis 
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are often contradictory and much is still unknown. They also stated that research 
also found that metastases were more similar to the normal tissue of the organ 
they came from than the one they had settled in. They concluded that the inherent 
characteristics of malignancies are conservative, and whilst some differences 
occur between metastasis and site of origin these are minor and the majority of 
features remain similar. Therefore, their similarities might allow for primary site 
identification if more samples and a larger model could be produced. Knösel et 
al.279 observed differences between lymph node and liver metastases, the former 
more likely to exhibit predominant tubular differentiation and a strong 
desmoplastic stroma reaction. These morphological changes they attribute to the 
biological behaviour and as a result of a higher presence of normal cells in the 
lymphatic system than the haematic.    
 
 
There is a dramatic difference between the backgrounds of the HL and 
NHL spectra. Although the backgrounds of acquisitions alter slightly for every 
measurement they are normally not too different and vector normalisation tends 
to be able to reduce the difference even further. This change in background is 
most likely due to a difference in auto-fluorescence. This difference is more likely 
accentuated through measurements from only one sample in the HL group, rather 
than biochemical differences between the pathologies. More HL samples are 
needed to investigate further and make a more informed decision on the cause 
of this background change between the pathological groups. 
 
 
 
Conclusion 
 
 This study shows the ability of Raman spectroscopy to recognise spectral 
differences between benign and malignant head and neck lymph nodes in a two 
group PLSDA model and identify primary and secondary cancer based on 
changes in their biochemical compositions. This shows the potential for Raman 
spectroscopy to be used as a diagnostic tool clinically to aid real-time in-situ 
analysis of lymph nodes, direct surgeries and reduce healthcare costs. The ability 
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to implement a better sensitivity using the ROC curve allows a lower number of 
false negatives, even if at the expense of more false positives.  
  
The main findings include: 
1. The main differences observed throughout the study between benign and 
malignant lymph nodes are a decrease in signal attributed to DNA, 
carotenoids, nucleic acids, some amino acids and an increase in lipids, 
proteins, collagen and some amino acids such as phenylalanine. 
2. In the three group PLSDA model, lymphoma appears to be more similar 
to non-cancer measurements than to metastatic, indicated through its 
misclassification. This may suggest that benign and malignant lymphocyte 
populations are more similar than two separate malignant populations of 
different tissue types.    
3. From the two group PLSDA model between lymphoma and metastatic, the 
confusion matrix shows that the metastatic group has a much lower 
sensitivity, suggesting the sample set is too small, metastatic tissue is less 
homogenous than lymphoma and often primary, or that the SCC, AC and 
PC are spectrally different leading to a poor ability to classify them as one 
individual group.  
4. From analysis of the PLSDA and the weights, lymphoma appears to have 
more DNA, amide III and carotenoid assigned and less amino acid and 
lipid assigned peaks than metastatic. 
5. Both the sensitivity and specificity increased by just over 10% when 
identifying metastatic samples from non-cancer, when compared with 
discriminating between lymphoma and non-cancer. This could be due to a 
higher level of biochemical similarities that leads to more similar spectral 
signals between the benign and malignant lymphocytes, regardless of 
pathology. Whilst phenylalanine is selected every time for classification, it 
is more indicative of non-cancer nodes when compared to lymphoma, yet 
less indicative when compared to metastatic.  
 
A larger sample set of metastatic samples would be of great interest in 
taking this area of research further. The metastatic samples could also be 
subdivided, not only based on cell type, but also based on primary site. A 
much larger study would allow for more accurate inferences to be drawn and 
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for further hypotheses to be investigated. The collection of matched primary 
site tissue could also be useful to gain an understanding into any similarities 
to the metastatic site for diagnostic purposes for cases of UPC. Also, 
differences between the secondary and primary site would be interesting to 
analyse if any changes occur between them or whether biochemical changes 
are already present in certain cells that enable them to better metastasise and 
survive to set up a secondary site.    
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Chapter 6: Feasibility Study of a Raman Needle Probe 
 
6.1 Results 
 
 
 Before lymph node measurements were performed using the needle 
probe, it was subjected to several provisional experiments to assess its 
performance and understand how best to measure biological samples. Intralipid 
and ink was used as a phantom to mimic the scattering and absorption properties 
of light in soft biological tissue, such as lymph nodes. India ink is often suspended 
in low absorbing diffusive media, such as lipid solutions like intralipid, in different 
quantities to obtain the desired absorption properties in a phantom to reflect that 
of actual samples. India ink acts as an absorber due to insoluble carbon particles 
suspended in the liquid. Its advantages for spectroscopic use is that it is 
spectroscopically stable, non-toxic, does not fluoresce and its absorption 
spectrum is smooth over the visible and NIR regions with little variation. However, 
it does not act only as an absorber but also as a scatterer making it difficult to 
obtain an accurate absorption coefficient.280       
 
 
 
Figure 6.94- PTFE measurements in intralipid and ink solution measured at increasing distances 
of a 0.5 mm step size from the PTFE. 
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The PTFE measurements at different depths within the intralipid/ink 
phantom, displayed in Figure 6.94, shows the expected decrease in signal as the 
needle tip is pulled further away and measurements are taken at a greater 
distance from the sample. The strongest peak at 733 cm-1 is still observed until 
the last measurement was taken at 3.5 mm away. Additionally, the two peaks at 
1299 and 1382 cm-1 are visible until 3.5 mm away, however the smaller peak at 
1217 cm-1 is much more difficult to detect and is not as obvious.  
 
 For in vivo use, laser safety is an important consideration clinically. 
Although no burning was witnessed or measured when utilising the maximum 
output power of the laser (230 mW at the tip), spectral signals were acquired 
using just 20 mW of laser power. The time taken to take a measurement is also 
of surgical interest for faster diagnosis, both in the interest of treatment time and 
limiting patient discomfort.      
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Figure 6.95- Measurement of pork meat with both 20 mW (top) and 230 mW (bottom) of power 
and measurement times of 1, 2 and 5 seconds with standard deviation plotted around the mean 
spectra. 
 
 
 Measurements of pork meat were taken using both 20 mW and 230 mW 
of laser power at 1, 2 and 5 seconds, displayed in Figure 6.95. Both sets of 
measurements at 20 mW and 230 mW at different times all have recognisable 
peaks throughout the spectra. Strong peaks at around 600 cm-1 and 800 cm-1 
represent signal from the silica fibres of the system and are not biological. The 
system design uses optical filters to reduce this instrumental contribution, 
however the silica fibres still contribute to spectra and are responsible for these 
peaks. It is clear from the standard deviation that the measurements using 230 
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mW do not have as much variation between acquisitions as the 20 mW. The 1, 2 
and 5 seconds spectra are also more similar to one another than the 20 mW 
measurements. The spectra are much smoother in the 230 mW spectra than the 
20 mW. Lymph node measurements were eventually taken at 150 mW to get 
good signal whilst not probing with too much energy.  
 
Figure 6.96 exhibits the spectra acquired from various tissues in two 
porcine samples. For visualisation, the data have been averaged across the ten 
measurements from each tissue type (5 from each sample) to represent the mean 
spectra for bone, fat, muscle and skin tissue in pork. Visual differences are 
present between the spectra. Stronger peaks representing the lipid contributions 
in the fat tissue at 1441 cm-1 and 1750 cm-1 and the peak around 960 cm-1, 
assigned to the calcium-phosphate stretch17 in bone tissue.  
 
 
 
Figure 6.96- Mean spectra of bone (blue), fat (orange), muscle (green) and skin (red) averaged 
across 10 measurements each acquired over two pork samples. 
 
 
Obvious grouping and separation is seen in the PLSDA score plot, Figure 
6.97, across components 1, 2 and 3. This was further supported through a 10-
fold cross-validation which yielded a preliminary classification accuracy of 100%, 
227 
 
where four spectra, one from each group, were omitted from the training model 
to blind test and predict classifications.  
 
 
 
Figure 6.97- PLSDA scores plot for bone (blue), fat (yellow), muscle (green) and skin (red) 
measurements. 
 
 
The weights in Figure 6.98, show the peaks in the spectra that contribute 
the most variance between the groups. The biochemical peaks are primarily 
responsible for the separation between groups rather than any spectral noise, 
signal or baseline. This shows that the needle probe is sensitive enough to 
measure signal attributed to different biochemical signals within tissue samples, 
to identify them as variable in the PLSDA model. Also, coupled with MVA, unseen 
spectra can be blind tested and correctly classified, in this small initial feasibility 
study for testing the needle probes validity for pathological samples.     
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Figure 6.98- PSDA weight from the top three components for the model of pork bone, fat, muscle 
and skin. 
 
 
To assess the ability of the Raman needle system to distinguish between 
more subtle biochemical differences, the skeletal muscle across four different 
animal species were measured at an acquisition time of 1 second and analysed 
using MVA. The muscle spectra from, beef, chicken, lamb and pork meat were 
obtained. Figure 6.99 shows data averaged over 10 spectra for ease of 
visualisation. The differences between the spectra from the different tissue 
samples are more subtle than between the spectra from different tissue types 
within pork meat. The gross quantities of many proteins, lipids and nucleic acids 
are similar throughout the different samples of skeletal muscles and are reflected 
in similar peak intensities and ratios in their spectra. Similar biochemical 
concentrations within the tissue samples are most likely due to the functions 
required of the muscles being similar across the animals measured.  
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Figure 6.99- Mean spectra averaged across 10 muscle measurements of beef (blue), chicken 
(orange), lamb (green) and pork (red) samples. 
 
 
The PLSDA scores plot, Figure 6.100, shows the grouping of the different 
muscle tissues and separation between the different species. The measurements 
are clearly grouped but their separation is less obvious with some slight overlap. 
As a result, the classification accuracy, calculated from 10-fold cross-validation, 
reflects this lack of complete delineation and was calculated to be 97.5% on 
average. The weights of the PLS components, Figure 6.101, show the peaks in 
the spectrum which are considered to contribute the most to the variance 
between the groups. The first and second components contain most of the 
spectral variance attributed to biochemicals whilst the third component is heavily 
composed of peaks from spectral noise.  
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Figure 6.100- PLSDA scores plot of muscle measurements of beef (blue), chicken (yellow), lamb 
(green) and pork (red). 
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Figure 6.101- PLSDA weights from the first three components of the beef, chicken, lamb and pork 
model. 
 
 
The lymph node samples obtained for this study were much smaller than 
the bulk animal tissues samples, usually measuring less than 10 mm in diameter. 
To examine the suitability of the signal gained using the needle probe, one bulk 
non-cancer oesophageal lymph node was analysed after the section had been 
obtained for inVia measurements. Both the lymph node tissue and the 
surrounding adipose tissue was measured to provisionally ensure that the 
spectral quality was good enough to observe differences between these two 
different tissue types so the correct tissue was measured when the lymph nodes 
are harder to detect amongst the adipose. The biochemical differences between 
lymph node tissue and adipose tissue is evident, observed in their spectra in 
Figure 6.102. Peaks attributed to lipids, at 1068, 1123, 1303, 1441 and 1750 cm-
1, are more intense. Those attributed to amino acids and DNA, such as the 
phenylalanine peak at 1002 cm-1 and the DNA peak at 824 cm-1, are weaker in 
the adipose tissue than the lymph node tissue. MVA was not carried out on the 
oesophageal lymph node data as only one sample was investigated and a few 
spectra taken due to limited sampling areas due to the nodes small size. 
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Figure 6.102- Mean spectra of lymph node tissue and the surrounding adipose averaged over 2 
measurements. 
 
 
 After provisionally assessing the Raman needle probes proficiency to 
measure lymph node samples, the bulk head and neck lymph nodes were then 
analysed. The samples were usually half of the lymph node sample excised. 
Occasionally in the metastatic cases where many lymph nodes were taken, a 
whole node might be used. Therefore, the samples were not as large as a whole 
malignant lymph node, again limiting the sampling area. Measurements were 
taken from areas over the whole sample to collect representative data. The mean 
spectra of the cancer and non-cancer measurements, Figure 6.103, show visual 
spectral differences between the two groups.        
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Figure 6.103- Mean spectra of the non-cancer (green) and cancer (red) lymph node 
measurements. 
 
 
PLSDA was performed on the data and the scores plot can be seen in 
Figure 6.104. Separation of the data based on their groups is present primarily in 
component 1. Neither component 2 or 3 appears to separate the groups visually. 
The non-cancer measurements are more dispersed across these components 
whilst the cancer data appear closer to 0. There are more non-cancer data and 
samples and therefore dispersion is a more likely occurrence due to a higher level 
of natural variation. Cross-validation calculated the sensitivity and specificity of 
identifying cancer lymph node measurements from non-cancer as 79% and 81% 
(Table 6.50).  
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Figure 6.104- PLSDA scores plots of the top three components of the cancer and non-cancer 
measurements. 
 
 
 
 
 
Table 6.50- Confusion matrix of from the cross-validation of the PLSDA model of cancer and non-
cancer. 
  True group 
  Non-Cancer Cancer 
Predicted group Non-Cancer 29 3 
Cancer 7 11 
 Total Samples 36 14 
 Sensitivity 0.8056     0.7857 
 Specificity 0.7857 0.8056     
  
 
 The ROC curve, Figure 6.105, shows that to achieve a 90% and 95% 
sensitivity, a compromised specificity of 36% and 23% would occur. However 
clinically, a higher sensitivity may be of higher importance to avoid false negatives 
whilst still reducing the number of unnecessary biopsies.  
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Figure 6.105- ROC curve for the classification of non-cancer and cancer measurements. 
 
 
 Figure 6.106 shows the etaloning of the CCD in the green glass 
measurements. The green glass, though measured on different days, can be 
seen to exhibit a very similar pattern, thus this effect is relatively consistent. 
However, the etaloning is not consistent enough to simply correct for it during 
pre-processing and much more work is needed to reproducibly and correctly 
eliminate its effect from the spectra, and not interfere with the biochemical signal.  
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Figure 6.106- Green glass measurements across different days showing the effect of etaloning. 
 
 
6.2 Discussion 
 
The phantom measurements were able to provide a preliminary indication 
of the sampling volume that could be measured using the Raman needle probe. 
A distance of 3.5 mm from the tip still suitable to detect the peaks of PTFE. 
Normal lymph nodes are usually up to 1 cm in diameter, therefore a large 
proportion of the node could be sampled using this needle probe. However, PTFE 
has stronger signals than biological samples, so while the sampling area might 
be large, the signal might be much weaker. Matousek et al.151 showed that the 
spectral signature of bone can be detected at 3 mm distance using spatially offset 
Raman spectroscopy (SORS) but believed it could be increased to 5 mm and 
more, limited only by the lack of inelastic scattered photons detected.    
 
Although Raman spectroscopy utilises non-ionising radiation and 
considered safer than many current diagnostic techniques, such as CT, it can still 
result in thermal burning. There is currently a lack of consensus surrounding an 
acceptable power limit. The difference in wavelengths of light used and area 
probed, contributes more variables that further complicates a solution for the 
standard safe exposure limit. The tissue type irradiated also contributes to the 
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difference in response observed. Bergholt et al.281 found that using a 785 nm 
laser at 30 mW with a 200 µm spot size could only increase the temperature of a 
sample by a maximum of 0.15 oC when probing a tissue sample for at least a 
minute. They stated that the temperature rise is far below that which could cause 
cell cytotoxicity. This study showed that both a laser power of 60 mW and 230 
mW at the sample produced biological spectra with identifiable peaks at 1, 2 and 
5 second acquisitions. However, the main difference between the two laser 
powers was the reduced noise when using 230 mW. A laser power of 150 mW 
was used for the rest of the study to provide a mid-range power that was both 
enough to reduce noise contributions but also probe the tissue without causing 
concern regarding tissue burning. A more in-depth study regarding the laser 
power and acquisition time would be useful in order to optimise measurement 
quality, measurement time and patient safety.      
 
Another issue that has been observed is the influence of different light 
sources on measurements and their resulting contamination of the spectra. As 
Raman scatering is a weak phenomenon, the resulting spectra of biological 
samples can easily be contaminated by the detection of ambient light and is thus 
better carried out in the dark to reduce or remove this effect. In theatre settings, 
lights are essential in order to carry out surgery.282 Nyberg et al.282 noted the 
presence of three ambient fluorescent light peaks 985 cm-1–993 cm-1, 1343 cm-1–
1353 cm-1, 1537 cm-1 and 1547 cm-1. However, they detected and removed these 
peaks by replacing the values with those ot the neighbouring pixels. Nyberg et 
al.283 combatted the issue, through probe insertion of at least 1 mm into tissue 
samples and acquiring spectra in the dark, to reduce ambient light contribtutions 
in measured spectra.  
 
Desroches et al.284 studied the effect of common operating room (OR) light 
sources on measured spectra. Through measurements taken of veal and the 
inclusion of various light powers and sources both indirectly and directly, coupled 
with principal component analysis, they found that whilst some light sources could 
be kept on during measurements, others had too much of an effect on the 
spectra. They concluded that indirect OR lights, liquid crystal display (LCD) 
screens and exterior radiation entering from windows do not need to be 
eliminated whilst taking measurements. However, microscope, fluorescent and 
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direct OR lights cannot be used without significantly affecting the resulting 
spectra. They also observed that whilst IR sources do not contribute 
distinguishable peaks to measured spectra and any contribution can be reduced 
through background correction algorithms, they can result in detector saturation. 
Therefore, IR sources must be pointed away from the spectroscopic probe during 
measurements to avoid this problem. They note the importance and encourage 
specific OR measurements to be carried out prior to using probe spectrometers 
in surgery as different light sources and intensities may vary the spectral 
contributions experienced whilst taking measurements. They stress the 
importance of situating PC monitors and other LCD screens away from the area 
where measurements take place to avoid spectral artefacts that could occur.  
 
 The preliminary biological tissue study carried out on different animal 
samples demonstrated the feasibility of the Raman needle probe for its use on 
human tissue. The ability of the probe to detect the spectral differences between 
the different tissue types in two porcine samples is demonstrated both through 
visual variations in the spectra but also after multivariate analysis. The probe is 
also capable of detecting more subtle biochemical changes between muscle 
samples from the different animals, less visually obvious in the spectra, but 
shown via multivariate analysis.  
 
The initial set of lymph node measurements have shown a promising use 
of the needle probe as a surgical tool, through very clear spectral differences 
between adipose tissue and lymph node tissue based on the biochemical makeup 
of the two tissue types. Lymph nodes are typically firmly situated in adipose 
tissue.231 The lymphatic fluid contains large amounts of emulsified lipids, and fat 
deposition often occurs initially along lymphatic structures. Lymphatic fluid 
leakage from lymphatic vessels appears to promote fat accumulation.232 An 
increased number of adipocytes surrounding the lymph nodes is frequently 
associated with chronic inflammation of nodes.233 Lymph nodes resected during 
surgery are often removed due to their enlarged appearance and therefore may 
be surrounded by a large concentration of adipocytes.242 Surgeons often mistake 
adipose tissue for fat when taking a biopsy. Whilst collecting head and neck 
lymph node samples for this study, 5 out of the 84 collected samples turned out 
to be tissue other than lymph node when analysed by a pathologist, three were 
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fat and the other two were connective tissue. The obvious spectral differences 
observed between these two tissue types could allow real-time surgical guidance 
to help locate lymph nodes during surgery and avoid the unnecessary removal of 
fat tissue and wasted time in pathology.  
 
 The measurement and analysis of the head and neck lymph node samples 
resulted in a 79% and 81% sensitivity and specificity for the classification of 
cancer from non-cancer lymph node samples using a leave-one-sample-out 
cross-validation. This is similar to the inVia Raman measurements of 77% and 
89% and shows its comparability to ex vivo techniques. This feasibility study 
shows that the needle probe can measure biological tissue samples at a good 
sensitivity, able to differentiate between pathological types using MVA based on 
subtle spectral differences.  
 
 Although the needle probe has a retracting needle tip to allow minimum 
debris build-up, it will still be inserted through skin, muscles and adipose tissue 
before reaching the lymph node. Thus, the collection of tissue debris should still 
be examined through extensive experimentation where the needle probe is 
inserted through these different tissues to assess whether this could be a problem 
or whether the retracting tip provides enough protection.   
 
As a result of etaloning, and the inability to fully correct for its contributions 
and those of the instrument, interpretation of the spectra are limited and 
biochemical inferences were not made at this stage. Etaloning is caused by the 
interaction of the light with the front and back silicon surfaces of the back thinned 
deep depletion CCD, resulting in its reflectance back and forth. The reflected light 
interferes with itself and an interference pattern in the spectrum is then produced. 
A different laser wavelength or CCD chip would have an altered etalon pattern 
and produce spectra that reflect this. As a result, in order to use multiple units, 
the etaloning needs to be removed from spectra, either through the use of a 
different CCD that does not produce this phenomenon or through pre-processing, 
in order to correctly interpret measurements and assess its clinical use. Andor285 
suggest alternative detectors that limit this, such as those that have deeper 
depletion regions to avoid re-reflectance of the light. Front illuminated CCDs are 
also suggested as an alternative, although these have lower sensitivity due to 
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photon interaction with the polysilicon electron structure. A radiometric calibration 
may be applied, binning to potentially average out the etalon signal or a fringe-
suppression to the CCD where the back wall is roughened to avoid re-reflectance 
may also help to reduce this phenomenon in spectra.  
 
6.3 Conclusions      
   
 This feasibility study has shown the ability of this Raman needle probe for 
measuring biological samples and has demonstrated its comparability to current 
techniques for the blind identification of pathology using MVA. The potential for 
in vivo use and as a clinical tool has also been shown in this study. The speed at 
which measurements can be taken and the quality of spectral acquisitions 
demonstrate the usefulness of this technique both clinically and scientifically.  
 Further work should be carried out to correct for etaloning and instrument 
contributions to better interpret measurements. A larger study would also be 
useful to gain a better indication of the diagnostic potential. The ability to 
differentiate between the different types of cancer within the lymph node would 
also be of interest to compare the technique to current ex vivo Raman methods 
and assess if there are any limitations to the use of the probe. A clinical trial would 
be needed to implement the technique in clinics and laboratories to offer a tool to 
guide surgeries and initially assess samples in pathology laboratories.    
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Conclusions and Future Work 
 
 This study has successfully demonstrated and evaluated the ability of 
Raman spectroscopy for the detection of biochemical changes between cancer 
and benign tissue from lymph nodes of different areas.  
 
 A sensitivity and specificity of 71% and 89% was calculated for identifying 
metastatic from non-cancer lymph nodes for oesophageal, femoral and head and 
neck lymph nodes collectively. Primary differences between malignancy and non-
cancer appear to be due to lower DNA and carotenoid and higher lipid and 
collagen concentrations indicated through variations in their assigned peak 
intensities. PLSDA and cross-validation of the separate lymph node regions led 
to sensitivities of 50%, 83% and 80% and specificities of 83%, 75% and 92% for 
identification of oesophageal, femoral and head and neck metastases from non-
cancer lymph nodes respectively. A much lower sensitivity in the oesophageal 
lymph nodes analysis may have been influenced by a large level of carbon 
particle deposits and strong lipid peak contributions, resulting difficulty measuring 
and analysing samples. Whilst femoral and head and neck nodes can be better 
classified individually, oesophageal classification may be improved when 
compared against data from the other lymph node regions. The spectral maps 
taken from the same head and neck nodes were analysed and produced the 
same sensitivity and specificity as the PLSDA model of point acquisitions. This 
provides support for the ability of classifying in vivo measurements based on 
pathology, where sampling would be limited to a few point acquisitions.  
 
 The larger head and neck lymph node study, analysing the classification 
capabilities of both metastatic and primary lymphomas, resulted in sensitivities of 
64% and 75% and specificities of 86% and 97% for identifying lymphoma and 
metastatic samples respectively from non-cancer samples. The sensitivity and 
specificity of classification for cancer overall was 82% and 90%. The needle 
probe measurements demonstrated the feasibility for in vivo use. The sensitivity 
and specificity for classification of the needle probe data using the bulk lymph 
node of the same samples as the sections were 81% and 79%. A similar accuracy 
to the confocal Raman section measurements shows the functionality of the 
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needle probe for analysing subtle biochemical changes and indicates its potential 
as a clinical tool for real-time diagnosis and as a surgical assistant.  
  
 This study has resulted in the development of further hypotheses that 
should be investigated to benefit this area of research. The main limitation of this 
study is the sample size, and therefore conclusions cannot be drawn based on 
being representative of the general population. 
  
The collaboration of different research centres and hospitals would enable 
the collection of a larger sample-set, likely to represent a higher number of 
pathologies, more measurements and a faster output of data. Larger studies are 
more able to pave the way for clinical trial. Therefore, after the issues with the 
needle probe are overcome and a larger ex vivo trial is found to be successful for 
accurate classification of lymph nodes, its use clinically, in vivo, would be an 
obvious next step. A clinical trial would introduce the technique into hospitals and 
enable analysis of the diagnostic potential and its use as a surgical tool.   
 
The presence of benign diseases is a frequent occurrence with lymph 
node biopsies. Hence, a study utilising Raman spectroscopy for the identification 
of different diseases would be advantageous to support the diagnostic potentials 
of the technique for different lymph node pathologies. When a patient is first seen 
by a physician regarding a suspected cancer, it is usually as a result of a 
noticeably inflamed lymph node or as a result of suspected metastasis from a 
primary cancer. In both cases the cancer would be at a further stage of 
progression than a pre-cancer. Therefore a Raman needle probe is more likely 
to investigate these cancers, where they would be more discernible from a non-
cancerous lymph node. It would be of great interest to investigate pre-cancers 
and early-stage cancers of the lymph node to determine the suitability of a needle 
probe as a screening method for primary cancers. This would enable better 
patient care from clinicians and allow the early removal of any tissue that may 
pose a metastatic threat.    
 
Overall this study provides a thorough investigation into the use of Raman 
spectroscopy for the analysis of metastatic and primary malignancies found in 
various the lymph nodes from different anatomical locations. Furthermore it 
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demonstrates the potential for the in vivo use of Raman spectroscopy for 
diagnostic and surgical purposes. The technique contributes to the fast-growing 
field through expanding on research previously undertaken and providing the 
introduction and analysis of a novel technique that delivers the technology 
needed to support clinical implementation.          
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